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Abstract   V 
Abstract 
More than 300 million people world-wide are affected by diabetes, the majority 
suffering from type 2 diabetes. Type 2 diabetes is characterized by insulin resistance, 
usually caused by obesity and overweight. Enhanced pancreatic insulin secretion largely 
compensates insulin resistance for years. A failure of pancreatic -cells to meet 
increased insulin demands drastically increases blood glucose levels and marks the onset 
of type 2 diabetes. Besides environmental influences, mainly elevated food intake and 
reduced physical activity, also genetic mutations are important factors in the 
pathophysiology of type 2 diabetes.  
Recent literature highlights the role of microRNA 375 (miR-375) in the growth and 
function of pancreatic insulin-producing -cells. MiR-375 gene expression is regulated in 
diabetic humans and rodents, suggesting that this microRNA is involved in the 
pathogenesis of type 2 diabetes. Genes regulated by miR-375 have been described in 
pancreatic -cells. Nevertheless, the exact mechanisms how miR-375 regulates -cell 
growth and insulin secretion have not been understood. 
Cell adhesion molecule 1 (CADM1) is a known target of miR-375 and has mainly been 
described as regulator of synapse number and synaptic function in the brain. CADM1 is 
also expressed in pancreatic -cells and might regulate -cell growth and function and 
might be involved in the control of glucose and energy homeostasis. The aim of this 
work was to investigate whether CADM1 in pancreatic -cells or neuronal tissue 
contributes to the regulation of energy and glucose homeostasis by using total and 
conditional Cadm1 deficient mice.  
Total Cadm1 deficient (Cadm1KO) mice showed increased sensitivity to glucose and 
insulin as well as enhanced glucose-stimulated insulin secretion compared to littermate 
control mice. Elevated glucose-stimulated insulin secretion after Cadm1 depletion could 
be confirmed in an in vitro -cell model. In addition, enhanced insulin sensitive was 
evident in diet and genetic-induced obese Cadm1KO mice. Furthermore, Cadm1KO mice 
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showed significantly reduced body weight during postnatal development and adulthood, 
which was already apparent at four days of age. However, body weight increase of adult 
Cadm1KO mice was unchanged under CHOW diet as well as in diet and genetic-induced 
obese Cadm1KO mice. Male Cadm1KO mice further displayed reduced relative body fat 
content and increased relative lean body mass. Analysis of energy homeostasis yielded 
increased locomotor activity in male Cadm1KO mice. Enhanced insulin and glucose 
sensitivity as well as reduced body weight and altered body composition could be 
confirmed in mice with conditional Cadm1 deficiency only in neuronal and glia cells 
(Cadm1NesCreKO). From these data we conclude that Cadm1 deficiency enhances -cell 
insulin secretion and whole body insulin sensitivity. In addition, CADM1 influences 
locomotor activity and body composition in male mice, while susceptibility to obesity is 
not influenced by CADM1 action. Alterations in insulin sensitivity, body weight and body 
composition are caused by CADM1 action in neuronal or glia cells. The described results 
indicate that CADM1 might contribute to the development of type 2 diabetes by 
influencing -cell insulin secretion and insulin sensitivity. 
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Zusammenfassung 
Mehr als 300 Millionen Menschen sind weltweit von Diabetes betroffen, die Mehrheit 
davon leidet an Typ-2-Diabetes. Typ-2-Diabetes ist durch eine Insulinresistenz 
charakterisiert, welche meistens durch Übergewicht und Adipositas verursacht wird. 
Diese Insulinresistenz kann zunächst durch eine erhöhte pankreatische Insulinsekretion 
kompensiert werden, jedoch können langfristig die pankreatischen -Zellen den 
erhöhten Insulinbedarf nicht mehr decken. Dies verursacht einen starken Anstieg der 
Blutglucosespiegel und stellt den Beginn der Typ-2-Diabetes Erkrankung dar. Neben 
genetischen Veränderungen sind Umweltfaktoren, wie erhöhte Nahrungsaufnahme und 
reduzierte Bewegung, wichtige Faktoren in der Pathogenese des Typ-2-Diabetes.  
Frühere Forschungsergebnisse zeigten eine wichtige Rolle von microRNA 375 (miR-375) 
im Wachstum und in der Funktion der Insulin produzierenden -Zellen. Die 
Genexpression von miR-375 ist in diabetischen Nagetieren und Menschen verändert, 
was auf eine wichtige Rolle dieser microRNA in der Pathogenese des Typ-2-Diabetes 
hindeutet. Gene, die durch miR-375 reguliert werden, wurden in den pankreatischen -
Zellen beschrieben, jedoch ist der Mechanismus wie miR-375 das Wachstum und die 
Funktion der pankreatischen -Zellen beeinflusst noch nicht im Detail verstanden.  
Das Cell Adhesion Molecule 1 (CADM1) ist ein bekanntes Zielgen der miR-375 und vor 
allem im Gehirn als Regulator von Anzahl und Funktion der Synapsen bekannt. Da es 
außerdem in den pankreatischen β-Zellen exprimiert ist, könnte es auch dort an der 
Regulation von β-Zellwachstum und –funktion beteiligt sein und die Glucose- und 
Energiehomöostase verändern. Ziel dieser Arbeit war es, in vollständig oder konditionell 
Cadm1-defizienten Mäusen den Einfluss von CADM1 in pankreatischen -Zellen und 
neuronalem Gewebe an der Regulation von Glucose- und Energiehomöostase zu 
untersuchen. 
Vollständig Cadm1-defiziente (Cadm1KO)-Mäuse zeigten eine erhöhte Glucose- und 
Insulinsensitivität, sowie eine vermehrte glucosestimulierte Insulinsekretion im 
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Vergleich zu Geschwisterkontrolltieren. Eine erhöhte glucosestimulierte Insulinsekretion 
nach Cadm1-Defizienz konnte auch in einem in vitro -Zellmodell gezeigt werden. Eine 
vermehrte Insulinsensitivität war auch in nahrungs- und genetisch induzierten 
übergewichtigen Cadm1KO-Mäusen nachzuweisen. Außerdem zeigten Cadm1KO-Mäuse 
signifikant reduziertes Körpergewicht im Erwachsenenalter und während der 
postnatalen Entwicklung, was bereits im Alter von vier Tagen messbar war. Die 
Körpergewichtszunahme von adulten Cadm1KO-Mäusen war jedoch unter CHOW-
Fütterung sowie in nahrungs- und genetisch induzierten übergewichtigen Cadm1KO-
Mäusen unverändert. Männliche Cadm1KO-Mäuse hatten zudem einen reduzierten 
relativen Körperfettgehalt und eine erhöhte relative Muskelmasse. Die Analyse der 
Energiehomöostase ergab eine erhöhte lokomotorische Aktivität von männlichen 
Cadm1KO-Mäusen. Eine gesteigerte Insulin- und Glucosesensitivität sowie reduziertes 
Körpergewicht und veränderte Körperzusammensetzung konnte auch in Mäusen mit 
konditioneller Cadm1-Defizienz in Neuronal- und Gliazellen (Cadm1NesCreKO) bestätigt 
werden. Aus diesen Daten kann geschlussfolgert werden, dass Cadm1-Defizienz die -
Zellen-Insulinsekretion und die Insulinsensitivität im Körper erhöht. Zudem beeinflusst 
CADM1 die lokomotorische Aktivität und die Körperzusammensetzung in männlichen 
Mäusen, während die Prädisposition gegenüber Übergewicht durch CADM1 in beiden 
Geschlechtern nicht beeinflusst wird. Veränderungen in Insulinsensitivität, 
Körpergewicht und Körperzusammensetzung werden anscheinend durch den Einfluss 
von CADM1 in Neuronal- oder Gliazellen verursacht. Diese Ergebnisse deuten darauf hin, 
dass CADM1 in der Pathogenese von Typ-2-Diabetes beteiligt sein könnte, indem es die 
Insulinsekretion der -Zellen und die Insulinsensitivität beeinflusst.  
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1 Introduction 
Diabetes is characterized by chronic hyperglycemia caused by insufficient release of 
insulin or insufficient response to insulin. The consequences of chronically elevated 
blood glucose levels are cardiovascular disease, neuropathy and retinopathy (Stolar 
2010). Currently, diabetes affects 346 million people world-wide. It is estimated that in 
2004 3.4 million people died from diabetes-related diseases. 90 % of diabetic patients 
world-wide are affected by type 2 diabetes (WHO 2012). Unlike type 1 diabetes, which is 
an auto-immune disease causing deficient insulin production, type 2 diabetes is 
characterized by an insulin resistant state and subsequent -cell failure to meet high 
insulin demands of the body by increased insulin production (Skyler 2004). Obesity is a 
major cause of insulin resistance and therefore largely contributes to the development 
of type 2 diabetes (Kahn and Flier 2000).  
The step from obesity-induced insulin resistance to type 2 diabetes is largely dependent 
on the ability of the pancreas to meet increased insulin demands by induction of islet 
hyperplasia. MicroRNA-375 (miR-375) is the highest expressed microRNA (miRNA) in the 
pancreas and recent investigations highlighted the importance of miR-375 in the control 
of islet hyperplasia as well as insulin secretion (Poy, Eliasson et al. 2004; Poy, Hausser et 
al. 2009). These studies suggested that miR-375 influences the development of type 2 
diabetes. However, the molecular mechanisms of how miR-375 regulates -cell mass 
and -cell function could not be established. Nevertheless, several genes targeted by 
this microRNA were identified. One of these genes is cell adhesion molecule 1 (Cadm1) 
(Poy, Hausser et al. 2009).  
In order to address whether CADM1 is involved in -cell growth and -cell function, we 
investigated mice with a complete deletion of Cadm1 (Cadm1KO) for changes in glucose 
homeostasis. During the course of our studies we also observed changes in insulin 
sensitivity and body weight in Cadm1KO mice. Body weight is a major determent in the 
development of insulin resistance and therefore in the pathogenesis of type 2 diabetes 
(Kahn 2003). We therefore extended our studies to understand how CADM1 regulates 
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body weight by investigating the influence of CADM1 on energy homeostasis. Taken 
together, our studies are the first step in uncovering the role of CADM1 in the 
pathogenesis of type 2 diabetes. 
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1.1 Regulation of glucose and energy homeostasis 
 Regulation of blood glucose homeostasis by insulin 1.1.1
Carbohydrates and especially glucose are important energy sources for several tissues. 
In particular, blood cells derive fuel only from glucose and the brain relies mainly on 
glucose (Biesalski and Grimm 2002). In an acute state, absolute or relative insulin 
deficiency can lead to life threatening hyperglycemic crises caused by diabetic 
ketoacidosis or a hyperglycemic hyperosmolar state (Chaithongdi, Subauste et al. 2011). 
Chronic insulin deficiency causes glucose toxicity, leading to nephropathy, retinopathy, 
neuropathy and atherosclerosis (Stolar 2010). A tight regulation of blood glucose 
homeostasis to avoid hyper- or hypoglycemia is therefore important.  
Blood glucose homeostasis is mainly maintained by insulin. The hormone is produced in 
pancreatic -cells where its release is initiated by increased postprandial blood glucose 
levels (Figure 1) (Felig, Wahren et al. 1976). Insulin-stimulated decrease of blood glucose 
levels is mediated by glucose uptake in skeletal muscle and adipose tissue (Klip and 
Paquet 1990). In addition, hepatic glucose production (HGP) is inhibited by insulin 
directly through decreasing glycolytic enzymes and increasing gluconeogenic enzymes. 
Furthermore, insulin inhibits HGP indirectly through stimulation of agouti-related 
protein (AGRP)-expressing neurons in the hypothalamus of the brain and subsequent 
innervation of the liver and inhibition of gluconeogenic enzymes (1.1.4) (Pilkis and 
Granner 1992; Konner, Janoschek et al. 2007). While insulin lowers blood glucose levels, 
-cell-produced glucagon increases blood glucose levels by stimulating HGP (Felig, 
Wahren et al. 1976; Pilkis and Granner 1992; Shah, Vella et al. 2000). Glucagon release is 
inhibited by high postprandial blood glucose levels and stimulated when blood glucose 
levels are too low (Weir, Knowlton et al. 1974).  
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Figure 1: Regulation of blood glucose homeostasis 
Blood glucose levels are mainly determined by HGP and glucose uptake in skeletal 
muscle and adipose tissue. High blood glucose levels stimulate insulin release from 
pancreatic -cells and inhibit glucagon release from -cells. Insulin in turn stimulates 
insulin-dependent glucose uptake in skeletal muscle and adipose tissue. In addition, 
insulin inhibits HGP in liver directly and indirectly through stimulation of AGRP-
expressing neurons in the hypothalamus. In total, insulin-mediated effects decrease 
blood glucose levels. Glucagon released from pancreatic -cells stimulates HGP, 
increasing blood glucose levels.  
Abbreviations: Agouti-related protein (AGRP); Hepatic glucose production (HGP) 
Modified from (Saltiel and Kahn 2001) 
 Mechanisms of insulin release from pancreatic -cells 1.1.2
The pancreas is mainly comprised of an enzyme-producing exocrine portion and a 
hormone-producing endocrine portion, the islets of Langerhans or simply called 
pancreatic islets. These islets are built of different cell types such as insulin-producing 
cells, glucagon-producing -cells, somatostatin-producing -cells and pancreatic 
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polypeptide (PP)-producing PP cells. In addition, neuronal and vascular cells highly 
infiltrate pancreatic islets (Halban 2004). 
Glucose is specifically transported into -cells by the insulin-independent glucose 
transporter (GLUT)2, a transporter with high capacity and low affinity that facilitates the 
glucose transport in direct proportion to blood glucose concentrations (Figure 2) 
(Johnson, Newgard et al. 1990). The following glucokinase-mediated phosphorylation of 
glucose to glucose-6-phosphate is the rate-limiting step of glucose uptake (De Vos, 
Heimberg et al. 1995). Mutations in the glucokinase gene lead to maturity-onset 
diabetes of the young (MODY), emphasizing this gene as essential for insulin release 
from pancreatic -cells (Froguel, Vaxillaire et al. 1992). The glycolytic break-down of 
glucose produces nicotinamide adenine dinucleotide (NADH), which is transported into 
mitochondria by the glycerol phosphate-dihydroxyacetone phosphate and the malate-
aspartate shuttles (Dukes, McIntyre et al. 1994; Mertz, Worley et al. 1996). In addition, 
pyruvate produced through glycolysis is metabolized to acetyl-coenzyme A, generating 
NADH and flavine adenine dinucleotide (FADH2) via the tricarboxylic acid (TCA) cycle in 
mitochondria (MacDonald 1993). The electron transport chain converts NADH and 
FADH2 to adenosine-5'-triphosphate (ATP), increasing cytosolic ATP/adenosine 
diphosphate (ADP) ratio.  ATP released into the cytosol blocks ATP-sensitive K+-channels, 
leading to membrane depolarization (Cook and Hales 1984; Rorsman and Trube 1985) 
und subsequent opening of voltage-sensitive calcium channels (Keahey, Rajan et al. 
1989). The influx of calcium ions triggers docking and release of insulin-containing 
secretory vesicles (Ashby and Speake 1975). 
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Figure 2: Model of insulin secretion in pancreatic -cells 
Glucose is taken up by insulin-independent GLUT2 and metabolized to NADH and 
pyruvate through glycolysis. Pyruvate is fueled into the TCA cycle, generating FADH2 and 
NADH. The electron transport chain in mitochondria converts NADH and FADH2 to ATP, 
increasing cytosolic ATP/ADP ratio. Enhanced ATP/ADP ratio closes ATP sensitive K+-
channels, which depolarizes the membrane and opens voltage-gated Ca2+-channels. 
Increased cytosolic Ca2+ concentrations trigger docking of insulin-containing secretory 
vesicles and insulin release. Furthermore, GABA contained in secretory vesicles and 
synaptic like microvesicles is secreted similarly to insulin. Autocrine GABA signaling and 
sympathic innervation negatively regulate insulin secretion. Parasympathic innervation 
positively regulates insulin secretion. 
Abbreviations: Adenosine diphosphate (ADP); Adenosine-5'-triphosphate (ATP); -
aminobutyric acid (GABA); -aminobutyric acid receptor (GABAR); Glucose transporter 2 
(GLUT2); Muscarinic acetylcholine receptor 3 (M3); Nicotinamide adenine dinucleotide 
(NADH); Sympathetic nervous system (SNS); Parasympathetic nervous system (PSNS); 
Tricarboxylic acid cycle (TCA)  
Glucose functions as the main secretagogue for insulin secretion but the mechanism of 
insulin secretion is sensitive to nutrients such as fatty acids (FAs) (Dobbins, Chester et al. 
1998), autocrine -aminobutyric acid (GABA) signaling (Braun, Wendt et al. 2004; Dong, 
Kumar et al. 2006) or autonomic innervations (Conaway, Griffey et al. 1975) (Figure 2). 
Autonomic innervations of pancreatic -cells increase insulin secretion through the 
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parasympathic muscarinic acetylcholine receptor 3 (M3), while blocking of M3 reduces 
insulin secretion in mice (Gautam, Han et al. 2006). Autonomic innervations through 
sympathic innervations inhibit glucose-mediated insulin release through activation of 
2-adrenoceptors (Skoglund, Lundquist et al. 1988; Kurose, Seino et al. 1990). GABA is 
released from secretory vesicles, in parallel to insulin, and from synaptic-like 
microvesicles (Figure 2) (Reetz, Solimena et al. 1991; Gammelsaeter, Froyland et al. 
2004). Both types of vesicles secret GABA in a glucose-dependent manner (Thomas-
Reetz, Hell et al. 1993; MacDonald, Obermuller et al. 2005). In the presence of high 
glucose concentrations, GABA inhibits insulin secretion in an autocrine manner (Braun, 
Wendt et al. 2004; Dong, Kumar et al. 2006).  
 Molecular mechanisms of insulin signaling 1.1.3
Insulin signaling in insulin sensitive tissues is activated by binding of insulin to the insulin 
receptor (Figure 3) or by binding of insulin-like growth factor 1 (IGF-1) to the insulin-like 
growth factor-1 receptor (IGF1R) or to the insulin receptor (Steele-Perkins, Turner et al. 
1988). The insulin receptor belongs to the growth factor receptor tyrosine kinase 
superfamily (McInnes, Wang et al. 1998) and is located at the plasma membrane as a 
dimer to control several signaling cascades (Freychet, Roth et al. 1971; Boni-Schnetzler, 
Rubin et al. 1986). Insulin receptors can be found in many different tissues, including 
skeletal muscle, liver, adipose tissue, different brain areas and pancreas (Havrankova, 
Roth et al. 1978; Watanabe, Hayasaki et al. 1998). Upon binding of insulin or IGF-1, the 
insulin receptor undergoes a conformational change followed by autophosphorylation of 
distinct tyrosine residues of the  subunit (Kasuga, Zick et al. 1982; Kasuga, Zick et al. 
1982), which results in a second conformational change (Donner and Yonkers 1983). The 
second conformational change activates the receptor protein tyrosine kinase activity, 
enabling recruitment of ATP and tyrosine phosphorylation of recruited substrates 
(Rosen, Herrera et al. 1983; Cobb, Sang et al. 1989). These substrates include insulin 
receptor substrate (IRS)1-6 and Src homology 2-containing (SHC) protein (Shoelson, 
Chatterjee et al. 1992) (Figure 3).  
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Figure 3: The insulin signaling pathways 
The insulin signaling cascade is activated by binding of insulin to its receptor, leading to 
conformational changes and autophosphorylation on tyrosine (Y) residues of the insulin 
receptor. Recruited substrates, such as SHC and IRS, are tyrosine phosphorylated by the 
insulin receptor tyrosine kinase activity. SHC is an activator of the MAPK pathway, which 
is responsible for insulin-mediated effects on cell growth, differentiation and protein 
synthesis. IRS proteins facilitate activation of PI3K, which phosphorylates PIP2 to PIP3. 
PIP3 is an activator of PDK, which further phosphorylates AKT on serine (S) and 
threonine (T) residues. AKT-regulated downstream targets are responsible for glycogen 
synthesis, lipid synthesis, glucose uptake, cell growth, differentiation and protein 
synthesis, inhibition of gluconeogenesis and food intake.  
Abbreviations: V-akt murine thymoma viral oncogene homolog (AKT); Growth factor 
receptor bound 2 (GRB2); Hepatic glucose production (HGP); Insulin receptor substrate 
(IRS); Mitogen-activated protein kinase (MAPK); Phosphoinositide-dependent kinase 
(PDK); Phosphatase and tensin homologue deleted on chromosome 10 (PTEN); 
Phosphatidylinositol 3-kinase (PI3K); Serine (S); Src-homology-2-containing (SHC); 
Threonine (T); Tyrosine (Y) 
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Six different IRS isoforms have been identified so far. IRS1 and IRS2 are ubiquitously 
expressed (Araki, Sun et al. 1993; Sun, Wang et al. 1995). IRS1 knock-out (Irs1KO) mice 
are growth retarded pre- and postnatal. Furthermore, resistance to insulin occurs in 
adipocytes but not in skeletal muscle and liver in Irs1KO mice. Serum insulin levels in 
these mice are high in order to compensate for insulin resistance (Araki, Lipes et al. 
1994; Tamemoto, Kadowaki et al. 1994). These data showed that IRS1 is important in 
insulin-stimulated somatic growth and glucose uptake but its effects can be 
compensated in skeletal muscle, liver and pancreatic -cells. This compensation is 
thought to be facilitated by IRS2. Unlike Irs1KO mice, Irs2KO mice do not show 
compensation for insulin resistance and develop -cell dysfunction and diabetes. Insulin 
resistance occurs in skeletal muscle and liver of Irs2KO mice. Somatic growth is only 
slightly reduced in these mice (Withers, Gutierrez et al. 1998). These data showed that 
IRS1 mainly regulates somatic growth and insulin-stimulated glucose uptake in adipose 
tissue. IRS2 is essential for -cell growth regulation as well as insulin signaling in skeletal 
muscle and liver. IRS3 occurs in many rodent tissues, especially in liver, lung and 
adipocytes (Sciacchitano and Taylor 1997; Liu, Wang et al. 1999), but is absent in human 
tissues (Bjornholm, He et al. 2002). Irs3KO mice do not show alterations in glucose 
homeostasis and somatic growth, suggesting that IRS3 is not involved in these processes 
(Liu, Wang et al. 1999). IRS4 is mainly detected in pituitary and thyroid glands but absent 
in insulin-sensitive tissues, indicating that IRS4 does not play a major role in insulin 
signaling (Uchida, Myers et al. 2000). IRS5 and IRS6 have truncated c-terminals and do 
not bind to proteins involved in the regulation of glucose homeostasis, suggesting that 
these two IRS isoforms do not contribute to the control of glucose homeostasis (Cai, 
Dhe-Paganon et al. 2003).  
The IRS proteins bind to src homology 2 (SH2) domains of recruited proteins, such as 
phosphatidylinositol 3-kinase (PI3K) (Backer, Myers et al. 1992; Lavan, Kuhne et al. 1992; 
Myers, Backer et al. 1992) and growth factor receptor-bound protein 2 (GRB2) (Skolnik, 
Lee et al. 1993; Tobe, Matuoka et al. 1993) (Figure 3). GRB2, together with SHC, 
activates the Ras–mitogen-activated protein kinase (MAPK) pathway (Skolnik, Lee et al. 
1993), promoting cell growth, differentiation and protein synthesis in several different 
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tissues (Bonni, Brunet et al. 1999). PI3K is responsible for phosphorylation of 
phosphatidylinositol-4,5-disphosphate (PIP2), generating phosphatidylinositol-3,4,5-
trisphosphate (PIP3) as important second messenger (Ruderman, Kapeller et al. 1990; 
Hawkins, Jackson et al. 1992). This reaction can be reversed by phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN), one mechanism to inhibit the insulin 
signal (Maehama and Dixon 1998). PIP3 activates proteins via pleckstrin homology (PH) 
domains, with 3-phosphoinositide-dependent protein kinase (PDK) 1 and 2 being the 
most important PH domain-containing proteins. PDK then activates v-akt murine 
thymoma viral oncogene homolog (AKT), also called protein kinase B (PKB), a group of 
kinases that phosphorylate other kinases, proteins or transcription factors (Anderson, 
Coadwell et al. 1998). Insulin-mediated AKT activation is facilitated by phosphorylation 
of threonine (Thr)308 and serine (Ser)473 (Alessi, Andjelkovic et al. 1996). Knock-out 
studies in mice identified the role of each AKT isoform. AKT1 was shown to be 
dispensable for the regulation of glucose homeostasis but facilitates somatic growth in 
mice (Cho, Thorvaldsen et al. 2001). Contrary, Akt2 knock-out (Akt2KO) mice are born 
with mild growth deficiency, loss of pancreatic β-cells and adipose tissue and develop 
severe insulin resistance in liver and skeletal muscle (Cho, Mu et al. 2001; Garofalo, 
Orena et al. 2003). These studies showed that AKT2 is the dominant AKT isoform 
regulating glucose homeostasis through control of insulin sensitivity and maintenance of 
tissue mass in organs involved in glucose homeostasis. AKT1 is the major form regulating 
organismal growth. AKT3 does not play a role in regulating glucose homeostasis but 
controls brain development by influencing cell size and number (Easton, Cho et al. 2005; 
Tschopp, Yang et al. 2005). 
In skeletal muscle, insulin-mediated AKT activation increases glucose uptake and 
induction of glucose storage (Figure 3). Signaling for glucose uptake is facilitated by the 
AKT effector AKT substrate of 160 kDa (AS160) (Bruss, Arias et al. 2005). AKT signaling 
induces phosphorylation of AS160 and subsequent translocalization of GLUT4 to the 
plasma membrane (Sano, Kane et al. 2003). GLUT4 is the major insulin responsive 
glucose transporter in heart, skeletal muscle and adipose tissue (Bell, Murray et al. 
1989). Glucose storage in skeletal muscle is induced through signaling of glycogen 
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synthase kinase (GSK)3. GSK3 is phosphorylated and inactivated by AKT, increasing 
glycogen synthesis in skeletal muscle (Cross, Alessi et al. 1995).  
Similar to skeletal muscle, insulin-mediated AKT activation phosphorylates AS160 and 
subsequent translocates GLUT4 to the plasma membrane in adipocytes (Sano, Kane et 
al. 2003) (Figure 3). However, this tissue contributes only to 3 – 5 % to the whole body 
insulin-dependent glucose uptake (James, Burleigh et al. 1985). The most important 
function of insulin signaling in adipocytes is the induction of lipogenesis and inhibition of 
lipolysis. This could be shown in animals with insulin receptor knock-out in white adipose 
tissue (FIRKO) (Bluher, Michael et al. 2002). These animals are resistant to obesity and 
obesity-induced glucose intolerance, since lipid synthesis in white adipose tissue is 
largely impaired. Insulin regulates lipid metabolism in adipocytes by controlling 
important enzymes, such induction of lipogenesis through AKT-dependent activation of 
fatty acid synthase (FAS) (Wang and Sul 1998) or inhibition of lipolysis through reduction 
of adipose triglyceride lipase (ATGL) or hormone sensitive lipase (HSL) (Kralisch, Klein et 
al. 2005). 
Insulin signaling in the liver is highly relevant for the control of blood glucose levels. This 
could be shown in mice with liver-specific insulin receptor knock-out (LIRKO) (Michael, 
Kulkarni et al. 2000). LIRKO mice exhibit severe glucose intolerance due to unsuppressed 
HGP. Circulating insulin levels of these mice are increased due to a combination of 
insulin resistance and impaired insulin clearance, showing that the liver is also 
responsible for insulin uptake and degradation. Hepatic AKT targets include GSK3, 
increasing glycogen synthesis in liver (Cross, Alessi et al. 1995) (Figure 3). Furthermore, 
AKT inhibits the transcription factors forkhead box protein (FOX)O1 and peroxisome 
proliferator-activated receptor-γ coactivator (PGC)1, leading to inhibition of 
gluconeogenic genes in the liver (Puigserver, Rhee et al. 2003). In addition, insulin 
stimulated AKT signaling is responsible for increased lipid synthesis through activation of 
sterol regulatory element binding protein (SREBP)-1c in the liver (Foretz, Pacot et al. 
1999; Yecies, Zhang et al. 2011). 
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Last, AKT facilitates growth and proliferation signals of insulin (Figure 3). Especially 
pancreatic islets show increased -cell growth in response to AKT activation (Tuttle, Gill 
et al. 2001). Conversely, -cell-specific insulin receptor knock-out (IRKO) decreases -
cell mass in aged mice, showing that autocrine insulin signaling in -cells is necessary for 
increased -cell mass in response to insulin resistance (Kulkarni, Bruning et al. 1999). In 
addition, IRKO mice showed reduced glucose-stimulated insulin release (Kulkarni, 
Bruning et al. 1999), since insulin induces transcription of the insulin and glucokinase 
genes (Leibiger, Leibiger et al. 2001; Meur, Qian et al. 2011). These genes are 
responsible for glucose utilization in -cells. 
 Effects of neuronal insulin signaling 1.1.4
Insulin was the first described peripheral hormone with catabolic effects in the brain 
(Woods, Lotter et al. 1979). Insulin receptors are widely distributed in the brain, 
including areas such as olfactory bulb, cerebellum, hippocampus and hypothalamus 
(Havrankova, Roth et al. 1978; van Houten, Posner et al. 1979; Marks, Porte et al. 1990). 
Deletion of the insulin receptor in neuronal tissues leads to hypertriglyceridemia, 
hyperinsulinemia, hyperphagia, diet-induced obesity and reduced fertility, suggesting 
that central insulin signaling regulates glucose homeostasis, energy homeostasis and 
fertility (Bruning, Gautam et al. 2000).  
Early studies indicated that insulin exerts its effects at least partially through increasing 
expression of melanocortins in the hypothalamus (Benoit, Air et al. 2002). Melanocortins 
are transcribed from a single precursor gene, called pro-opiomelanocortin (Pomc) 
(Nakanishi, Inoue et al. 1979). Besides the pituitary gland, also the hypothalamus is a 
known site of strong Pomc expression (Gee, Chen et al. 1983). Pomc deletion in mice 
and POMC mutations in humans induce severe obesity, emphasizing the role of POMC in 
the regulation of energy homeostasis (Krude, Biebermann et al. 1998; Yaswen, Diehl et 
al. 1999). Besides insulin, also leptin is a potent inducer of Pomc expression (Schwartz, 
Seeley et al. 1997; Mizuno, Kleopoulos et al. 1998) (1.1.6). Insulin signaling induces Pomc 
expression through phosphorylation and inhibition of FOXO1, which is an inhibitor of the 
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Pomc promoter (Kitamura, Feng et al. 2006) (Figure 4). Dissection of insulin-mediated 
effects on energy and glucose homeostasis showed that insulin signaling in 
hypothalamic Pomc-expressing neurons increases locomotor activity (Lin, Plum et al. 
2010). Nevertheless, insulin signaling in Pomc-expressing neurons does not affect body 
weight regulation (Konner, Janoschek et al. 2007; Lin, Plum et al. 2010).  
Further studies indicated that hypothalamic insulin signaling regulates whole body 
glucose homeostasis through inhibition of HGP (Obici, Feng et al. 2002; Obici, Zhang et 
al. 2002). These studies also showed that antagonism of melanocortins does not 
influence insulin-mediated effects on glucose homeostasis, suggesting that other genes 
than Pomc are involved in this process. Early studies showed that insulin decreases 
expression of neuropeptide Y (Npy) (Schwartz, Sipols et al. 1992; Sipols, Baskin et al. 
1995) and insulin-mediated effects on HGP involve reduction of Npy expression (van den 
Hoek, Voshol et al. 2004). Npy is an inducer of obesity by stimulating food intake and 
decreasing energy expenditure (Stephens, Basinski et al. 1995) and insulin as well as 
leptin negatively regulate expression of Npy (Schwartz, Seeley et al. 1996; Korner, 
Savontaus et al. 2001). Insulin-mediated effects on HGP involve opening of ATP-sensitive 
K+-channels, leading to hyperpolarization of Agrp-expressing neurons (Konner, 
Janoschek et al. 2007; Lin, Plum et al. 2010) (Figure 4). Agrp is coexpressed with Npy in 
the same Agrp/Npy-expressing neurons (Hahn, Breininger et al. 1998). Insulin-mediated 
hyperpolarization decreases AGRP release from Agrp/Npy-expressing neurons and leads 
to innervation of the liver (Konner, Janoschek et al. 2007). Insulin-mediated innervation 
of the liver activates signal transducer and activator of transcription (STAT)3 and inhibits 
hepatic glucose-6-phosphatase and subsequent hepatic gluconeogenesis. Agrp/Npy-
expressing neurons inhibit Pomc-expressing neurons through GABA-mediated 
innervation (Cowley, Smart et al. 2001; Tong, Ye et al. 2008), suggesting that insulin-
mediated hyperpolarization of Agrp/Npy-expressing neurons activates Pomc-expressing 
neurons (Figure 4). Similar to Pomc-expressing neurons, also insulin signaling in 
Agrp/Npy-expressing neurons does not affect body weight regulation (Konner, 
Janoschek et al. 2007; Lin, Plum et al. 2010), indicating that body weight regulation is 
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mediated by insulin signaling in other neurons, such as dopaminergic neurons (Konner, 
Hess et al. 2011). 
 
Figure 4: Effects of hypothalamic insulin signaling on energy and glucose homeostasis 
Insulin signaling in 1st order neurons expressing insulin receptor and Agrp (left) leads to 
opening of ATP-sensitive K+-channels and subsequent hyperpolarization. Insulin-
mediated hyperpolarization of Agrp-expressing neurons represses release of 
neurotransmitters, such as NPY, AGRP and GABA. Reduced neurotransmitter release 
signals through 2nd order neurons and hepatic innervation and results in decreased HGP. 
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In Pomc-expressing neurons (right), insulin signaling causes release of -MSH, a 
transcribed protein of the Pomc gene, directly through inhibition of FOXO1 and 
indirectly through inhibited release of NPY, AGRP and GABA. Insulin-mediated -MSH 
release promotes locomotor activity.  
Abbreviations: Agouti-related protein (AGRP); Forkhead box protein O1 (FOXO1); -
aminobutyric acid (GABA); Hepatic glucose production (HGP); Insulin receptor (IR); α-
Melanocyte-stimulating hormone (α-MSH); Neuropeptide Y (NPY); Pro-opiomelanocortin 
(Pomc)  
 Components and regulation of energy homeostasis 1.1.5
Energy homeostasis is regulated by different tissues controlling uptake, digestion, 
circulation and break-down of nutrients. Digested nutrients can be stored for later use 
or broken-down, while exergonic energy is stored and transported in small metabolites, 
such as ATP, guanosine-5'-triphosphate (GTP) and NADH, for short term usage. The 
energy is used for maintaining basal metabolic rate, physical activity and diet-induced 
thermogenesis (Biesalski 2004; Pinheiro Volp, Esteves de Oliveira et al. 2011). The basal 
metabolic rate is the energy necessary for maintenance of all body functions at rest, 
such as chemical reactions, transport processes or involuntary movements. Diet-induced 
thermogenesis includes energy that is used for digestion, absorption and converting of 
nutrients. Physical activity can be separated into exercise and non-exercise activity, 
called non-exercise activity thermogenesis (Levine 2004).  
Since the early 1940s, it became apparent that energy homeostasis is strongly regulated 
by the brain (Brobeck 1946), a picture that was quickly defined by the notion that also 
peripheral signals produced by fat tissue play a role in this regulation (Kennedy 1953). 
The occurrence of genetic mutations in laboratory mice, such as obese (ob) (Ingalls, 
Dickie et al. 1950) and diabetes (db) (Hummel, Dickie et al. 1966), helped to identify 
leptin as an important adipose-derived hormone regulating energy homeostasis (Zhang, 
Proenca et al. 1994) and its regulated networks (Leibel, Chung et al. 1997). Leptin as well 
as insulin are the major hormones regulating energy homeostasis in the brain. The brain 
is responsible for short-term and long-term regulation of food intake and energy 
expenditure (Figure 5). Short-term afferent signals include chemical signals, such as 
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cholecystokinin (CCK), ghrelin and gastrin-releasing peptide (Baile and Della-Fera 1985; 
Figlewicz, Stein et al. 1985; Nakazato, Murakami et al. 2001). Short-term afferent signals 
also include mechanical signals released from the digestive system upon gastrointestinal 
loads. Mechanical signals are transported by vagal afferent neuronal signaling to the 
brain (Schwartz and Moran 1996). In addition, long-term signals, including leptin and 
insulin, modulate food intake as well as energy expenditure by stimulating neurons, 
which mainly originate in the arcuate nucleus (ARC) of the hypothalamus (van Houten, 
Posner et al. 1980; McGowan, Andrews et al. 1992; Satoh, Ogawa et al. 1997). 
Furthermore, cytokines, neuropeptides, circadian rhythms and visceral sensory input 
have been described in regulating energy homeostasis (Larue and Le Magnen 1972; 
Plata-Salaman 1995; Hillebrand, de Wied et al. 2002; Turek, Joshu et al. 2005). These 
afferent signals are detected and processed in multiple areas of the brain, with 
hypothalamus playing a crucial role in regulating energy and glucose homeostasis 
(Figure 5). Further integrating areas include telencephalic, hippocampus and brain stem 
structures (Berthoud 2002). Efferent signals then coming from the brain include 
neuroendocrine responses through hormone release from hypothalamus and pituitary 
gland, autonomic responses via sympathic and parasympathic nerves and cognitive 
responses (Berthoud 2002) (Figure 5). Insulin and leptin are key components of this 
complex neuronal network and development of resistance to these hormones is a 
crucial step in the pathogenesis of obesity and type 2 diabetes (Schwartz and Porte 
2005) (1.2.1). 
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Figure 5: Afferent and efferent hypothalamic signals controlling energy homeostasis 
Afferent signals (black) influence the brain to regulate energy homeostasis. Long-term 
afferent signals include leptin and insulin (left). Short-term afferent signals are food-
related chemical and mechanical signals sensed by the digestive system and transported 
to the brain through vagal afferents (right). All signals are integrated by activation of 
neuropeptides and neurotransmitters in different areas of the hypothalamus, such as 
ARC, VMN, DMN, LatH and PVN, and non-hypothalamic areas including brain stem and 
spinal cord. Efferent signals from the brain (red) include endocrine responses, cognitive 
responses and autonomic control.  Efferent signals regulate energy expenditure, glucose 
homeostasis and food intake.  
Abbreviations: Arcuate nucleus (ARC); Dorsomedial nucleus (DMN); Lateral 
hypothalamus (LatH); Paraventricular nucleus (PVN); Ventromedial nucleus (VMN). 
Modified from (Szarek, Cheah et al. 2010) 
 Leptin signaling in the brain regulates energy homeostasis 1.1.6
In 1950, the spontaneous ob mutation occurred in an inbred mouse strain of the Jackson 
Laboratory, which led to sever obesity and infertility (Ingalls, Dickie et al. 1950). It was 
the first description of a gene associated with obesity. Despite the discovery of more 
genetic mutations leading to obesity in mice (Friedman and Leibel 1992), it was not until 
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1994 that the ob gene was identified to be expressed in white adipose tissue of humans 
and rodents by the group of Jeffrey Friedman (Zhang, Proenca et al. 1994). Later on, the 
ob protein product was termed leptin. Leptin is secreted relative to body fat mass and 
signals for the amount of body fat (Maffei, Halaas et al. 1995). The hormone decreases 
food intake and increase energy expenditure, therefore having negative impact on body 
fat storages (Halaas, Gajiwala et al. 1995). Leptin mediates its effects on energy 
homeostasis through regulation of neuronal networks mainly in the hypothalamic ARC 
(Campfield, Smith et al. 1995; Satoh, Ogawa et al. 1997).  
In 1966, the spontaneous mutation db occurred in the Jacksons Laboratory, leading to 
obesity in mice (Hummel, Dickie et al. 1966). Mice carrying this mutation express an 
abnormally spliced leptin receptor (Lepr) variant, leading to LEPR deficiency (Maffei, Fei 
et al. 1995). Different LEPRs isoforms were identified in several tissues with functions in 
metabolism, angiogenesis, immunity, reproduction and blood pressure regulation 
(Fruhbeck 2001). LEPRs belong to the group of the cytokine receptor superfamily 
(Tartaglia, Dembski et al. 1995). All LEPRs isoforms carry the same extracellular 
sequence but differ in the length of the intracellular domain, which is important for the 
signaling properties of the receptors (Lee, Proenca et al. 1996). The longest isoform, 
LEPRb, plays the most important role in regulating energy and glucose homeostasis in 
the brain with little involvement of the short LEPR isoforms (LEPRa, LEPRc and LEPRd) 
(Osborn, Sanchez-Alavez et al. 2010). The short LEPR isoforms have an important role in 
leptin uptake by the brain and the impairment of leptin uptake into the brain during 
obesity (Hileman, Pierroz et al. 2002). 
LEPRs exist as preformed dimer at the plasma membrane (Figure 6). Binding of leptin 
leads to subsequent conformational changes of the receptor dimers (Devos, Guisez et al. 
1997; Couturier and Jockers 2003). Like all members of the cytokine receptor 
superfamily, LEPRs lack an intrinsic tyrosine kinase domain (Kaczmarski and Mufti 1991). 
The recruitment of intracellular kinases to the LEPRs is therefore necessary for leptin 
receptor signaling. Janus kinase 2 (JAK2) is the main intracellular kinase that 
autophosphorylates upon conformational changes of the LEPRs and phosphorylates 
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tyrosine residues on the LEPRs (Ghilardi and Skoda 1997). This receptor tyrosine 
phosphorylation allows proteins with SH2 domains to bind to the LEPRs (Heim, Kerr et 
al. 1995). The transcription factor STAT3 is one of the most important SH2 domain-
containing proteins binding to the LEPRs at tyrosine residues (Baumann, Morella et al. 
1996; Ghilardi, Ziegler et al. 1996; Vaisse, Halaas et al. 1996). STAT3 is phosphorylated 
by JAK2, dimerizes and translocates to the nucleus, inducing expression of target genes 
such as Pomc (Schwartz, Seeley et al. 1997) and suppressor of cytokine signaling 3 
(Socs3), an inhibitor of leptin receptor signaling (Bjorbaek, El-Haschimi et al. 1999; 
Bjorbak, Lavery et al. 2000). Besides the JAK/STAT signaling pathway, leptin also 
activates other signaling pathways, such as insulin signaling (Kellerer, Koch et al. 1997; 
Zhao, Shinohara et al. 2000; Kitamura, Feng et al. 2006) and MAPK signaling, facilitating 
cell growth, protein synthesis and differentiation (Takahashi, Okimura et al. 1997) 
(Figure 6). 
The most important leptin targets in the regulation of energy homeostasis are cells 
expressing Pomc or Agrp, which are mainly situated in the hypothalamic ARC 
(Jacobowitz and O'Donohue 1978; Pelletier and Desy 1979; Haskell-Luevano, Chen et al. 
1999). In Pomc-expressing neurons, leptin activates STAT3 and inactivates FOXO1 
through phosphorylation of FOXO1 (Kitamura, Feng et al. 2006; Ernst, Wunderlich et al. 
2009) (Figure 6). FOXO1 is an inhibitor of Pomc expression (Kitamura, Feng et al. 2006). 
Leptin-mediated increased expression of Pomc induces expression of the anorexic 
neuropeptide -MSH, the most relevant protein product of the Pomc gene in regards to 
food intake (Tung, Piper et al. 2006). In addition, leptin-mediated STAT3 activation and 
FOXO1 inactivation represses Agrp in Agrp-expressing neurons, inhibiting the expression 
of the orexic neuropeptides AGRP and coexpressed NPY (Muraoka, Xu et al. 2003; 
Kitamura, Feng et al. 2006). Leptin signaling in Pomc- and Agrp-expressing neurons 
reduces food intake and increases energy expenditure. However, mutations of leptin or 
Lepr also affects glucose homeostasis and fertility, showing that leptin also has 
important roles in other than Pomc- and Agrp-expressing neurons (Coleman 1978; van 
de Wall, Leshan et al. 2008). 
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Figure 6: Leptin signaling pathways 
Leptin binds to its preformed receptor dimers in order to recruit intracellular JAK2 
tyrosine kinase. JAK2 autophosphorylates and induces phosphorylation (P) of tyrosine 
residues on the intracellular tail of the leptin receptor, activating the transcription factor 
STAT3. STAT3 is responsible for most of the leptin-induced effects by activating genes 
such as Pomc, translating into the protein product α-MSH, and Socs3. SOCS3 represses 
leptin signaling, providing a negative feedback for the leptin signaling pathway. JAK2 
furthermore activates the insulin signaling pathway by activating PI3K and the MAPK 
pathway, facilitating cell growth and differentiation. In addition, leptin-induced PI3K 
activation inhibits FOXO1 through phosphorylation and translocation to the nucleus. 
FOXO1 is an inhibitor of Pomc expression and an inducer of Agrp expression. 
Abbreviations: Melanocyte-stimulating hormone (α-MSH); V-akt murine thymoma viral 
oncogene homolog (AKT); Forkhead box protein 01 (FOXO1); Janus kinase (JAK); 
Mitogen-activated protein kinase (MAPK); Phosphoinositide-dependent kinase (PDK); 
Phosphatidylinositol 3-kinase (PI3K); Phosphatidylinositol-4,5-diphosphate (PIP2); 
Phosphatidylinositol-3,4,5-trisphosphate (PIP3); Phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN); Suppressors of cytokine signaling 3 (SOSC3); Signal 
transducer and activator of transcription 3 (STAT3) 
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1.2 Type 2 diabetes: mechanisms of insulin resistance and -cell 
failure 
The first clinical symptom of type 2 diabetes is impaired glucose tolerance due to insulin 
resistance (Osei, Rhinesmith et al. 2004; Hong, Gui et al. 2008; Cali, Man et al. 2009). 
Main consequences of insulin resistance are reduced suppression of hepatic 
gluconeogenesis and decreased peripheral glucose uptake in skeletal muscle (DeFronzo, 
Gunnarsson et al. 1985; Consoli, Nurjhan et al. 1989). Elevated pancreatic insulin 
production, reflected in islet hyperplasia, compensates insulin resistance for years 
before the onset of type 2 diabetes (LeRoith 2002). Obesity-induced lipo- and 
glucotoxicity can lead to stress in pancreatic -cells (Robertson, Harmon et al. 2004). 
Eventually, pancreatic -cells fail to produce sufficient amounts of insulin and plasma 
glucose levels dramatically increase, marking the onset of type 2 diabetes (Prentki and 
Nolan 2006). 
 Obesity as a major cause for insulin resistance 1.2.1
Obesity is associated with increased intra-abdominal fat content and decreased insulin 
sensitivity, showing that fat tissue-derived factors are major determents of whole body 
insulin sensitivity (Park, Rhee et al. 1991; Carey, Jenkins et al. 1996). Adipose tissue-
derived factors, which have been implicated to correlate with insulin sensitivity or 
insulin resistance, include FAs and adipokines such as leptin, adiponectin, resistin, tumor 
necrosis factor  (TNF- or interleukin 6 (IL-6) (Hotamisligil, Shargill et al. 1993; Carey, 
Jenkins et al. 1996; Barzilai, Wang et al. 1997; Bastard, Maachi et al. 2002; Kubota, 
Terauchi et al. 2002; Satoh, Nguyen et al. 2004; Yang, Graham et al. 2005). In addition, 
cytokines released from macrophages attracted to adipocytes contribute to obesity-
caused insulin resistance (Weisberg, McCann et al. 2003). Furthermore, ectopic lipid 
accumulation in muscle and liver enhances local cytokine production in these tissues 
(Pan, Lillioja et al. 1997; Fabbrini, Magkos et al. 2009). The increased expression of 
cytokines from adipose tissue, macrophages, liver and skeletal muscle is responsible for 
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a chronic local and systemic inflammation in obesity (Saghizadeh, Ong et al. 1996; Cai, 
Yuan et al. 2005; Wellen and Hotamisligil 2005).  
Gene variations, also called single-nucleotide polymorphisms (SNPs), which have been 
identified to contribute to the development of insulin resistance in type 2 diabetes are 
often associated with their effect on obesity (Li, Zhao et al. 2011). One of the strongest 
associations with obesity has the genetic variation rs9939609 of the fat mass and 
obesity associated (FTO) gene. 16 % of the European and Asian populations are 
homozygous for this SNP and have a 30 % increased risk to become obese or overweight 
(Frayling, Timpson et al. 2007; Zhou, Liu et al. 2012). However, the FTO polymorphism 
exclusively affects type 2 diabetes by influencing obesity (Frayling, Timpson et al. 2007). 
Recent studies implicated that FTO regulates food intake by controlling oxytocin 
(Olszewski, Fredriksson et al. 2009; Tung, Ayuso et al. 2010; Olszewski, Fredriksson et al. 
2011), a protein with previously described functions in food intake (Kublaoui, Gemelli et 
al. 2008). One of the most common risk alleles affecting release of adipose-derived 
factors is an alanine to proline substitution in codon 12 of the gene peroxisome 
proliferator-activated receptor G2 (PPARG2) Around 85 % of the population are carriers 
of the proline allele of PPAR, which is associated with a 1.25 fold risk increase for type 
2 diabetes (Altshuler, Hirschhorn et al. 2000). PPARG2 is exclusively expressed in 
adipocytes and the low risk alanine allele of PPAR suppresses insulin-mediated release 
of FAs and secretion of TNF-, resistin and adiponectin (Stumvoll and Haring 2002).  
Cytokines and FAs derived from adipose tissue are inducers of serine/threonine kinases 
(Figure 7) (Hotamisligil, Peraldi et al. 1996; Paz, Hemi et al. 1997). Phosphorylation of 
serine residues on IRS1 and IRS2 through serine/threonine kinases is a central step in 
the development of insulin resistance. Serine phosphorylation of IRS1 and IRS2 inhibits 
tyrosine phosphorylation of both IRS isoforms and subsequent insulin signaling (Paz, 
Hemi et al. 1997). Serine phosphorylation of IRS is mediated by serine/threonine kinases 
like c-Jun NH(2)-terminal kinase (JNK) (Aguirre, Uchida et al. 2000), protein kinase C zeta 
(PKCζ) (Liu, Paz et al. 2001), inhibitor of kappaB kinase beta (IKK) (Gao, Hwang et al. 
2002), mitogen-activated protein kinase p38 (p38 MAPK) (de Alvaro, Teruel et al. 2004) 
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or mechanistic target of rapamycin (mTOR) (Ozes, Akca et al. 2001). SOCS3 is a target of 
cytokine signaling with inhibitory function on tyrosine IRS phosphorylation (Emanuelli, 
Peraldi et al. 2001). IRS1 activity can also be influenced by genetic variations (Ohshige, 
Iwata et al. 2011). The most common risk locus for IRS1 is rs2943641, situated 500 kb 
upstream of IRS1 (Rung, Cauchi et al. 2009). The risk cytosine allele of IRS1 is associated 
with decreased IRS1 protein expression and reduced insulin-mediated PI3K activation 
(Rung, Cauchi et al. 2009). The cytosine allele increases the risk for type 2 diabetes 
about 15 - 35 % (Rung, Cauchi et al. 2009; Ohshige, Iwata et al. 2011).  
Reduced insulin signaling causes hyperglycemia in type 2 diabetic patients mainly by 
decreasing suppression of hepatic gluconeogenesis (Consoli, Nurjhan et al. 1989; 
Mitrakou, Kelley et al. 1990; Meyer, Woerle et al. 2004) (Figure 7). In accordance, LIRKO 
mice are severely insulin resistant and hyperglycemic (Michael, Kulkarni et al. 2000). 
Although hepatic gluconeogenesis is increased by reduced insulin signaling, insulin-
mediated stimulation of hepatic fatty acid synthesis is maintained through induction of 
the transcription factor SREBP-1c (Shimomura, Matsuda et al. 2000). Increased hepatic 
fatty acid synthesis can lead to non-alcoholic fatty liver disease (NAFLD), a disease often 
diagnosed in obese and diabetic patients (Angulo and Lindor 2002). In skeletal muscle, 
type 2 diabetes patients show normal or increased glucose uptake compared to non-
diabetic patients despite an insulin resistant state (DeFronzo, Gunnarsson et al. 1985; 
Consoli, Nurjhan et al. 1989; Mitrakou, Kelley et al. 1990; Meyer, Woerle et al. 2004). 
These studies are in line with studies on mice with muscle-specific insulin receptor 
knock-out (MIRKO) (Bruning, Michael et al. 1998). MIRKO mice are normoglycemic and 
have normal glucose tolerance and circulating insulin levels. However, in skeletal muscle 
from type 2 diabetes patients, glucose uptake is not appropriate for increased plasma 
glucose concentrations (DeFronzo, Gunnarsson et al. 1985; Cusi, Maezono et al. 2000). 
Therefore, insulin resistance in hepatic and non-hepatic tissues contributes to the 
development of hyperglycemia in type 2 diabetes (Figure 7).  
24  Introduction 
 
Figure 7: Serine phosphorylation of IRS causes insulin resistance 
The above explained insulin cascade (Figure 3) is inhibited by FAs and cytokines derived 
from adipose tissue, macrophages and ectopic lipid accumulation in muscle and liver. 
Cytokines and FAs activate serine/threonine kinases, such as IKK, JNK, p38 MAPK, PKC 
or mTOR. Serine/threonine kinases phosphorylate serine (S) residues on IRS1 and IRS2, 
inhibiting tyrosine (Y) phosphorylation of IRS. Subsequent insulin signaling cascades are 
impaired, resulting in decreased glucose uptake and glycogen synthesis and enhanced 
food intake, HGP and hepatic gluconeogenesis. Resulting hyperglycemia can partially be 
rescued by increased insulin secretion from pancreatic -cells until -cells fail to produce 
sufficient amounts of insulin and type 2 diabetes develops. 
Abbreviations: V-akt murine thymoma viral oncogene homolog (AKT); Diacylglycerol 
(DAG); Fatty acids (FA); Hepatic glucose production (HGP); Inhibitor of kappaB kinase 
beta (IKK); Insulin receptor substrate (IRS); c-Jun NH(2)-terminal kinase (JNK); Mitogen-
activated protein kinase p38 (p38 MAPK); Mechanistic target of rapamycin (mTOR); 
Phosphoinositide-dependent kinase (PDK); Protein kinase C zeta (PKCζ); Phosphatase 
and tensin homologue deleted on chromosome 10 (PTEN); Phosphatidylinositol 3-kinase 
(PI3K); Serine (S); Suppressor of cytokine signaling 3 (SOCS3); Threonine (T); Tyrosine (Y) 
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Obesity-induced insulin resistance is also evident in the central nervous systems (CNS), 
mainly in the hypothalamus (De Souza, Araujo et al. 2005; Zhang, Zhang et al. 2008; 
Posey, Clegg et al. 2009). Similar to peripheral insulin resistance, hypothalamic insulin 
resistance is induced by local cytokine production and subsequent activation of 
serine/threonine kinases (De Souza, Araujo et al. 2005; Posey, Clegg et al. 2009). 
Impaired hypothalamic insulin signaling increases food intake, further worsening the 
progression of obesity-caused insulin resistance and type 2 diabetes (De Souza, Araujo 
et al. 2005; Posey, Clegg et al. 2009) (Figure 7). Furthermore, hypothalamic insulin 
resistance is associated with impaired regulation of glucose homeostasis through 
induction of hepatic insulin resistance (Belgardt, Mauer et al. 2010; Purkayastha, Zhang 
et al. 2011) and impaired pancreatic insulin release (Calegari, Torsoni et al. 2011). 
 Obesity and genetic predispositions cause -cell failure 1.2.2
Insulin resistance, the failure of the body to react to insulin appropriate, is usually 
induced by obesity and is the first step in the development of type 2 diabetes (1.2.1). 
Enhanced insulin release from pancreatic -cells compensates obesity-induced insulin 
resistance for years (Rhodes 2005). Increased -cell growth, called islet hyperplasia, 
caused by mechanisms such as enhanced -cell survival and proliferation, is essential for 
compensation of insulin resistance (Jetton, Lausier et al. 2005). Elevation of insulin 
release per -cell, through mechanisms such as increased glucose sensitivity or 
increased glucose metabolism, further plays an important role in insulin resistance 
compensation (Chen, Hosokawa et al. 1994; Liu, Jetton et al. 2002).-cell compensation 
of insulin resistance normalizes blood glucose concentration completely or almost 
completely (LeRoith 2002; Poitout, Amyot et al. 2010). However, -cell compensation 
fails in obese patients with susceptible pancreatic -cells (Osei, Rhinesmith et al. 2004; 
Hong, Gui et al. 2008; Cali, Man et al. 2009).  
In susceptible pancreatic -cells, obesity-induced elevated circulating FAs and glucose 
concentrations induce gluco- and lipotoxicity. Glucotoxicity is caused by enhanced 
intracellular glucose levels, which are metabolized through anaerobic glycolysis, 
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glycosylation, glucose autoxidation and the glucosamine pathway (Robertson, Harmon 
et al. 2003). These processes form reactive oxygen species (ROS), which have a high 
potential for cellular damage. Similar, also metabolism of FAs, which are elevated in the 
blood stream of obese patients (1.2.1), cause the production of ROS, a process called 
lipotoxicity (Robertson, Harmon et al. 2004). Low levels of antioxidant enzymes in 
pancreatic -cells make the insulin release process vulnerable for oxidative stress 
(Robertson, Harmon et al. 2003). The loss of pancreatic and duodenal homeobox 1 
(PDX1), an important transcription factor regulating the insulin gene, and increased 
apoptosis through increased nuclear factor kappa B (NFB) activity are two of many 
possible molecular consequences of glucose toxicity and lipotoxicity  (Robertson, 
Harmon et al. 2003). Eventually, glucolipotoxicity enhances apoptosis and leads to -cell 
failure and subsequently dramatically increased blood glucose levels, marking the onset 
of type 2 diabetes (Butler, Janson et al. 2003). 
Susceptibility to -cell failure is largely influenced by genetic predisposition, accounting 
for more than 50 % (Nolan, Damm et al. 2011). Most of the gene variations involved in 
the pathogenesis of type 2 diabetes regulate pancreatic -cell maturation or insulin 
secretion (Bonnefond, Froguel et al. 2010; Nolan, Damm et al. 2011; Ashcroft and 
Rorsman 2012). Through employment of large-scale, high-resolution genome-wide 
association studies (GWAS), risk SNPs in many human genes have been identified, such 
as  KCNJ11, TCF7L2, WFS1, HNF1B, SLC30A8, CDKAL1 or IGF2BP2 (Nolan, Damm et al. 
2011). One of the strongest risk alleles for type 2 diabetes was found in the gene 
transcription factor 7-like 2 (TCF7L2). The strongest risk SNP of TCF7L2, thymine 
rs7903146, decreases glucose-mediated insulin secretion, increasing the risk for type 2 
diabetes about 50 % (Grant, Thorleifsson et al. 2006; Saxena, Gianniny et al. 2006). 
TCF7L2 is an crucial component in the WNT signaling pathway, effecting transcription of 
many genes during embryogenesis and adulthood (Jin and Liu 2008). TCF7L2 and other 
so far identified genetic variations associated with increased type 2 diabetes risk explain 
only 10 % of the heritability of the disease, leaving room for future investigations aiming 
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to identify rare genetic variations and genetic variations with small effects on the 
progression of type 2 diabetes (Herder and Roden 2011). 
Type 2 diabetes can also be caused by genetic mutations in one of the essential genes 
for the insulin release machinery. This monogenic diabetes, called maturity onset 
diabetes of the young (MODY), effects 1 - 2 % of all diabetic patients  and occurs shortly 
after birth or during childhood (Bonnefond, Froguel et al. 2010). Despite the low 
relevance for the pathophysiology of type 2 diabetes, human monogenic diabetes 
helped to improve the understanding of the molecular basis of insulin secretion. These 
findings include genes responsible for the development of pancreatic -cells, such as 
PDX1 (MODY4) (Stoffers, Zinkin et al. 1997), neurogenic differentiation 1 (NeuroD1, 
MODY6) (Malecki, Jhala et al. 1999) or paired box gene 4 (PAX4, MODY 9) (Smith, 
Watada et al. 2000), as well as genes responsible for controlling insulin secretion, such 
as hepatocyte nuclear factor 4α (Hnf-4, MODY1) (Herman, Fajans et al. 1997) or 
hepatocyte nuclear factor 1α (Hnf-1, MODY3) (Shih, Screenan et al. 2001). Also genes 
for glucose uptake and break-down, such as glucokinase (GCK, MODY2) (Vionnet, Stoffel 
et al. 1992), and genes encoding membrane channels, such as potassium inwardly-
rectifying channel (KCNJ11) and ATP-binding cassette transporter sub-family C member 8 
(ABCC8) (Gloyn, Weedon et al. 2003), are known to  be mutated in diabetic patients and 
improved the understanding of the mechanisms of insulin release. 
 MiR-375-targeted CADM1 expression in type 2 diabetes  1.2.3
MicroRNAs (miRNAs) are RNAs, consisting of about 21 nucleotides, and are repressors of 
posttranscriptional gene expression (Bartel 2004; Krol, Loedige et al. 2010). Expression 
of many miRNAs is regulated in obesity and miRNA-regulated genes contribute to the 
development of type 2 diabetes (Zhao, Keller et al. 2009), opening the possibility that 
miRNAs play an essential role in the pathophysiology of type 2 diabetes. So far, many 
miRNAs have been identified with a role in -cell apoptosis (miR-34a, miR-146) (Lovis, 
Roggli et al. 2008), insulin expression (miR-24, miR-26, miR-182, miR-148) (Melkman-
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Zehavi, Oren et al. 2011) or glucose-stimulated insulin secretion (miR-369-5p, miR-130a, 
miR-27a, miR-410, miR-200a, miR-337) (Williams and Mitchell 2012). 
MiR-375 is the highest expressed miRNA in pancreatic islets (Poy, Eliasson et al. 2004). 
MiR-375 expression negatively correlates with glucose-induced insulin secretion in vivo 
and in vitro (Poy, Eliasson et al. 2004; Poy, Hausser et al. 2009). In addition, miR-375 
knock-out (miR-375KO) mice exhibit reduced pancreatic -cell mass due to impaired 
proliferation (Poy, Hausser et al. 2009), showing that miR-375 is a regulator of 
pancreatic -cell growth and function. MiR-375 expression is regulated in islets from 
hyperplastic ob/ob mice, diabetic rats and diabetic patients, further emphasizing a 
possible role of this miRNA in the development of type 2 diabetes (El Ouaamari, Baroukh 
et al. 2008; Poy, Hausser et al. 2009; Zhao, Guan et al. 2010). Recent investigations 
showed that pyruvate dehydrogenase kinase 1 (PDK1) is one target of miR-375 (El 
Ouaamari, Baroukh et al. 2008). Increased miR-375 expression reduces PDK1 expression 
and subsequent induction of insulin gene expression and DNA synthesis. In addition to 
PDK1, miR-375 also regulates expression of cell adhesion molecule (CADM)1 (Poy, 
Hausser et al. 2009). The exact role of CADM1 in pancreatic islets has not been fully 
established (1.3.2). However, the targeting of CADM1 by miR-375 suggests that CADM1 
might be involved the miR-375-mediated effects on -cell growth and pancreatic insulin 
secretion. 
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1.3 Cell adhesion molecule 1 (CADM1) 
Cell adhesion molecules are proteins targeting cells to their specific locations by 
facilitating cell to cell or cell to matrix interactions. In addition, cell adhesion molecules 
have important roles in signaling within and between cells, influencing processes such as 
growth, cell differentiation or vesicle trafficking. CADM1 belongs to a family of calcium-
independent cell adhesion molecules that is characterized by immunoglobulin (Ig)-like 
domains and therefore called immunoglobulin superfamily (IgSF) (Bork, Holm et al. 
1994). The Ig-like domain functions as a binding domain, facilitating protein to protein or 
protein to ligand interactions, regardless of the function of the protein inheriting the Ig-
like domain. The founding members of the IgSF are immunoglobulins, also called antigen 
receptors or antibodies. Additional, Ig-like domains can be found in a vast amount of 
protein families, which function as cell surface receptors, matrix proteins, enzymes or 
cell adhesion molecules.  
The CADM protein family consist of four members termed  CADM1, CADM2, CADM3 and 
CADM4 (Biederer 2006). The proteins of the CADM family have been described by 
several independent groups, giving them different names. Although CADM has been 
accepted as the official symbol, early names such as synaptic cell adhesion molecule 
(SynCAM), spermatogenic immunoglobulin superfamily (SgIgSF), tumor suppressor in 
lung cancer (TSLC), nectin-like protein (NECL) or immunoglobulin superfamily member 
(IgSF) have still been used in recent publications. The individual names for each CADM 
protein are referenced elsewhere (Pietri, Easley-Neal et al. 2008). 
Like other IgSF proteins, the proteins of the CADM family contain three Ig-like domains 
at the extracellular N-terminus (Figure 8). These Ig-like domains are formed by 
repetitive antiparallel -strands in a loop-like structure and stabilized by sulphydryl 
bridges (Gomperts, Kramer et al. 2003). The Ig-like domains facilitate homophilic binding 
between each CADM protein to itself or heterophilic binding between CADM1 and 2 or 
CADM3 and 4. The binding affinity between the CADM proteins is regulated by the 
degree of N-glycosylation of the Ig-like domains (Fogel, Akins et al. 2007). Furthermore, 
the Ig-like domains allow a lateral self-assembly of CADM1 as cis oligomers, which 
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enhances trans-binding of CADM1 from cell to cell (Fogel, Stagi et al. 2011). Lastly, the 
Ig-like domains have been described in mediating binding of CADM proteins to growth 
factor receptors, such as epidermal growth factor receptors (EGFR) (Kawano, Ikeda et al. 
2009). 
The first description of CADM1 as a cell adhesion molecule came from in vitro cell 
studies, where CADM1 was found to be expressed at boundaries between non-polarized 
cells as well as at the basolateral membrane of polarized cells (Masuda, Yageta et al. 
2002). Later on, these results could be confirmed in vivo in murine lung and gall bladder 
epithelium (Fujita, Soyama et al. 2003; Shingai, Ikeda et al. 2003). In addition, these 
studies showed that CADM1 is expressed outside of specialized cell to cell junctions, 
such as tight-, adherens- and gap junctions. In the following years, CADM1 expression 
was confirmed between several different cell types such as nerve to nerve (Biederer, 
Sara et al. 2002), nerve to mast cell (Ito, Hagiyama et al. 2008), nerve to astrocytes 
(Sandau, Mungenast et al. 2011), smooth to mast cell (Ito, Hagiyama et al. 2008), mast 
cell to fibroblasts (Ito, Jippo et al. 2003), epidermal to epidermal cells (Giangreco, Jensen 
et al. 2009), spermatogenic cells to Sertoli cells (van der Weyden, Arends et al. 2006) 
and tumor cells to lymphocytes (Boles, Barchet et al. 2005). The respective functions of 
CADM1 seems to be largely dependent on the expressing cell type and include roles in 
synaptogenesis, tumor suppression, fertility, epithelial structure formation and 
cytotoxicity (Murakami 2005). The most relevant CADM1 functions for this work are 
explained in the following sections.  
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Figure 8: CADM1 protein interactions at the synapse 
CADM1 (blue) is expressed at the pre- (top) and postsynaptic (bottom) membrane 
spanning the synaptic cleft. Each CADM1 molecule is clustered to itself in cis-binding, 
enhancing binding to CADM1 molecules bound to the opposing cell type in trans-
conformation. Cis- and trans-binding is facilitated by immunoglobulin (Ig)-like domains 
(blue ovals) at the extracellular part of CADM1. The intracellular PDZ-binding domain of 
CADM1 can bind to proteins with corresponding PDZ domains, such as MUPP1. MUPP1 
binds to GABBR2 in inhibitory neurons or SynGAP in excitatory neurons. SynGAP further 
binds to glutamate receptors in excitatory neurons. Other binding partners of CADM1 
with PDZ domains include CASK and MINT1. MINT1 and CASK recruit Ca2+ channels 
which are important for release of synaptic vesicles. MINT1 can also bind to MUNC18-1, 
which is directly involved in synaptic vesicle fusion. The intracellular part of CADM1 can 
bind to protein 4.1N via its protein 4.1-binding domain to recruit glutamate receptors at 
the postsynaptic membrane.  
Abbreviations: Cell adhesion molecule 1 (CADM1); Calcium/calmodulin-dependent 
serine protein kinase (CASK); -aminobutyric acid receptor B receptor 2 (GABBR2); 
Munc-18-interacting protein (MINT1); Mammalian uncoordinated-18-1 (MUNC18-1); 
Multiple PDZ domain protein 1 (MUPP1); Synaptic Ras GTPase activating protein 1 
(SynGAP) 
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 CADM1 as an enhancer of synaptic function 1.3.1
All four CADM proteins are highly expressed during embryonic and postnatal 
development in several parts of the nervous system. In addition, CADM1 shows a lower 
expression in peripheral tissues, such as lung and testis (Fogel, Akins et al. 2007). Early 
studies identified CADM1 as inducer of synaptic transmissions when being 
overexpressed together with the glutamate receptor 2 (GluR2) (Biederer, Sara et al. 
2002). Later on, it was shown that the CADM proteins are highly enriched in pre- and 
postsynaptic membranes especially two weeks after birth, when synapse formation 
peaks (Fogel, Akins et al. 2007). In addition, CADM1 negatively regulates the structural 
complexity and number of synapses during postnatal synaptogenesis (Stagi, Fogel et al. 
2010). It is therefore thought that regulation of synaptogenesis in the nervous system 
during development is one of the main functions of the CADM family. It was 
furthermore shown that adult Cadm1 deficient mice have increased spatial learning and 
altered synaptic plasticity (Robbins, Krupp et al. 2010). Synaptic plasticity is a process 
altering synaptic strength and efficacy in response to synaptic activity and is important 
for cognitive tasks, such as spatial learning. The studies by Robbins et al. also showed 
that CADM1 influences the number of excitatory synapses, while inhibitory synapses are 
not regulated by this protein. CADM1 therefore plays an important role in regulating 
synaptic connections and synaptic efficacy also in adult rodents, mainly by regulating 
excitatory synapses. 
Several putative binding partners of CADM1 have been identified, which might explain 
how CADM1 influences synaptic formation and function. The cytoplasmic tail of CADM1 
contains a post synaptic density-95/disc large/zonula occludens-1 (PDZ)-binding domain 
(Biederer, Sara et al. 2002; Fogel, Akins et al. 2007). Putative CADM1 binding partners 
with PDZ domains include multiple PDZ domain protein 1 (MUPP1) (Fujita, Tanabe et al. 
2012) (Figure 8). MUPP1 interacts with GABA B receptor 2 (GABBR2) in postsynaptic 
inhibitory neurons or synaptic Ras GTPase activating protein 1 (SynGAP) in postsynaptic 
excitatory neurons (Krapivinsky, Medina et al. 2004; Balasubramanian, Fam et al. 2007). 
SynGAP further binds to glutamatergic N-methyl-D-aspartate receptors (NMDAR). 
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Although the exact physiological role of CADM1 binding to MUPP1 has not been 
established, CADM1 might positively regulate neurotransmitter receptor signaling at 
postsynaptic membranes by stabilizing the respective receptor complexes. Other 
putative CADM1 binding partners with PDZ domains include calcium/calmodulin-
dependent serine protein kinase (CASK) and munc-18-interacting protein 1 (MINT1) 
(Biederer, Sara et al. 2002) (Figure 8) . MINT1 displays one possible link between CADM1 
and its function as enhancer of synaptic activity, since MINT1 binds to mammalian 
uncoordinated-18-1 (MUNC18-1), an essential protein in synaptic neurotransmitter 
release (Biederer and Sudhof 2000). Furthermore, VELI, CASK and MINT1 form a 
tripartite complex, which localizes and stabilizes cell surface and signaling proteins, such 
as -neurexins. The -neurexins-neuroligins binding is known to facilitate 
synaptogenesis at the postsynaptic membrane (Graf, Zhang et al. 2004). In addition, 
MINT1 and CASK are known to recruit Ca2+ channels, which are important for synaptic 
vesicle release (Maximov, Sudhof et al. 1999) (Figure 8).  
Besides the PDZ-binding domain, the intracellular c-terminus of CADM1 contains a 
highly conserved protein 4.1-binding domain (Biederer 2006), which might be involved 
in the CADM1-mediated regulation of synaptic growth and function. The protein 4.1-
binding domain binds to protein 4.1N, which recruits excitatory glutamate receptors in 
vitro (Hoy, Constable et al. 2009) (Figure 8). In addition, FERM, RhoGEF (Arhgef) and 
pleckstrin domain protein 1 (Farp1), a regulator of synapse complexity and number, was 
recently identified to bind to the protein 4.1-binding domain of CADM1 (Cheadle and 
Biederer 2012). 
 CADM1 and type 2 diabetes 1.3.2
A role of CADM1 in type 2 diabetes has not been investigated yet. However, recent 
investigation highlighted a potential role of CADM1 in pancreatic islets. Obesity-induced 
insulin resistance is compensated by enhanced insulin secretion and the failure of -cells 
to produce sufficient insulin amounts marks the onset of type 2 diabetes (1.2). In 
pancreatic -cells, insulin resistance increases glucagon production, which contributes 
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to hyperglycemia of diabetic patients through enhanced HGP (Hamaguchi, Fukushima et 
al. 1991). 
CADM1 was detected in all four cell types of the pancreatic islet in humans, whereas 
murine islets were reported to express CADM1 in - and -cells only (Koma, Furuno et 
al. 2008). In contrast, other studies identified CADM1 in murine -cells, although to a 
lesser degree than in non-cells (Suckow, Comoletti et al. 2008; Shimada, Tachibana et 
al. 2012). In human-cells, CADM1 seems to be involved in insulin secretion, since 
CADM1 expression correlates with hormone function in human islet cell tumors (Koma, 
Furuno et al. 2008). In addition, CADM1 was proposed in these studies to be important 
in cell to cell contact within pancreatic islets. In rodent-cells, recent studies identified 
CADM1 as inhibitor of glucagon release through mediation of communication between 
-cells (Ito, Ichiyanagi et al. 2012).  
Furthermore, CADM1 expression was identified in neuronal crest cells in pancreatic 
islets (Shimada, Tachibana et al. 2012). Neuronal crest cells are important for the 
maturation of pancreatic -cells and they are progenitors of the nervous system, such as 
autonomic nerves (Shimada, Tachibana et al. 2012). - and -cells expressing CADM1 
were found in close proximity to CADM1 expressing neuronal crest cells, suggesting that 
CADM1 facilitates binding between endocrine and neuronal cells in pancreatic islets. 
However, the exact role of CADM1 mediating these interactions has not been 
established.  
 CADM1 and its role in autism 1.3.3
Two missense mutations in the CADM1 gene were found in patients with autism 
spectrum disorder (ASD) (Zhiling, Fujita et al. 2008). ASD is an inherited 
neurodevelopmental disorder characterized by impaired social interaction and impaired 
communication as well as repetitive behavior (American Psychiatric Association 2011). 
The disease is linked to mutations in many different genes causing alterations in 
synaptogenesis and neuronal development (Persico and Bourgeron 2006). The missense 
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mutations in the CADM1 gene translate into mutations in the Ig-like domain of CADM1, 
weakening its extracellular binding and leading to increased intracellular CADM1 
accumulation and degradation (Zhiling, Fujita et al. 2008). 
Features of the human ASD phenotype were observed in Cadm1 deficient mice. Besides 
impaired social behavior, Cadm1KO mice have increased anxiety behavior and impaired 
motor function (Takayanagi, Fujita et al. 2010). Furthermore, Cadm1 deficient pups 
showed decreased postnatal ultrasonic vocalizations (USVs), a phenotype which 
resembles language impairments in autistic humans (Boucher 2012; Fujita, Tanabe et al. 
2012). CADM1 is well expressed in Purkinje cells of the cerebellum and dendrite 
development of these cells is impaired in Cadm1 deficient mice (Thomas, Akins et al. 
2008; Fujita, Tanabe et al. 2012). Loss of cerebellar Purkinje cells was also found in ASD 
patients and in mice with autistic-like behavior (Ritvo, Freeman et al. 1986; Fatemi, Halt 
et al. 2002; Martin, Goldowitz et al. 2010; Tsai, Hull et al. 2012). CADM1 is furthermore 
known to bind to MUPP1, which interacts with GABBR2, in the cerebellum of mice 
(Fujita, Tanabe et al. 2012). This interaction is postulated to stabilize the synaptic 
MUPP1–GABBR2 complex. These studies also showed that GABBR2 expression is altered 
in the cerebellum of Cadm1 deficient mice, similar to autistic patients (Fatemi, Folsom et 
al. 2009). Alterations in GABBR2 expression in the absence of CADM1 are therefore 
thought to induce autistic-like behavior in humans and mice (Fujita, Tanabe et al. 2012).   
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1.4 Objectives 
The pathogenesis of type 2 diabetes is marked by obesity-induced insulin resistance and 
-cell failure. The ability of the pancreas to meet increased insulin demands by induction 
of islet hyperplasia determines whether type 2 diabetes develops in obese patients. 
MiR-375, the highest expressed miRNA in the pancreas, is an important regulator of 
hyperplasia as well as insulin secretion. MiR-375 is therefore expected to influence the 
pathogenesis of type 2 diabetes. CADM1 is one of the genes targeted by miR-375. 
Nevertheless, the molecular mechanisms how miR-375 regulates -cell mass and 
function and the contribution of miR-375-targeted CADM1 expression to these 
processes have not been understood yet. The pathogenesis of type 2 diabetes is strongly 
influenced by the brain through regulation of energy homeostasis and subsequent 
resistance or susceptibility to obesity as well as through regulation of glucose 
homeostasis. Besides its expression in pancreatic -cells, CADM1 is also highly expressed 
in several parts of the brain. So far, a role of CADM1 in the regulation of energy or 
glucose homeostasis in the brain or pancreatic -cells has not been investigated.  
The aim of this work is to evaluate the influence of CADM1 in peripheral and central 
tissues of the body on glucose and energy homeostasis. For this, it will be addressed 
whether CADM1 influences sensitivity to insulin or leptin, the most important hormones 
in the regulation of glucose and energy homeostasis. Furthermore, the role of CADM1 in 
pancreatic insulin release will be investigated. Ultimately, the studies should uncover 
the role of CADM1 in the development of type 2 diabetes.  
First, it will be questioned if CADM1 influences energy and glucose homeostasis by 
investigating the phenotype of mice completely deficient for Cadm1 (Cadm1KO). These 
studies include analyses of body weight and body composition as well as measurements 
of energy intake and energy expenditure. In addition, insulin and glucose sensitivity will 
be analyzed in Cadm1KO mice and glucose sensitivity in Cadm1-depleted pancreatic -
cells to evaluate the effects of CADM1 on glucose homeostasis. Second, it will be studied 
whether CADM1 influences the susceptibility to obesity and insulin resistance by 
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induction of obesity in Cadm1 deficient mice through genetic modification or high fed 
diet feeding and subsequent analyses of energy and glucose homeostasis as above. 
Third, the role of CADM1 in energy and glucose homeostasis in neuronal tissues will be 
addressed by analyzing mice with Cadm1 deficiency specifically in neuronal and glia cells 
for changes in energy and glucose homeostasis. These studies will help to narrow the 
mechanisms of CADM1 action on energy and glucose homeostasis. 
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2 Materials and Methods 
2.1 Animal Experiments 
 Mouse lines 2.1.1
Mice carrying a Cadm1 null allele and conditional Cadm1 allele (Cadm1lox/lox) mice were 
kindly provided by Allan Bradley (Wellcome Trust Genome Campus, Cambridge, UK) (van 
der Weyden, Arends et al. 2006). Mice heterozygous for the Cadm1 null allele on a 
mixed 129/Sv - C57BL/6 background were backcrossed on C57BL/6N mice (Charles River 
Laboratories, Inc., Wilmington, USA) for four generations before using them for 
experiments. Breeding colonies were maintained by intercrossing mice heterozygous for 
the Cadm1 null allele. Resulting mice homozygous for the Cadm1 null allele (Cadm1KO) 
were compared to gender-matched littermates heterozygous or wild-type for the 
Cadm1 null allele (control) unless otherwise stated. Multiple litters were analyzed for 
each experiment in order to reduce background effects. 
For generating mice expressing POMC-enhanced green fluorescent protein (eGFP) cells 
(Cowley, Smart et al. 2001), homozygous mice for the Cadm1 null allele were crossed to 
C57BL/6J-Tg(POMC-EGFP)1Low/J mice (The Jackson Laboratory, Bar Harbor, USA). 
Breeding colonies were maintained by crossing male mice heterozygous for the Cadm1 
null and positive for POMC-eGFP transgene with female mice homozygous for the 
Cadm1 null allele. Neurons from resulting mice deficient for Cadm1 and positive for 
POMC-eGFP (Cadm1KO POMC-eGFP) were compared to neurons from gender-matched, 
littermate control mice heterozygous for the Cadm1 null allele and positive for POMC-
eGFP (control POMC-eGFP). 
To generate mice deficient for Cadm1 and leptin (Cadm1/ob), B6.V-Lepob/J mice were 
purchased (The Jackson Laboratory, Bar Harbor, USA) and crossed to female Cadm1KO 
mice. Breeding colonies were maintained by crossing male mice heterozygous for the 
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Cadm1 null and ob allele with female mice homozygous for the Cadm1 null allele and 
heterozygous for the ob allele. Resulting mice deficient for ob and Cadm1 (Cadm1/ob) 
were compared to gender-matched, littermate control mice deficient for ob and 
heterozygous for the Cadm1 null allele (ob/ob). 
For generating tissue specific Cadm1 deficient mice, B6.Cg-Tg(Nes-cre)1Kln/J (NesCre) 
and B6.129-Leprtm2(cre)Rck/J (LepRCre) were purchased (The Jackson Laboratory, Bar 
Harbor, USA). These lines were crossed to Cadm1lox/lox animals. Breeding colonies were 
maintained by crossing Cadm1lox/+ cre+ with Cadm1lox/lox cre— mice. Gender-matched, 
littermate Cadm1+/+ and Cadm1lox/+ mice were used as controls (control) for tissue 
specific Cadm1 deficient mice (Cadm1NesCreKO, Cadm1LeprCreKO). Mice expressing cre 
recombinase were included as controls to avoid differences due to phenotypic effects of 
cre expression. For Cadm1NesCreKO mice, only control mice carrying cre recombinase 
were used, since mice carrying the NesCre transgene are known to have a 
hypopituitarism phenotype (Galichet, Lovell-Badge et al. 2010). 
To visualize LeprCre expression, LepRCre mice were crossed to B6.129X1-
Gt(ROSA)26Sortm1(EYFP)Cos/J, which carry yellow fluorescent protein (YFP) under the control 
of the ubiquitously expressed Rosa26 promoter (Rosa26-YFP) and were kindly provided 
by Prof. Kai Schmidt-Ott, Max-Delbrück-Centrum (MDC) für Molekulare Medizin, Berlin-
Buch. Breeding colonies were maintained by crossing mice carrying Rosa26-YFP with 
mice carrying LepRCre and Rosa26-YFP. Resulting animals carrying LepRCre and Rosa26-
YFP were used for immunohistochemistry. 
All mice were housed in pathogen-free facilities in a 12 h light/dark cycle with light on 
from 7 am till 7 pm and fed ad libitum on CHOW diet with 11 % of calories from fat 
(ssniff Spezialdiäten GmbH Soest, Germany; M-Z V1124-0;) unless otherwise stated. For 
high fat diet (HFD) experiments, control and Cadm1KO animals were fed HFD with 56 % 
of calories from fat (ssniff Spezialdiäten GmbH Soest, Germany; EF R/M acc. D12492 
mod.), starting between 4 and 7 weeks of age. Gender-matched littermates 
heterozygous or wild-type for the Cadm1 null allele were used as control animals 
(control) unless otherwise stated.  
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 Collection and analysis of blood parameters 2.1.2
Blood glucose concentrations were determined from whole venous blood from the tail 
tip using an automated glucose monitor (Glucometer Elite, Bayer) according to 
manufacturer’s guidelines. For fasted blood glucose measurements animals were fasted 
overnight (16 h) before glucose measurements. Random glucose was measured in the 
afternoon.  
For analyzing blood parameters other than glucose, whole venous blood was taken from 
the tail vein. For serum blood samples, blood without additions was kept at room 
temperature for 30 min before centrifuging. For plasma samples, 
ethylenediaminetetraacetic acid (EDTA) or heparin was added and blood was 
centrifuged immediately. All samples were centrifuged twice for 5 min at 10.000 rpm 
and supernatants were stored at -20 °C for short term or -80 °C for long term storage. 
Insulin, leptin, IGF-1 and growth hormone (GH) concentrations were measured by 
enzyme-linked immunosorbent assay (ELISA) according to manufacturers’ guidelines 
(Mouse/Rat Insulin ELISA, Crystal Chem, Downers Grove, IL, USA; ELISA Development 
Kits: Murine Leptin ELISA Development Kit, Murine IGF-I ELISA Development Kit, 
PeproTech, Hamburg, Germany; Rat/Mouse Growth Hormone ELISA, Millipore, MA, 
USA).  
 Glucose tolerance test, insulin tolerance test, in vivo insulin release 2.1.3
For glucose tolerance tests (GTT), mice were fasted overnight (16 h). Animals were 
injected intraperitoneally (i.p.) with glucose (2 g/kg body weight) in phosphate buffered 
saline (PBS, 136.8 mM NaCl, 2.68 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH = 7.4). 
For insulin tolerance tests (ITT) animals were starved for 6 h during the day and injected 
i.p. with bovine insulin in PBS (0.75 U/kg body weight) (Sigma Aldrich, Seelze, Germany). 
Plasma glucose was measured before (0 min) and 15, 30, 60, and 120 min after injection 
as described above. In vivo insulin release was determined after overnight fasting by 
glucose injection (2 g/kg body weight) and determination of blood insulin 
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concentrations before (0 min) and 2.5, 5, and 15 min after glucose injection as described 
before (2.1.2).  
 Growth hormone release challenge 2.1.4
Growth hormone (GH) release challenge was conducted as described by Tennese et al. 
(Tennese and Wevrick 2011). Briefly, random fed animals were injected i.p. with 120 
µg/kg rat ghrelin (Tocris Bioscience, MO, USA Bioscience, MO, USA) in PBS and blood 
samples were taken 15 min after injections. GH levels were measured as described 
before (2.1.2).  
 Measurements of body length 2.1.5
Adult animals were briefly anesthetized with isoflurane (CP-Pharma Handelsgesellschaft 
mbH, Burgdorf, Germany) and placed on a ruler while being completely relaxed. All 
animals recovered shortly after anesthesia. 
 Random body weight measurements and body composition 2.1.6
measurements by NMR 
Body weight measurements were conducted in random fed mice using standard 
laboratory scales. Body composition was determined by nuclear magnetic resonance 
(NMR). NMR measurements were conducted by the Mouse Phenotyping Platform, Dr. 
Arnd Heuser, AG Thierfelder, Max-Delbrück-Centrum (MDC) für Molekulare Medizin 
Berlin-Buch. The Minispec Model LF90 II (6.5 mHz) (Bruker Scientific Instruments, 
Billerica, MA, USA) was used for the measurements. Animals were fasted from 9 am and 
drinking water was taken away at 12 am. Body composition was measured between 2 
and 3 pm.  
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 Measurement of pancreatic insulin content 2.1.7
Whole pancreata were taken from random fed mice. Weights of pancreata were 
measured immediately and pancreata were stored in acidic ethanol (95 % ethanol, 5 % 
HCl) at -20 °C until use. Pancreata were homogenized and further incubated for at least 
24 h at -20 °C. Insulin content was measured by radioimmunoassay (RIA) (Rat insulin RIA 
kit, Millipore, MA, USA) according to manufacturer’s guidelines and normalized to 
pancreatic weight. 
 Refeed experiments and indirect calorimetry 2.1.8
For refeeding experiments, mice were individually housed and given 48 h for acclimation 
before start of refeeding experiments. Food was taken away in the morning and given 
back 24 h later. Food intake was measured 3 h after refeeding. Body weight difference 
was calculated as body weight at the time when food was given back subtracted by body 
weight at the same time when food was taken away. 
Indirect calorimetry, locomotor activity and basal food intake measurements were 
conducted with the PhenoMaster System (TSE Systems, Bad Homburg, Germany). After 
24 h of acclimatization, CO2 and O2 respiration, food intake and locomotor activity was 
measured for three days. Locomotor activity was measured three-dimensionally by 
infrared-light beams. VCO2 and VO2 were calculated as difference between reference 
and sample cage. Energy expenditure (EE) was calculated using the following equation 
(Weir 1949): 
   [    ]           [ ]             [ ] 
RER was calculated using the following equation: 
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 Collection and homogenization of hypothalami for Western Blotting 2.1.9
and qRT-PCR    
Tissues were taken at random fed state or after 24 h starvation as indicated. Animals 
were killed by cervical dislocation and tissues dissected. The limits of the hypothalamus 
for dissection were the optic chiasma at the anterior border, the mammillary bodies at 
the posterior border, the lateral ventricles at the position of the optic chiasma at the 
lateral borders and the ventral end of the lateral ventricles at the position of the optic 
chiasma at the dorsal border. Tissues were snap frozen in 2-methylbutan (Acros 
Organics, Geel, Belgium) on dry ice and stored at -80 °C until use. For Western Blotting, 
tissues were thawed quickly and homogenized in protein lysis buffer containing 
protease inhibitor (cOmplete, EDTA-free Protease Inhibitor Cocktail Tablets, Roche, 
Basel, Switzerland) and for measurements of phosphorylated proteins also phosphatase 
inhibitor (PhosSTOP Phosphatase Inhibitor Cocktail Tablets, Roche, Basel, Switzerland). 
Samples were homogenized using a dounzer and centrifuged at 10,000 g for 10 min at 4 
°C (Ender, Krek et al. 2008). For quantitative real time polymerase chain reaction (qRT-
PCR), tissues were thawed and homogenized in TRIzol reagent (Invitrogen, Carlsbad, 
USA) by pipetting up and down. 
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2.2 Cell culture 
 Freezing, thawing and growth of cells 2.2.1
Mouse insulinoma cells (MIN6) cells were washed twice with sterile PBS and harvested 
with trypsin (0.05 % trypsin-EDTA, Gibco, Billings, USA). After centrifuging at 200 g for 3 
min, cells were either resuspended in growth medium (89 % Dulbecco's Modified Eagle's 
medium (DMEM, Gibco, Billings, USA), 10 % fetal bovine serum (FBS) heat inactivated 
(56 °C for 30 min, PAN-Biotech GmbH, Aidenbachove, Germany), 1 % 
penicillin/streptomycin (Gibco, Billings, USA), 5.5 mM 2-mercaptoethanol (Sigma-
Aldrich, Seelze, Germany)) for splitting or resuspended in freezing medium (10 % DMSO 
(Sigma-Aldrich, Seelze, Germany), 40 % FBS heat inactivated , 50 % DMEM) for freezing. 
Cells were aliquoted in cryotubes and frozen at – 80 °C overnight and transferred for 
long-term storage in liquid nitrogen.  
After thawing, cells were transferred to growth medium, centrifuged at 200 g for 3 min 
and resupended in growth medium. Cells were transferred to cell culture plates and 
incubated at 37 °C and 5 % CO2. Cells were harvested and split every 2 - 3 days as 
described before (2.1.9). 
 Transfection of cells 2.2.2
Transfections were conducted by using Amaxa Nucleofector electroporation kit V (Lonza 
Cologne GmbH, Cologne, Germany) according to the manufacturer’s guidelines and 
experiments were performed 48 h after electroporation. 0.2 pmol siRNA SMARTpool 
(Table 1) against Cadm1 (Dharmacon Inc., Chicago, USA) or control (siGENOME Non-
Targeting siRNA Pool #2, Dharmacon Inc., Chicago, USA ) was used per electroporation. 
For Western blotting analysis, cell culture plates were washed twice with PBS and stored 
at -80 °C until use. Cells were lysed with protein lysis buffer containing protease inhibitor 
as described above. 
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 Sequence (5’-3’) 
siRNA 1 CCC AUG UCT UAA AUA CGU AUU 
siRNA 2 GUA UAA ACC GCA AGU GCA UUU 
siRNA 3 UUU GCA UUC UCU AAA GCT AUU 
siRNA 4 CGC AUA GCU ACU AAA AUA AUU 
Table 1: siRNA SMARTpool against Cadm1 
 In vitro insulin secretion  2.2.3
MIN6 cells were transfected with siRNA against Cadm1 or control as described before 
(2.2.2). 48 h after transfections, MIN6 cells were preincubated with 5 mM glucose in 
Dulbeco’s PBS-HEPES-BSA (DPH) (0.90 mM CaCl2, 2.67 mM KCl, 1.47 mM KH2PO4, 0.5 
mM MgCl2-6H20, 138 mM NaCl, 8.10 mM Na2HPO4-7H20, 20 mM HEPES, 0.2 % BSA, pH = 
7.4) for 30 min at 37 °C and 5 % CO2. After washing with DPH, cells were incubated with 
2.8 mM or 25 mM glucose in DPH for 1 h at 37 °C and 5 % CO2. An aliquot of the 
supernatant was collected and centrifuged at 200 g for 5 min. Supernatants were frozen 
at - 20 °C until insulin measurements. Plates containing cells were washed with DPH and 
frozen at - 20 °C until further use. Cells were briefly incubated with cold acidic ethanol 
(95 % ethanol, 5 % HCl) and cell lysates frozen at -20 °C until insulin measurements. 
Insulin concentrations were measured by RIA (Rat insulin RIA kit, Millipore, MA, USA) 
according to manufacturer’s guidelines. Insulin content of supernatants was normalized 
to insulin content of the cells. 
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2.3 Molecular Biology  
 Isolation of genomic DNA 2.3.1
Mouse tail tips were incubated in lysis buffer (4 M Urea, 10 mM EDTA pH = 8.0, 0.1 M 
Tris/HCl pH = 8.0, 0.5 % sodium sarcosyl, 0.2 M NaCl) with 0.18 mg/ml proteinase K 
(PAN-Biotech GmbH, Aidenbachove, Germany) overnight at 55 °C. Desoxyribonucleic 
acid (DNA) was precipitated in 60 mM sodium acetate and 75 % (v/v) ethanol, 
centrifuged for 5 min at maximal speed. Precipitates were washed with 70 % (v/v) 
ethanol. DNA pellets were dried at room temperature for 30 - 45 min and resuspended 
in Tris/EDTA-buffer (10 mM Tris-HCl, 1 mM EDTA, pH = 8.0). Isolated genomic DNA was 
stored at 4 °C. 
 Quantification of RNA and DNA concentrations 2.3.2
DNA and RNA concentrations were determined at 260 nm with a NanoDrop ND-1000 
UV-Vis spectrophotometer (Peqlab, Erlangen, Germany) according to manufacturer’s 
guidelines. The ratio of adsorptions at 260 nm versus 280 nm was used as control for 
purity of DNA and ribonucleic acid (RNA) samples. 
 Polymerase chain reaction (PCR) 2.3.3
Polymerase chain reaction (PCR) was used for genotyping of all mouse lines. 50 - 200 ng 
mouse tail DNA and PCR mastermix (1 x PCR buffer homemade (67 mM Tris-HCl pH = 
9.1, 16 mM (NH4)2SO4, 3.5 mM MgCl2, 0.15 mg/ml BSA), 25 pmol of each primer (Table 
2), 25 µM dNTP Mix (Fermentas GmbH, St. Leon-Rot, Germany), 0.5 units Taq DNA 
Polymerase, Nativ (Invitrogen, Carlsbad, USA)) were made up to 20 µl. PCR programs in 
a thermocycler T3000 (Biometra, Göttingen, Germany) started with 5 min denaturation 
at 95°C, followed by 30 cycles consisting of denaturation at 95 °C for 45 sec, annealing at 
oligonucleotide-specific temperatures (Table 2) for 30 sec and elongation at 72 °C for 30 
sec. After a final elongation step at 72 °C for 10 min, the PCR product was chilled at 4 – 
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10 °C. For genotyping of ob mutant mice, 10 µl of PCR product was digested with 1 x 
NEBuffer 3 (New England Biolabs, Ipswich, USA) and 5 units of enzyme Dde1 (New 
England Biolabs, Ipswich, USA) for at least 6 h at 37 °C. All PCR and digested PCR 
products were analyzed on agarose gel electrophoresis.  
Primer          Sequence (5’-3’) Tannealing (°C) Orientation 
Cadm1 wt for CCA TGC TAT GCT TGC TCA TC 60 sense 
Cadm1 wt rev AAA GAT GAT TGC CCA TCC AG 60 antisense 
Cadm1KO for AGC ATC CCT TTC CAC CAT AGT TTT CTC TCT 65 sense 
Cadm1KO rev TAC CAG GAG GGG AGA AGA GGC CCA GAG C 65 antisense 
Cre3 for ATG CTT CTG TCC GTT TGC CG 55 sense 
Cre1 rev CCT GTT TTG CAC GTT CAC CG 55 antisense 
Ob for TGT CCA AGA TGG ACC AGA CTC 62 sense 
Ob rev ACT GGT CTG AGG CAG GGA GCA 62 antisense 
POMC-eGFP for AAG TTC ATC TGC ACC ACC G 60 sense 
POMC-eGFP rev TCC TTG AAG AAG ATG GTG CG 60 antisense 
Rosa26-YFP for CGT AAA CGG CCA CAA GTT CAG 65 sense 
Rosa26-YFP rev GAA CTC CAG CAG GAC CAT GTG 65 antisense 
Table 2: Sequence and orientation of PCR primer 
 
 RNA Extraction, RT-PCR and qRT-PCR 2.3.4
Gene expression analysis was conducted by Sudhir Gopal Tattikota, AG Poy, MDC Berlin-
Buch. RNA was isolated from homogenized cell lysates or tissues using TRIzol reagent 
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(Invitrogen, Carlsbad, USA) according to manufacturer’s guidelines. 5 µg RNA was 
reversed transcribed (reverse transcription polymerase chain reaction (RT-PCR)) into 
cDNA using SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, USA) according to 
manufacturer’s guidelines. Gene expression analysis was performed by qRT-PCR using 
FastStart Universal SYBR Green Master (Roche, Mannheim, Germany) with a 
StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, USA) according to 
Primer Sequence (5’-3’) Orientation 
36B4 for TCC AGG CTT TGG GCA TCA sense 
36B4 rev CTT TAT CAG CTG CAC ATC ACT CAG A antisense 
Gh for TCA GCA GGA TTT TCA CCA sense 
Gh rev ATC TTC CAG CTC CTG CAT antisense 
Ghrh for TTG TGA TCC TCA TCC TCA CCA GTG sense 
Ghrh rev ATG ATG TCC TGG ATC ACT TTC CGG antisense 
Npy for CTG ACC CTC GCT CTA TCT CTG sense 
Npy rev AGT ATC TGG CCA TGT CCT CTG antisense 
Pomc for CCC AAG GAC AAG CGT TAC GG sense 
Pomc rev GTG CGC GTT CTT GAT GAT GG antisense 
Prkaa1 for GCA CCC TCA CAT CAT CAA AC sense 
Prkaa1 rev ATC AAG CAG GAC GTT CTCA G antisense 
Prkaa2 for TAC GAA CTA GCT GTG GAT CG sense 
Prkaa2 rev GGA TCT TCT TGA AGA GCG TAG G antisense 
Table 3: Sequence and orientation of qRT-PCR primers 
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manufacturer’s guidelines. Primers were designed to span introns avoiding DNA 
amplification. The annealing temperature was set to 60 °C for all experiments. 36B4 
gene expression was used for normalizing unknown gene expression. 
 Western blot analysis 2.3.5
Frozen protein lysates were thawed and protein concentrations were measured by using 
bicinchoninic acid (BCA) assay. Per reaction, 200 µl of BCA (Sigma-Aldrich, Seelze, 
Germany) were mixed with 4 µl copper (II) sulfate solution (Sigma-Aldrich, Seelze, 
Germany) and added to a 96- well plate containing equal volumes (5 - 15 µl) of protein 
lysate. Bovine serum albumin (BSA) (SERVA Electrophoresis GmbH, Heidelberg, 
Germany) solubilized in lysate buffer at varying concentrations was used as protein 
standard. Absorptions were read with a photometer Infinite 200 PRO (Tecan Group Ltd., 
Männedorf, Switzerland) at 562 nm and protein concentrations were calculated in 
comparison to BSA standard concentrations. 
Aliquots of protein lysates containing equal protein amounts (20 - 80 ng) were diluted in 
5 x SDS loading buffer (310 mM Tris, 10 % (w/v) sodium dodecyl sulfate (SDS), 50 % (v/v) 
glycerol, 5 mM EDTA, 0.05 % (w/v) bromophenol blue, 5 % (v/v) 2-mercaptoethanol) and 
incubated for 5 min at 95 °C. Protein lysates were subjected to SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) (Bio-Rad Laboratories, CA, USA) on 10 % (v/v) SDS gels in 
SDS running buffer (25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS, pH = 8.3) at room 
temperature. Afterwards, protein lysates were blotted onto 0.2 µm nitrocellulose or 
polyvinylidenfluorid (PVDF) membranes (Carl Roth GMBH, Karlsruhe, Germany) in mini 
trans-blot cell system (Bio-Rad Laboratories, CA, USA) in transfer buffer (25 mM Tris-HCl 
pH = 8.4, 192 mM glycine, 20 % (v/v) methanol) for 100 min at 80 V at 4 °C. Membranes 
were blocked in blocking buffer (2.5 % dry milk, 20 mM Tris, 137 mM NaCl, pH = 7.6) for 
at least one hour at room temperature. Primary antibodies (Table 4) were diluted in 
blocking buffer and incubated with membranes at 4 °C overnight. Membranes were 
finally incubated with secondary antibodies (Calbiochem, La Jolla, USA) diluted 1:10,000 
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in blocking buffer for at least one hour at room temperature. After 3 x 10 min washing 
with washing buffer (20 mM Tris, 137 mM NaCl, pH = 7.6), bands were detected with 
homemade enhanced chemiluminescence (1 ml solution A (0.25 mg/ml luminol in 0.1 M 
Tris, pH = 8.6), 0.1 ml solution B (1.1 mg/ml in DMSO), 0.3 µl H2O2 (Sigma-Aldrich, Seelze, 
Germany)) or SuperSignal West Femto (Thermo Fisher Scientific, IL, USA) using a CCD-
camera (Fujifilm LAS-1000/ Intelligent Dark Box, Fujifilm, Japan). 
Densitometry of the protein bands was performed using AIDA Image Analyzer Software 
(Raytest Straubenhardt, Germany). Background was subtracted of each band and 
protein expression of each sample was normalized to -tubulin as internal loading 
control. 
 
Antigen Species Dilution Source 
CADM1 Polyclonal rabbit 1:2000 
Sigma-Aldrich, Seelze, 
Germany 
-tubulin Monoclonal mouse 1:2000 
Sigma-Aldrich, Seelze, 
Germany 
p-AMPK(Thr172) Polyclonal rabbit 1:1000 
Cell Signaling, Danvers, MA, 
USA 
T-AMPK Polyclonal rabbit 1:1000 
Cell Signaling, Danvers, MA, 
USA 
Table 4: Antibodies for Western blotting and immunocytochemistry 
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2.4 Cell biology  
 Immunocytochemistry 2.4.1
MIN6 cells were grown on glass coverslips coated with 0.1 % gelatin in PBS in 24 well 
plates. Transfection was done as described above (2.2.2). 48 h after transfection, cells 
were fixed with 4 % formaldehyde in PBS for 10 min at room temperature. After washing 
with PBS, cells were permeabilized 10 min in 0.25 % (v/v) Triton-X in PBS and blocked 
with 5 % donkey normal serum in PBS for at least 1 hour at room temperature. Staining 
was done at 4 °C overnight with primary antibody against CADM1 (Table 4) diluted in 
PBS in a wet chamber. After washing with PBS, cells were incubated for at least 1 hour in 
Alexa Fluor 488 goat anti-rabbit secondary antibody (Invitrogen, Carlsbad, USA) diluted 1 
: 300 in PBS. Finally, cells were incubated with TO-PRO-3 (Invitrogen, Carlsbad, USA) 
diluted 1 : 5000 in PBS for 5 - 10 min. Glass coverslips were washed intensively with PBS 
mounted on object holder with mounting medium (DAKO, Glostrup, Denmark). Confocal 
pictures were taken with a 100 x Plan-Apochromat oil objective on a Zeiss Laser 
Scanning Microscope (LSM510 Meta, Carl Zeiss AG, Germany). 
 Immunohistochemistry 2.4.2
Immunostainings from mouse brains were conducted by Kun Song, AG Siemens, MDC 
Berlin-Buch. Briefly, animals were deeply anesthetized and perfused with PBS followed 
by 4 % formaldehyde in PBS. Brains were dissected and stored in 30 % glucose (w/v) in 
PBS at 4 °C overnight. Brains were embedded and cut into free-floating sections using a 
microtome into 30 µm slices, transferred to a 24 - well plate filled with PBS and stored at 
4 °C until further use. Slices containing ARC were stained with DAPI and mounted on 
glass slides (VECTASHIELD HardSet Mounting Medium with DAPI, Vector Laboratories, 
Inc., Burlingame). Confocal pictures were taken with a 20 x dry objective on a Leica TCS 
SP5 Microscope (Leica Microsystems GmbH, Wetzlar, Germany). 
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 Electrophysiological analyses 2.4.3
Electrophysiological analyses from mouse brains were conducted by Dr. Mirko Moroni, 
AG Siemens, MDC Berlin-Buch. Pups between 16 and 21 days of age were subject to 
cervical dislocation and then decapitated. The entire brain was removed and 
immediately submerged in ice cold, carbogen-saturated (95 % O2 / 5 % CO2) artificial 
cerebrospinal fluid (aCSF) (2.5 mM NaCl, 126 mM KCl, 1.3 mM MgCl2, 2.0 mM CaCl2, 1.2 
mM KH2PO4, 21.4 mM NaHCO3, 10 mM glucose). 300 M coronal sections were cut with 
a Leica VT1000S Vibratome and then incubated in oxygenated aCSF at room 
temperature for at least 1 h before recording. Whole-cell voltage-clamp recordings from 
POMC-eGFP neurons were performed using a Multiclamp 700B amplifier (Molecular 
Devices) and filtered with an eight-pole Bessel filter at 6 kHz. Both voltage and current 
signals were sampled at 50 kHz using an Axon 1440A interface device (Molecular 
Devices, Sunnyvale, USA) and the data were acquired using Clampex 10.2 software 
(Molecular Devices, Sunnyvale, USA). Electrodes were pulled using a micropipette puller 
(Sutter Instruments, Novato, USA) from thick-walled borosilicate glass GC150F capillaries 
(Harvard Apparatus, Massachusetts, USA, Massachusetts, USA) to a resistance of 3
MΩ. Series resistance compensation ranged from 50 - 70 % and recordings were 
discarded if the series resistance exceeded 10 MΩ. Electrodes were filled with an 
internal solution (140 mM CsCl, 4 mM NaCl, 0.5 mM CaCl2, 10 mM HEPES, 5 mM EGTA, 2
 mM Mg-ATP, QX-315 Br 3, pH 7.3 with CsOH, osmolarity of 290 mOsm). Cells were 
visualized using an infrared differential interference contrast (DIC) optics equipped with 
equipped ORCA-R2 camera (Hamamatsu Photonics K.K., Hamamatsu, Japan) mounted 
on a Slicescope (Multi Channel Systems, Reutlingen, Germany) with a 40 x water-
immersion objective. Neurons were voltage clamped at − 70 mV. In order to record 
inhibitory postsynaptic potentials (IPSC)s, the aCSF composition included 3 mM 
kynurenic acid (Sigma Aldrich, Seelze, Germany) to block excitatory glutamatergic 
activity. Excitatory postsynaptic potentials (EPSC)s were recorded in presence of 100 M 
picrotoxin (Tocris Bioscience, MO, USA) in order to block both GABA- and glycine-evoked 
currents. Both experimental conditions included 0.5 M tetrodotoxin (Tocris Bioscience, 
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MO, USA) to isolate miniature events. Events were excluded from the analysis if their 
amplitude was less than 3 standard deviations of the baseline noise and if there were 
overlapping events within 50 ms for IPSCs or 10 ms for EPSCs. All miniature events were 
automatically detected with Clampfit 10, followed by manual inspection of single events. 
For frequency distributions a minimum of 200 events were analyzed. 
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2.5 Statistical methods 
Data sets with two groups were analyzed for statistical significance using one-tailed 
unpaired student’s t-test with unequal variance. For comparing means of more than two 
groups, one-way analysis of variance (ANOVA) and following Tukey-Kramer test was 
used with the software GraphPad Prism 5 (GraphPad Prism Software, San Diego, 
CA/USA). For linear regression analysis GraphPad Prism 5 was used. Analysis of 
covariance (ANCOVA) was performed with the univariate general linear model module in 
PASW statistics (IBM, Chicago, IL). Adjusted average values were analyzed for significant 
differences using one-tailed unpaired student’s t-test with unequal variance. All 
displayed values are means ± SEM. All p-values below or equal 0.05 were considered 
significant ( p ≤ 0.05;  p ≤ 0.01;  p ≤ 0.001). 
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3 Results 
3.1 Energy and glucose homeostasis in murine models with total 
Cadm1 deletion  
In order to investigate effects of Cadm1 deficiency on energy and glucose homeostasis, 
total Cadm1 knock-out (Cadm1KO) mice, as previously described (van der Weyden, 
Arends et al. 2006), were obtained. Cadm1KO mice were backcrossed to C57BL/6N mice 
for four generations. Unless otherwise described, Cadm1KO mice were compared to 
gender-matched, littermate controls, which were heterozygous or wild-type for the 
Cadm1 null allele. 
 Reduced postnatal growth and decreased fat mass in Cadm1KO male 3.1.1
mice  
The physiological function of CADM1 in energy homeostasis was addressed first by 
measuring body weight of Cadm1KO animals in comparison to control mice. One day 
after birth, neither male nor female Cadm1KO mice showed significant differences in 
body weight compared to control animals (Figure 9A, B). However, between age of 4 
and 21 postnatal days both male and female Cadm1KO mice developed significantly 
lower body weight compared to littermate control mice. After weaning at 4 weeks of 
age, significant lower body weight in male (Figure 9C) and female Cadm1KO mice 
(Figure 9D) was observed at all measured time points. Between 4 and 12 weeks of age, 
average body weight gain per week was not different between the genotypes of both 
genders (Figure 9E). Furthermore, adult male Cadm1KO mice showed significantly 
reduced body length (Figure 9F), while body weight to body length ratio was 
significantly reduced in adult male and female Cadm1KO mice (Figure 9G). 
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Figure 9: Body weight and body length of Cadm1KO mice 
[A] Body weight of male control (N = 8 - 13) and Cadm1KO (N = 5 - 10) mice between 1 
and 21 days of age [B] Body weight of female control (N = 11 - 16) and Cadm1KO (N = 7 - 
9) mice between 1 and 21 days of age  [C] Body weight of male control (N = 12 - 29) and 
Cadm1KO (N = 15 - 21) mice between 4 and 16 weeks of age [D] Body weight of female 
control (N = 15 - 33) and Cadm1KO (N = 6 - 18) mice between 4 and 16 weeks of age [E] 
Average body weight gain per week of male control (N = 12) and Cadm1KO (N = 7) mice 
and female control (N = 19) and Cadm1KO (N = 10) mice between 4 and 12 weeks of age 
[F] Body length and [G] Body weight to body length ratio of male control (N = 9) and 
Cadm1KO (N = 7) mice and female control (N = 9) and Cadm1KO (N = 10) mice between 
12 and 16 weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.05;  p ≤ 0.01; 
 p ≤ 0.001 
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To investigate if body weight differences are only caused by different body lengths of 
Cadm1KO mice, body composition of Cadm1KO and control animals was measured by 
nuclear magnetic resonance (NMR). In Cadm1KO males, absolute fat mass as well as 
absolute lean body mass were significantly reduced (Figure 10A,B), confirming the 
reduced body weight of these animals. Fat mass relative to body weight was significantly 
reduced in male Cadm1KO mice, whereas lean body mass relative to body weight was 
significantly increased in these animals (Figure 10C,D). Cadm1KO females did not show 
differences in absolute fat mass but exhibited reduced absolute lean body mass (Figure 
10A,B). Furthermore, fat mass and lean body mass relative to body weight were not 
significantly changed in Cadm1KO females (Figure 10C,D). 
 
Figure 10: Body composition of Cadm1KO mice 
[A] Absolute body fat mass and [B] Absolute lean body mass and [C] Relative body fat 
mass normalized to body weight and [D] Relative lean body mass normalized to body 
weight of male control (N = 11) and Cadm1KO (N = 9) mice and female control (N = 19) 
and Cadm1KO (N = 23) mice between 12 and 20 weeks of age. Displayed values are 
means ± S.E.M.  p ≤ 0.05;  p ≤ 0.01;  p ≤ 0.001 
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 Decreased leptin levels, unchanged food intake and increased 3.1.2
locomotor activity in Cadm1KO male mice  
Reduced body fat content correlates with reduced circulating levels of leptin and 
increased sensitivity to leptin (1.2.1). Since Cadm1KO male mice showed reduced body 
fat content (Figure 10), it was questioned whether circulating leptin is altered in 
Cadm1KO mice. Circulating leptin levels of male Cadm1KO mice were reduced in 
comparison to littermate controls, corresponding to reduced body fat content (Figure 
11).  
 
Figure 11: Blood leptin levels in male Cadm1KO mice 
Random circulating leptin levels of male control (N = 16) and Cadm1KO (N = 7) mice 
between 12 and 16 weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.01 
To investigate the cause of the leaner phenotype, it was examined if Cadm1KO mice 
show changes in food intake. Compared to control animals, absolute basal food intake 
was similar in male and female Cadm1KO mice (Figure 12A). Since body weight and 
absolute lean body mass are significantly decreased in Cadm1KO male mice (Figure 10), 
absolute food intake has to be adjusted for comparison. As discussed by Kaiyala et al. 
and Tschöp et al. (Kaiyala, Morton et al. 2010; Tschop, Speakman et al. 2011), 
normalization by division by body weight or lean body mass can yield confounding 
results, since the intercept of the relation between lean or body mass and food intake is 
not zero. Therefore, analysis of covariance (ANCOVA) was used to adjust food intake for 
lean body mass (Meyer, Neubronner et al. 2007; Butler and Kozak 2010; Choi, Yablonka-
Reuveni et al. 2011; Tschop, Speakman et al. 2011). After adjustment of food intake for 
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lean body mass using ANCOVA, male and female Cadm1KO mice showed no significant 
differences in food intake compared to littermate control mice (Figure 12B,C,D). These 
data suggest that basal food intake of control and Cadm1KO mice would not be 
significantly different, if animals from both genotypes had the same lean body mass. 
Besides basal food intake, we also questioned whether food intake after food 
deprivation for 24 h (rebound feeding) might be changed. Cadm1KO mice ate 
significantly more during the first three hours after refeeding, suggesting that food 
desire is enhanced in Cadm1KO mice (Figure 12E). Body weight loss during the 24 h 
starvation time was not significantly altered in Cadm1KO mice, indicating that increased 
weight loss was not the cause of the increased starvation-induced food intake (Figure 
12F).  
Furthermore, gene expression of Pomc and Npy, important genes in the regulation of 
food intake (1.1.4, 1.1.6), were investigated in hypothalami of random fed control and 
Cadm1KO mice. Compared to control mice, Pomc expression was significantly decreased 
and Npy expression not significantly altered in the hypothalami of random fed Cadm1KO 
mice (Figure 12G). 
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Figure 12: Basal and post-starvation food intake of Cadm1KO mice 
[A] Absolute food intake and [B] For lean body mass at 20.0444 g adjusted food intake 
using ANCOVA for male control (N = 10) and Cadm1KO mice (N = 8) and for lean body 
mass at 16.4133 g adjusted food intake for female control (N = 15) and Cadm1KO mice 
(N = 16) [C] Scatterplot showing linear regression for food intake as a function of group 
and lean body mass for male control (N = 10) and Cadm1KO mice (N = 8) (control: 
                           ; Cadm1KO:                     
        between 12 and 20 weeks of age [D] Scatterplot showing linear regression for 
food intake as a function of group and lean body mass for female control (N = 15) and 
Cadm1KO mice (N = 16) (control:                           ; Cadm1KO: 
                             between 12 and 20 weeks of age [E] 3 h food 
intake and [F] relative body weight difference after 24 h starvation of female control (N 
= 3) and Cadm1KO (N = 3) mice between 12 and 16 weeks of age [G] Pomc and Npy gene 
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expression measured by qRT-PCR in hypothalami of random fed control (N = 4) and 
Cadm1KO (N = 4) mice between 12 and 16 weeks of age. Displayed values are means ± 
S.E.M.  p ≤ 0.05. Gene expression analysis was conducted by Sudhir Gopal Tattikota, 
AG Poy, MDC Berlin-Buch. 
To further investigate changes on food intake in Cadm1KO mice, gene expression, 
protein expression and protein activity of 5' adenosine monophosphate-activated 
protein kinase (AMPK) were investigated in hypothalami of Cadm1KO and control mice. 
AMPK activity in the hypothalamus directly correlates with food intake and body weight 
(Minokoshi, Alquier et al. 2004). First, deletion of CADM1 was confirmed by Western 
blotting. Western blotting of hypothalami revealed a protein band for CADM1 at around 
100 kDa in control mice, which was only weakly present in Cadm1KO mice (Figure 13A). 
CADM1 was detected at around 100 kDa instead of 75 kDa as expected from the 
molecular weight since the protein is highly glycosylated, as shown previously (Robbins, 
Krupp et al. 2010). However, other bands at lower sizes were detected in both Cadm1KO 
and control mice. This is likely due to cross-reactivity of the CADM1 antibody to CADM2, 
CADM3 and CADM4, since these proteins show strong homology at the c-terminus, the 
part that is detected by the antibody against CADM1 (Biederer, Sara et al. 2002).  
AMPK is activated by phosphorylation at threonine 172 (p-AMPK (Thr172)) (Woods, 
Dickerson et al. 2005). Abundance of p-AMPK (Thr172) (Figure 13B) was normalized to 
tubulin and divided by abundance of total-AMPKT-AMPK (Figure 13A) normalized 
to tubulin in order to estimate AMPK activity. Compared to control mice, AMPK activity 
was significantly increased in Cadm1KO mice after starvation (Figure 13C). Furthermore, 
Prkaa1 and Prkaa2 expression, genes coding for the catalytic subunits AMPK1 and 
AMPKa2 of AMPK (Lage, Dieguez et al. 2008), were significantly enhanced in 
hypothalami of random fed Cadm1KO mice (Figure 13D). Taken together, these data 
indicate that AMPK activity and expression is increased in hypothalami of Cadm1KO 
mice. 
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Figure 13: In vivo AMPK protein and gene expression of Cadm1KO mice 
[A] Western blot analysis for protein abundance of CADM1 and total-AMPK (T-AMPK) 
in hypothalami of 24 h fasted control (N = 5) and Cadm1KO (N = 5) mice [B] Western 
blot analysis for protein abundance of AMPK phosphorylated at Thr172 (p-AMPK 
(Thr172)) in hypothalami of 24 h fasted control (N = 5) and Cadm1KO (N = 5) mice [C] 
Quantification of p-AMPK (Thr172) protein abundance divided by -tubulin from [B] 
and normalized to T-AMPK divided by -tubulin from [A] [D] qRT-PCR for gene 
expression of Prkaa1 and Prkaa2 coding for AMPK1 and AMPK2, respectively, in 
random fed control (N = 5) and Cadm1KO (N = 4) mice. Displayed values are means ± 
S.E.M.  p ≤ 0.05. Gene expression analysis was conducted by Sudhir Gopal Tattikota, 
AG Poy, MDC Berlin-Buch. 
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To further address whether energy homeostasis of Cadm1KO mice is altered, energy 
expenditure of Cadm1KO mice and control mice was investigated. Energy expenditure is 
the sum of basal metabolic rate, thermogenesis and locomotor activity (1.1.5) and can 
be measured by indirect calorimetry. Therefore, oxygen (O2) and carbon dioxide (CO2) 
respiration was measured by using indirect calorimetry and locomotor activity was 
measured by infrared-light beams during indirect calorimetry measurements. In male 
Cadm1KO mice, absolute O2 consumption was significantly increased compared to 
littermate control mice, while absolute CO2 expiration was unchanged (Table 5). The 
calculated absolute energy expenditure was significantly increased in male Cadm1KO 
mice compared to control mice. The respiratory rate (RER), calculated by CO2 expiration 
divided by O2 consumption, was not significantly different in male Cadm1KO mice in 
comparison to control mice. Locomotor activity was significantly increased in male 
Cadm1KO mice.  
In female Cadm1KO animals, indirect calorimetry yielded no significant differences for 
absolute O2 and CO2 respiration, energy expenditure or respiratory rate (Table 5). Also 
locomotor activity was unchanged Cadm1KO females when comparing to control 
animals.  
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 Male Female 
 Control Cadm1KO Control Cadm1KO 
VO2 [l/h] 88.0 ± 1.1 91.3 ± 1.1  83.6 ± 1.2 81.6 ± 2.0 
VCO2 [l/h] 82.2 ± 1.4 83.9  ± 1.2 80.7 ± 1.4 80.0 ± 2.1 
EE                 
[kcal/h] 
0.44 ± 0.01 0.45 ± 0.01  0.42 ± 0.01 0.41 ± 0.01 




2094.0 ± 65.7 2459.0 ± 64.6 2485.1 ± 128.7 2448.4 ± 121.3 
Table 5: Energy expenditure, RER and locomotor activity of Cadm1KO mice 
Average oxygen (VO2) and carbon dioxide (VCO2) respiration, calculated energy 
expenditure (EE) and respiratory rate (RER) as well as locomotor activity of male control 
(N = 12) and Cadm1KO (N = 9) mice and female control (N = 15) and Cadm1KO (N = 16) 
mice between 12 and 20 weeks of age of 3 consecutive days. Displayed values are 
means ± S.E.M.  p ≤ 0.05;  p ≤ 0.001 
Since male Cadm1KO mice showed differences in lean body mass and body weight 
compared to control mice (Figure 9, Figure 10), O2 and CO2 respiration as well as energy 
expenditure have to be adjusted. ANCOVA was used to adjust energy expenditure for 
lean body mass as described above (Figure 12). After adjustment of energy expenditure 
for lean body mass using ANCOVA, male Cadm1KO mice showed significantly increased 
energy expenditure compared to littermate control mice (Figure 14A,B). In order to 
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evaluate whether the increase in energy expenditure might be explained by increased 
activity, ANCOVA was further used to adjust energy expenditure for locomotor activity. 
Energy expenditure adjusted for locomotor activity was unchanged between male 
Cadm1KO and control mice (Figure 14C,D). These results indicate that energy 
expenditure of control and Cadm1KO mice would not be significantly different, if 
animals from both genotypes had the same locomotor activity. Therefore, it can be 
suggested that increased locomotor activity is the main, if not the only factor leading to 
increased energy expenditure in Cadm1KO male mice. 
In female Cadm1KO mice, adjustment of energy expenditure for lean body mass did not 
show significant differences compared to control female mice (Figure 15A,B). In 
addition, energy expenditure adjusted for locomotor activity did not show significant 
differences between female control and Cadm1KO mice (Figure 15C,D).  
Taken together, Cadm1KO mice display reduced body weight gain between postnatal 
day four and postnatal day 21, while body weight gain after four weeks of age is not 
significantly different in comparison to control mice. Body length of adult Cadm1KO 
animals is decreased, while food intake is unchanged. Furthermore, Cadm1KO males 
exhibit reduced fat mass and increased lean body mass relative to body weight. 
Locomotor activity is increased in Cadm1KO males, causing increased energy 
expenditure. Cadm1KO female mice do not show differences on body composition, 
energy expenditure or locomotor activity. 
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Figure 14: Analysis of covariance (ANCOVA) of energy expenditure and locomotor 
activity in male Cadm1KO mice 
[A] Scatterplot showing linear regression for energy expenditure as a function of group 
and lean body mass (control:                           ; Cadm1KO: 
                              and [B] Energy expenditure adjusted for lean 
body mass at 20.0905 g using ANCOVA and [C] Scatterplot showing linear regression for 
energy expenditure as a function of group and locomotor activity (control:   
                          ; Cadm1KO:                       
        and [D] Energy expenditure adjusted for locomotor activity at 2.25 counts/h × 
10³ using ANCOVA for male control (N = 12) and Cadm1KO (N = 9) mice between 12 and 
20 weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.01 
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Figure 15: Analysis of covariance (ANCOVA) of energy expenditure and locomotor 
activity in female Cadm1KO mice  
[A] Scatterplot showing linear regression for energy expenditure as a function of group 
and lean body mass (control:                             ; Cadm1KO: 
                              and [B] Energy expenditure adjusted for lean 
body mass at 16.4226 g using ANCOVA and [C] Scatterplot showing linear regression for 
energy expenditure as a function of group and locomotor activity (control:   
                         ; Cadm1KO:                      
        and [D] Energy expenditure adjusted for locomotor activity at 2.429 counts/h × 
10³ using ANCOVA for female control (N = 15) and Cadm1KO (N = 16) mice between 12 
and 20 weeks of age. Displayed values are means ± S.E.M.  
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 Increased insulin sensitivity and insulin secretion in Cadm1KO mice  3.1.3
To validate the physiological function of CADM1 in glucose homeostasis, random and 16 
h starved blood glucose levels of Cadm1KO mice were measured. Compared to 
littermate controls, Cadm1KO mice did not show significant differences in blood glucose 
levels at either random or fasted state (Figure 16A,B). To further investigate the ability 
of Cadm1KO mice to control blood glucose levels, these mice were challenged by 
intraperitoneal injections of glucose (glucose tolerance test, GTT). Blood glucose levels 
were measured before (0 min) and at 15, 30, 60 and 120 min after injections. In male 
Cadm1KO mice, glucose levels at 0 and 15 min were not significantly changed compared 
to control animals (Figure 16C). However, the blood glucose levels of male Cadm1KO 
mice were significantly lower at 30, 60 and 120 min after glucose injections. Female 
Cadm1KO mice had significantly decreased glucose levels at 15 min and strongly 
decreased levels at 30 min after glucose injections compared to control mice (p = 0.058)  
(Figure 16D). These data suggest improved glucose tolerance in Cadm1KO mice. 
Lower blood glucose levels after glucose challenge can be caused by increased release of 
insulin or increased sensitivity to insulin. To establish whether insulin sensitivity was 
changed in Cadm1KO mice, an insulin tolerance test (ITT) was performed by measuring 
blood glucose levels before and after intraperitoneal insulin injections. Due to insulin 
stimulated glucose uptake by peripheral tissues, all animals showed decreasing blood 
glucose levels up to 60 min after insulin injections, followed by increasing glucose levels 
due to hepatic gluconeogenesis. Male Cadm1KO mice showed unchanged glucose levels 
after insulin injections compared to control mice (Figure 16E). However, Cadm1KO 
females had significantly decreased glucose levels at 30 and 120 min after insulin 
injections, suggesting improved insulin sensitivity in female Cadm1KO mice (Figure 16F).  
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Figure 16: Glucose and insulin sensitivity of Cadm1KO mice 
[A] 16 h fasted blood glucose levels of male control (N = 9) and Cadm1KO (N = 7) mice 
and female control (N = 5) and Cadm1KO (N = 5) mice [B] Random glucose of male 
control (N = 7) and Cadm1KO (N = 11) mice and female control (N = 18) and Cadm1KO (N 
= 9) mice [C] Glucose tolerance test of male control (N = 6) and Cadm1KO (N = 4) mice 
[D] Glucose tolerance test of female control (N = 15) and Cadm1KO (N = 10) mice [E] 
Insulin tolerance test of male control (N = 17) and Cadm1KO (N = 16) mice [F] Insulin 
tolerance test of female control (N = 5) and Cadm1KO (N = 5) mice. All animals were 
between 12 and 16 weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.05 
To investigate whether the release of insulin upon glucose challenge was changed in 
Cadm1KO animals, an in vivo insulin release test was performed by measuring blood 
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insulin levels before and after intraperitoneal glucose injections. At 5 min after glucose 
injection, male Cadm1KO mice showed significantly higher blood insulin levels than 
control mice, suggesting an improved pancreatic insulin release (Figure 17A). Female 
Cadm1KO mice showed a strong trend for increased blood insulin levels 2.5 min after i.p. 
glucose injections (p = 0.066) (Figure 17B). Pancreatic insulin content of Cadm1KO mice 
was unaltered in male and female mice (Figure 17C,D), suggesting that release rather 
than production of insulin was affected in Cadm1KO mice.  
 
 
Figure 17: Insulin release and pancreatic insulin content of Cadm1KO mice 
[A] In vivo insulin release of male control (N = 6) and Cadm1KO (N = 4) mice [B] In vivo 
insulin release of female control (N = 5) and Cadm1KO (N = 5) mice [C] Pancreatic insulin 
content of male control (N = 6) and Cadm1KO (N = 5) mice [D] Pancreatic insulin content 
of female control (N = 7) and Cadm1KO (N = 5) mice. All animals were between 12 and 
16 weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.05 
Results   73 
 Increased insulin release in Cadm1-depleted MIN6 cells 3.1.4
To further prove that insulin release was enhanced by depletion of CADM1, Cadm1 was 
knocked-down in vitro in MIN6 cells, a cell line derived from pancreatic murine -cells 
(Miyazaki, Araki et al. 1990). Knock-down was achieved by using a siRNA against Cadm1 
and the knock-down efficiency was confirmed by Western Blotting (Figure 18A) and 
immunofluorescence microscopy (Figure 18B). Secreted insulin was significantly higher 
in Cadm1-depleted MIN6 cells compared to control cells after treatment with high and 
low glucose concentrations, representing basal and postprandial glucose concentration 
respectively (Figure 18C). These in vitro data confirmed the in vivo findings that Cadm1 
deficiency increases pancreatic insulin release. 
74  Results 
 
Figure 18: Insulin secretion of Cadm1-depleted MIN6 cells 
[A] Confirming knock-down of CADM1 by Western blot analysis of MIN6 cells 
transfected with control siRNA and siRNA against Cadm1; upper panel: CADM1 
expression; lower panel: -tubulin used as loading [B] Confirming knock-down of CADM1 
by immunocytochemistry of MIN6 cells transfected with control siRNA (left) and siRNA 
against Cadm1 (right); CADM1 is stained in green; nuclei are stained in red [C] In vitro 
insulin secretion of MIN6 cells transfected with control siRNA and siRNA against Cadm1 
and treated with low glucose medium (2.8 mM glucose) or high glucose medium (25 mM 
glucose). Displayed values are means ± S.E.M.  p ≤ 0.05;  p ≤ 0.001 
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 Cadm1KO mice have decreased IPSC frequency onto POMC-eGFP 3.1.5
neurons 
Recent investigations showed that CADM1 influences synaptic plasticity, a process 
altering synaptic strength and efficacy in response to synaptic activity (1.3.1). Synaptic 
plasticity is also known to be influenced by peripheral hormones, such as leptin, ghrelin 
and estrogens (Pinto, Roseberry et al. 2004; Gao, Mezei et al. 2007) as well as high fat 
diet (HFD) feeding in the hypothalamus (Horvath, Sarman et al. 2010). In order to 
investigate whether changes in synaptic connections in the hypothalamus of Cadm1 
deficient mice might explain the metabolic phenotype of these mice, measurements of 
postsynaptic currents were conducted from the hypothalamus of young Cadm1KO mice. 
Young mice between postnatal day 14 and 21 were chosen to avoid disturbing effects by 
myelination. Postsynaptic currents were measured from POMC-Enhanced green 
fluorescent protein (eGFP) neurons (Cowley, Smart et al. 2001) in the ARC, since these 
neurons play an important role in the regulation of energy and glucose homeostasis 
(1.1.4, 1.1.6).  
Inhibitory postsynaptic potential (IPSC) firing frequency onto POMC-eGFP neurons from 
Cadm1KO mice (Cadm1KO POMC-eGFP) was significantly reduced compared to control 
mice (control POMC-eGFP) (Figure 19 A, B), while excitatory postsynaptic potential 
(EPSC) frequency was not significantly different between mice of the two genotypes 
(Figure 19 C, D). In accordance to previous reports, amplitudes of IPSCs and EPSCs were 
not significantly different between Cadm1KO and control mice (Figure 19 B, D) (Robbins, 
Krupp et al. 2010). These data suggest that synaptic connectivity of hypothalamic Pomc-
expressing neurons is influenced by Cadm1 expression in the brain and might explain 
altered energy and glucose homeostasis in Cadm1KO mice.  
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Figure 19: IPSCs and EPSCs onto POMC-eGFP neurons from control and Cadm1KO mice 
[A] Recording samples showing spontaneous inhibitory postsynaptic potentials (IPSC)s 
onto pro-opiomelanocortin (POMC)-enhanced green fluorescent protein (eGFP) neurons 
and [B] Pooled data of frequency or amplitude of IPSCs recorded from control POMC-
eGFP neurons (N = 12 cells from 4 mice) and Cadm1KO POMC-eGFP neurons (N = 15 
cells from 4 mice) [C] Recording samples showing spontaneous excitatory postsynaptic 
potentials (EPSC)s onto POMC-eGFP neurons and [D] Pooled data of frequency or 
amplitude of EPSCs recorded from control POMC-eGFP neurons (N = 11 cells from 4 
mice) and Cadm1KO POMC-eGFP neurons (N = 7 cells from 4 mice). Displayed values are 
means ± S.E.M.  p ≤ 0.05. Electrophysiological analyses were conducted by Dr. Mirko 
Moroni, AG Siemens, MDC Berlin-Buch. 
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 Cadm1 deletion does not disturb GH production or release 3.1.6
Growth hormone (GH) is produced in the anterior pituitary and is a major positive 
regulator of longitudinal growth (List, Sackmann-Sala et al. 2011). Furthermore, GH is 
responsible for maintenance of glucose homeostasis in caloric-restricted situations 
(Zhao, Liang et al. 2010). GH exerts its effects on glucose homeostasis through induction 
of hyperinsulinemia and subsequent insulin resistance (Dominici and Turyn 2002). 
Conversely, GH deficient mice exhibit decreased -cell mass and increased insulin 
sensitivity (Liu, Coschigano et al. 2004).  
Cadm1KO mice show reduced longitudinal length (Figure 9) and increased insulin 
sensitivity (Figure 16). A potential role of CADM1 in GH release or signaling has not been 
investigated yet. However, CADM1 was shown to be expressed in hypothalamic neurons 
producing gonadotropin-releasing hormone (GnRH) (Sandau, Mungenast et al. 2011). 
Disruption of CADM1 in mice diminishes GnRH release from these neurons, reducing 
fertility in female mice. It was therefore questioned whether CADM1 might also be 
necessary for the proper production or release of the hypothalamic growth hormone-
releasing hormone (GHRH). GHRH is responsible for releasing GH from the pituitary 
gland (Löffler and Petrides 2003). 
First, it was questioned whether circulating GH levels might be different in Cadm1KO 
mice compared to control mice. Since GH levels alter in a circadian pattern over the day 
and might not be comparable between mice, circulating IGF-1 levels were measured 
instead of GH levels (Shuto, Shibasaki et al. 2002). IGF-1 is produced in the liver and 
correlates with GH levels independent of circadian rhythms (Shuto, Shibasaki et al. 
2002). As shown before, IGF-1 levels were lower in female control mice than in male 
control mice (Mao, Yang et al. 2009) (Figure 20A). In addition, IGF-1 levels were 
significantly reduced in both male and female Cadm1KO mice compared to littermate 
controls. 
In order to investigate whether production of Ghrh, Gh or growth hormone receptor 
(Ghr) might be changed in Cadm1KO mice, qRT-PCR was performed on hypothalami, 
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pituitary glands and livers from adult Cadm1KO and littermate control mice. 
Hypothalamic Ghrh gene expression was not significantly different between Cadm1KO 
and littermate control mice (Figure 20B). Likewise, Gh gene expression in the pituitary 
gland and Ghr gene expression in the liver were unchanged in Cadm1KO mice. 
Next, it was investigated whether CADM1 might influence the secretion capacity of 
GHRH or GH by challenging the release of these hormones. Intraperitoneal ghrelin 
injections were used to challenge release of GHRH in neurons of the ARC, which triggers 
GH release from the pituitary gland (Tennese and Wevrick 2011). Circulating GH levels 
showed no significant difference in Cadm1KO mice compared to control mice after 
ghrelin challenge (Figure 20C). These data suggest that secretion of GHRH and GH is not 
diminished in Cadm1KO mice.  
Taken together, circulating IGF1 levels were decreased in Cadm1KO mice compared to 
control mice, reflecting reduced body length in Cadm1KO mice. However, these changes 
were not caused by alterations in production or release of hypothalamic or pituitary 
gland hormones of the GH-GHRH axis in Cadm1KO mice. Although GH signaling was not 
investigated, the unchanged expression of Ghr might indicate a normal response to GH 
in Cadm1KO mice. 
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Figure 20: Basal IGF-1 levels, Ghrh, Gh and Ghr gene expression and ghrelin-challenged 
GH levels in Cadm1KO mice 
[A] Circulating IGF-1 concentrations in random fed male control (N = 7) and Cadm1KO (N 
= 6) mice and female control (N = 6) and Cadm1KO (N = 5) mice between 12 and 16 
weeks of age [B] Gene expression assessed by qRT-PCR of hypothalamic growth 
hormone-releasing hormone (Ghrh) in control (N = 7) and Cadm1KO mice (N = 8), 
pituitary gland growth hormone (Gh) in control (N = 9) and Cadm1KO mice (N = 9) and 
hepatic growth hormone receptor (Ghr) in control (N = 4) and Cadm1KO mice (N = 5) at 
random fed state between 12 and 16 weeks of age [C] GH concentrations after i.p. 
ghrelin injections in random fed male control (N = 7) and Cadm1KO (N = 7) mice 
between 12 and 16 weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.05;  
p ≤ 0.01. Gene expression analysis was conducted by Sudhir Gopal Tattikota, AG Poy, 
MDC Berlin-Buch. 
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3.2 Cadm1 deletion in pathophysiologic models of insulin 
resistance and obesity  
Since Cadm1 deletion improves glucose homeostasis and decreases body fat content in 
CHOW fed mice (3.1), it was questioned whether CADM1 also effects susceptibility to 
obesity and insulin resistance. Two models of obesity were chosen: a genetic-induced 
model of obesity and insulin resistance that is caused by leptin deficiency (ob/ob mouse) 
and a diet-induced model of obesity and insulin resistance (diet-induced obesity, DIO) 
caused by 10 weeks on HFD. 
 Cadm1 deletion does not protect from weight gain but improves insulin 3.2.1
sensitivity in genetic-induced obesity  
In order to address the effects of Cadm1 deficiency on genetic-induced obesity, 
Cadm1KO mice were crossed to ob/ob mice (The Jackson Laboratory, Bar Harbor, USA). 
The resulting leptin deficient Cadm1KO mice (Cadm1/ob) were compared to littermate 
ob/ob animals.  
To elucidate whether Cadm1 deletion might rescue genetic-induced obesity, energy 
homeostasis of Cadm1/ob compared to ob/ob was investigated. At weaning, male and 
female Cadm1/ob animals showed reduced body weight compared to ob/ob animals, 
which was consistent over the time of observation (Figure 21A,B). However, average 
body weight gain per week was not significantly different between Cadm1/ob and ob/ob 
animals in both genders (Figure 21C). Similar to Cadm1KO mice, body length was 
significantly reduced in adult Cadm1/ob males and strongly reduced in Cadm1/ob 
females (p = 0.07) (Figure 21D).  
In order to investigate whether the differences in body weight in Cadm1/ob mice might 
be due to changes in body composition, body fat mass and lean body mass were 
measured in adult Cadm1/ob and ob/ob mice by NMR. Absolute fat mass was strongly 
reduced in Cadm1/ob mice of both genders, while absolute lean body mass was 
unchanged in these mice compared to ob/ob mice (Figure 22A,B). Body fat content 
Results   81 
relative to body weight was reduced, whereas lean body mass relative to body weight 
was increased in male and female Cadm1/ob mice (Figure 22C,D).  
 
Figure 21: Body weight and body length of Cadm1/ob mice 
[A] Body weight of male ob/ob (N = 5 - 7) and Cadm1/ob (N = 5 - 7) mice between 4 and 
12 weeks of age [B] Body weight of female ob/ob (N = 8 - 13) and Cadm1/ob (N = 4 - 8) 
mice between 4 and 12 weeks of age [C] Average body weight gain per week of male 
ob/ob (N = 4) and Cadm1/ob (N = 5) mice and female ob/ob (N = 8) and Cadm1/ob (N = 
6) mice between 6 and 12 weeks of age [D] Body length of male ob/ob (N = 5) and 
Cadm1/ob (N = 6) mice and female ob/ob (N = 5) and Cadm1/ob (N = 3) mice between 
12 and 16 weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.05;  p ≤ 0.01 
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Figure 22: Body composition of Cadm1/ob mice 
[A] Absolute body fat content and [B] Absolute lean body mass content and [C] Relative 
body fat content normalized to body weight and [D] Relative lean body mass content 
normalized to body weight of male ob/ob (N = 5) and Cadm1/ob (N = 7) mice and female 
ob/ob (N = 10) and Cadm1/ob (N = 7) mice at 13 weeks of age. Displayed values are 
means ± S.E.M.  p ≤ 0.05;  p ≤ 0.01 
To address whether changes in food intake might have caused the decrease in body 
weight and body fat content of Cadm1/ob mice, food intake of male Cadm1/ob and 
ob/ob mice was measured. Absolute food intake (Figure 23A) and food intake adjusted 
for lean body mass by using ANCOVA (Figure 23B,C) showed no significant differences 
between Cadm1/ob mice and ob/ob males. Unchanged food intake adjusted for lean 
body mass is in line with the results that neither absolute food intake nor lean body 
mass is changed in Cadm1/ob mice in comparison to ob/ob males. 
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Figure 23: Food intake of Cadm1/ob mice 
[A] Absolute food intake and [B] Scatterplot showing linear regression for food intake as 
a function of group and lean body mass (ob/ob:                           ; 
Cadm1/ob:                              and [C] Food intake adjusted for 
lean body mass at 16.2276 g using ANCOVA of 3 consecutive days of ob/ob (N = 6) and 
Cadm1/ob (N = 6) males between 12 and 16 weeks of age. Displayed values are means ± 
S.E.M.  
We further investigated the energy homeostasis of Cadm1/ob mice, by evaluating 
energy expenditure through indirect calorimetry and locomotor activity of ob/ob and 
Cadm1/ob males. Absolute O2 and CO2 respiration, calculated energy expenditure and 
respiratory rate were not significantly different between the genotypes (Table 6). 
However, locomotor activity was significantly increased in male Cadm1/ob mice 
compared to ob/ob mice. Energy expenditure adjusted for locomotor activity using 
ANCOVA was significantly reduced in Cadm1/ob compared to ob/ob mice (Figure 
24A,B). These data suggest that Cadm1/ob mice would have lower energy expenditure if 
these animals had the same locomotor activity like ob/ob mice. The reason might be 
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that lower body weight of Cadm1/ob mice decreases energy costs for locomotor activity 
and therefore reduces energy expenditure in these mice. 
 
ob/ob Cadm1/ob 
VO2  [l/h] 88.57 ± 5.77 93.74 ± 6.44 
VCO2 [l/h] 83.34 ± 4.87 87.2 ± 5.28 
EE [kcal/h] 0.44 ± 0.03 0.47 ± 0.04 
RER 0.94 ± 0.01 0.93 ± 0.01 
Locomotor activity 
[counts/h] 
1382.7 ± 161.1 2024.1 ± 237.8  
Table 6: Energy expenditure, RER and locomotor activity of Cadm1/ob mice 
Average oxygen (VO2) and carbon dioxide (VCO2) respiration, calculated energy 
expenditure (EE) and respiratory rate (RER) as well as locomotor activity of male ob/ob 
(N = 6) and Cadm1/ob (N = 6) mice of 3 consecutive days between 12 and 16 weeks of 
age. Displayed values are means ± S.E.M.  p ≤ 0.05 
Furthermore, changes on glucose homoeostasis of Cadm1/ob compared to ob/ob mice 
were investigated. At 12 weeks of age, when hyperglycemia and insulin resistance of 
ob/ob mice is highly developed (Tomita, Doull et al. 1992), Cadm1/ob animals of both 
genders showed reduced blood glucose at random fed statues compared to ob/ob mice 
(Figure 25A). Insulin sensitivity of Cadm1/ob mice was tested by performing an ITT. 
Cadm1/ob animals showed significantly reduced blood glucose levels at all time-points 
after insulin injections compared to ob/ob animals, suggesting an improved insulin 
tolerance in Cadm1/ob mice (Figure 25B). Likewise, pancreatic insulin content, which is 
highly elevated in ob/ob mice due to insulin resistance (Tomita, Doull et al. 1992), was 
decreased in Cadm1/ob mice compared to ob/ob mice (Figure 25C). These data suggest 
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that deletion of Cadm1 partially rescues insulin resistance that is caused by genetic-
induced obesity. 
 
Figure 24: Analysis of covariance (ANCOVA) of energy expenditure and locomotor 
activity in male Cadm1/ob mice 
[A] Scatterplot showing linear regression for energy expenditure as a function of group 
and locomotor activity (ob/ob:                            ; Cadm1/ob: 
                             and [B] Energy expenditure adjusted for 
locomotor activity at 1.714 counts/h × 10³ using ANCOVA for male control (N = 6) and 
Cadm1KO (N = 6) mice between 12 and 16 weeks of age. Displayed values are means ± 
S.E.M.  p ≤ 0.05. 
Taken together, deletion of Cadm1 in a genetic-induced model of obesity does not affect 
body weight gain but increases locomotor activity without affecting energy expenditure 
or food intake. Furthermore, Cadm1 deletion in genetically obese animals rescues the 
obesity-related insulin resistance partially. 
86  Results 
 
Figure 25: Glucose homoeostasis of Cadm1/ob mice 
[A] Random glucose of male ob/ob (N = 7) and Cadm1/ob (N = 9) mice and female ob/ob 
(N = 13) and Cadm1/ob (N = 10) mice at 12 weeks of age [B] Insulin tolerance test of 
male and female ob/ob (N = 6) and Cadm1/ob (N = 3) mice between 12 and 16 weeks of 
age [C] Pancreatic insulin content of male and female ob/ob (N = 6), Cadm1/ob (N = 6) 
and Cadm1KO (N = 7) mice between 12 and 16 weeks of age. Displayed values are 
means ± S.E.M.  p ≤ 0.05;  p ≤ 0.01;  p ≤ 0.001 
 Cadm1 deletion does not protect from weight gain but improves insulin 3.2.2
sensitivity in diet-induced obesity  
To further address effects of Cadm1 deletion on the pathophysiology of obesity, obesity 
induced by HFD feeding (56 % of calories from fat) for 10 weeks was chosen as a second 
obesity model. Cadm1KO mice together with littermate control mice were changed to 
HFD between 4 and 7 weeks of age. Control mice fed HFD for 10 weeks showed 
significantly increased body weight compared to age-matched control mice on CHOW 
diet (Figure 26), confirming that obesity was induced by HFD after this period.  
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Figure 26: Body weight of control mice fed with CHOW or HFD 
Body weight of male control mice after 10 weeks on CHOW diet (N = 20) or high fat diet 
(HFD) (N = 7) and female control mice on CHOW diet (N = 24) or high fat diet (HFD) (N = 
9). Displayed values are means ± S.E.M.  p ≤ 0.001 
Before starting the HFD period, body weight measurements of multiple litters showed 
significant lower body weight for male and female Cadm1KO mice compared to control 
animals (Figure 27A,B), confirming the results above (Figure 9). During the following 10 
weeks on HFD, Cadm1KO males displayed a significantly reduced body weight in 
comparison to control mice (Figure 27A). Cadm1KO females had significantly reduced 
body weight at 1, 4, 6 and 8 weeks after starting HFD feeding (Figure 27B). Overall, 
average body weight gain per week between 0 and 10 weeks after the start of HFD 
feeding was not significantly different between control and Cadm1KO mice (Figure 27C).  
Measurements of body composition by NMR showed that male Cadm1KO mice did not 
display significant differences in absolute fat mass, fat mass relative to body weight and 
lean body mass relative to body weight (Figure 28A, C, D). Absolute lean body mass was 
significantly lower in male Cadm1KO mice compared to control mice (Figure 28B). These 
data showed that decreased body weight in HFD fed Cadm1KO males is mainly caused 
by decreased lean body mass. Female Cadm1KO mice did not show significant 
differences in absolute fat mass, lean body mass, fat mass relative to body weight or 
lean mass relative to body weight (Figure 28A, B, C, D). These data suggest that 
Cadm1KO mice are not protected from weight gain and elevated fat mass induced by 
HFD feeding.  
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Figure 27: Body weight of Cadm1KO mice during 10 weeks of HFD feeding 
[A] Body weight of male control (N = 7) and Cadm1KO (N = 6) mice and [B] Body weight 
of female control (N = 9) and Cadm1KO (N = 7) mice on high fat diet (HFD) [C] Average 
body weight gain per week of male control (N = 7) and Cadm1KO (N = 6) mice and 
female control (N = 9) and Cadm1KO (N = 7) mice between 0 and 10 weeks after start of 
HFD. Mice were changed to HFD between 4 and 7 weeks of age. Displayed values are 
means ± S.E.M.  p ≤ 0.05;  p ≤ 0.01 
To investigate whether changes on energy expenditure occur in Cadm1KO mice after 
HFD feeding, indirect calorimetry was conducted with control and Cadm1KO mice after 
10 weeks of HFD feeding. For male HFD Cadm1KO mice, indirect calorimetry showed 
that absolute O2 consumption, CO2 expiration and calculated energy expenditure were 
decreased compared to control mice (Table 7). Locomotor activity was significantly 
increased, while RER was unchanged in male Cadm1KO mice. Female HFD mice did not 
show significant differences between the genotypes (Table 7). Linear regression showed 
that energy expenditure and body weight are positively correlated in HFD male mice of 
both genotypes (Figure 29A). These data explain why male Cadm1KO mice on HFD, 
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which have lower body weight than control mice on HFD (Figure 27), also show lower 
energy expenditure compared to control mice on HFD (Table 7). Nevertheless, energy 
expenditure adjusted for locomotor activity did not show significant differences 
between control and Cadm1KO mice on HFD (Figure 29B,C). These experiments suggest 
that energy expenditure of control and Cadm1KO mice on HFD would not be 
significantly different, if animals from both genotypes had the same locomotor activity. 
Food intake measurements were not conducted with HFD fed mice, since HFD is crumbly 
and spills into the cage bedding. 
 
Figure 28: Body composition of Cadm1KO mice after 10 weeks of HFD feeding 
[A] Absolute body fat mass and [B] Absolute lean body mass and [C] Relative body fat 
mass normalized to body weight and [D] Relative lean body mass normalized to body 
weight of male control (N = 7) and Cadm1KO (N = 6) mice and female control (N = 5) and 
Cadm1KO (N = 4) mice after 10 weeks of high fat diet (HFD). Mice were changed to HFD 
between 4 and 7 weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.001 
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  Male Female 
 Control Cadm1KO Control Cadm1KO 
VO2 [l/h] 102.3 ± 2.6 95.3 ± 2.2  87.9 ± 4.4 86.6 ± 6.7 
VCO2 [l/h] 81.2 ± 2.0 74.4  ± 1.8  69.7 ± 3.9 67.9 ± 4.3 
EE                 
[kcal/h] 
0.49 ± 0.01 0.46 ± 0.01  0.42 ± 0.02 0.44 ± 0.03 




1721.9 ± 68.5 2046.6 ± 133.7 2546.4 ± 379.2 2138.1 ± 123.5 
Table 7: Energy expenditure, RER and locomotor activity of Cadm1KO mice after 10 
weeks of HFD feeding 
Average oxygen (VO2) and carbon dioxide (VCO2) respiration, calculated energy 
expenditure (EE) and respiratory rate (RER) as well as locomotor activity of male control 
(N = 7) and Cadm1KO (N = 6) mice and female control (N = 5) and Cadm1KO (N = 4) mice 
after 10 weeks on HFD of 3 consecutive days. Mice were changed to HFD between 4 and 
7 weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.05 
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Figure 29: Analysis of covariance (ANCOVA) of energy expenditure and locomotor 
activity in male Cadm1KO mice after 10 weeks of HFD feeding 
[A] Scatterplot showing linear regression for energy expenditure as a function of group 
and body weight (control:                              ; Cadm1KO: 
                               and [B] Scatterplot showing linear 
regression for energy expenditure as a function of group and locomotor activity (control: 
                            ; Cadm1KO:              
                  [C] Energy expenditure adjusted for locomotor activity at 1.87 
counts/h × 10³ using ANCOVA for male control (N = 7) and Cadm1KO (N = 6) mice after 
10 weeks of HFD feeding. Displayed values are means ± S.E.M. 
Furthermore, it was questioned whether insulin resistance, which is induced by DIO 
(1.1.4), can be improved by Cadm1 deletion. Male mice of both genders were 
challenged with an ITT after 10 weeks on HFD. As previously shown (Mori, Hanada et al. 
2004), control mice showed an attenuated response to insulin 15 min after insulin 
injections, further confirming that insulin resistance was induced by 10 weeks on HFD 
(Figure 30). However, Cadm1KO male mice showed significantly lower blood glucose 
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levels compared to control mice at 60 and 120 min after insulin injections, suggesting 
improved insulin sensitivity in Cadm1KO mice after HFD feeding. 
 
Figure 30: Insulin sensitivity of Cadm1KO mice after 10 weeks of HFD feeding 
Insulin tolerance test of male control (N = 7) and Cadm1KO (N = 7) mice after 10 weeks 
on high fat diet (HFD). Mice were changed to HFD between 4 and 7 weeks of age. 
Displayed values are means ± S.E.M.  p ≤ 0.05 
In summary, deletion of Cadm1 in diet- and genetic-induced models of obesity increases 
locomotor activity without increasing energy expenditure. Body weight gain is 
unaffected by Cadm1 deletion in models of obesity, while obesity-induced insulin 
resistance is rescued partially. 
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3.3 Energy and glucose homeostasis in mice with tissue-specific 
Cadm1 deletion  
In order to assess in which tissues CADM1 exerts its effects on energy and glucose 
homeostasis, conditional Cadm1KO mice were bred by crossing Cadm1 floxed mice (van 
der Weyden, Arends et al. 2006) with mouse lines expressing cre-recombinase under the 
control of gene promoters that are specifically expressed in neuronal- and glia cells or in 
cells expressing the Lepr (The Jackson Laboratory, Bar Harbor, USA). The resulting 
animals with tissue-specific Cadm1 deletion were examined for the phenotype similar to 
Cadm1KO mice. 
 Increased lean body mass and increased insulin sensitivity in mice with 3.3.1
neuron and glia cell-specific Cadm1 deletion 
The brain is a major regulator of homeostasis and can regulate both energy and glucose 
homeostasis (1.1.1; 1.1.5). CADM1 is highly expressed in different areas of the brain 
(1.3.1). In order to address CADM1’s role in central regulation of energy and glucose 
homeostasis, mice with a specific deletion of Cadm1 in neuronal and glia cell were bred 
by crossing mice carrying a floxed Cadm1 allele (Cadm1lox/lox) with mice expressing cre 
recombinase under the control of the rat nestin (Nes) promoter (Cadm1NesCreKO). The 
Nes promoter is active in glia- and neuronal precursors only (Tronche, Kellendonk et al. 
1999). Tissue-specific recombination was confirmed by Western Blotting in brain and 
lung, organs with the highest CADM1 protein expression (Figure 31) (Fogel, Akins et al. 
2007). While CADM1 could not be detected in the hypothalamus of Cadm1NesCreKO 
animals, lung tissue of these mice showed CADM1 protein expression. In addition, high 
CADM1 protein expression was detected in pituitary gland of Cadm1NesCreKO mice, 
which is in accordance to the previously described expression pattern of the Nes 
promoter (Tronche, Kellendonk et al. 1999). Unlike Cadm1NesCreKO mice, Cadm1KO 
mice showed no CADM1 protein expression in any of the tested tissues (Figure 31). 
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Figure 31: CADM1 protein abundance in Cadm1NesCreKO and Cadm1KO mice 
Western blot analysis of CADM1 in lung, hypothalamus (hypo) and pituitary gland 
(pit.gl.) of control, Cadm1NesCreKO and Cadm1KO mice.-tubulin abundance was used 
as loading control. 
To address the contribution of the brain in the phenotype of Cadm1KO mice, energy 
homeostasis of Cadm1NesCreKO mice was investigated. Cadm1NesCreKO mice of both 
genders between 10 and 13 weeks showed significantly lower body weight compared to 
control animals (Figure 32A). In addition, body length was decreased in Cadm1NesCreKO 
males (Figure 32B). To further address whether the reduced body weight of 
Cadm1NesCreKO mice is also caused by changes in body composition, fat mass and lean 
body mass of Cadm1NesCreKO and control mice were measured by NMR. Male 
Cadm1NesCreKO mice exhibited strongly decreased absolute body fat content (p=0.087) 
and significantly reduced absolute lean body mass (Figure 32C,D), while body fat 
content relative to body weight and body lean mass relative to body weight were 
unchanged (Figure 32E,F). Female Cadm1NesCreKO mice showed a significant reduction 
in absolute fat mass but an unchanged absolute lean body mass (Figure 32C,D). When 
normalized to body weight, relative fat mass was significantly reduced, whereas relative 
lean body mass was significantly increased in female Cadm1NesCreKO mice compared to 
control mice (Figure 32E,F).  
Furthermore, food intake of Cadm1NesCreKO mice was measured to evaluate whether 
changes in food intake might cause the decrease in body weight and body fat of these 
mice. Similar to Cadm1KO mice (Figure 11), absolute basal food of Cadm1NesCreKO 
male mice was unchanged compared to control mice (Figure 33).  
Results   95 
 
Figure 32: Body weight and body composition of Cadm1NesCreKO mice 
[A] Body weight of male control (N = 8) and Cadm1NesCreKO (N = 4) mice and female 
control (N = 9) and Cadm1NesCreKO (N = 8) mice between 12 and 16 weeks of age [B] 
Body length of male control (N = 4) and Cadm1NesCreKO (N = 3) mice between 12 and 
16 weeks of age [C] Absolute body fat content and [D] Absolute lean body mass content 
and [E] Relative body fat content normalized to body weight and [F] Relative lean body 
mass normalized to body weight of male control (N = 8) and Cadm1NesCreKO (N = 4) 
mice and female control (N = 9) and Cadm1NesCreKO (N = 8) mice between 12 and 16 
weeks of age. Displayed values are means ± S.E.M.  p ≤ 0.05;  p ≤ 0.01 
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Figure 33: Food intake of Cadm1NesCreKO mice 
Absolute food intake of 5 consecutive days of male control (N = 4) and Cadm1NesCreKO 
(N = 3) mice between 12 and 16 weeks of age. Displayed values are means ± S.E.M.  
Next, glucose and insulin sensitivity of Cadm1NesCreKO mice were assessed to evaluate 
the influence of Cadm1 deletion in neuronal and glia cells on glucose homeostasis. 
Similar to Cadm1KO mice (Figure 16), Cadm1NesCreKO male mice showed lower glucose 
levels compared to control mice at 30, 60 and 120 min after intraperitoneal injections of 
glucose (Figure 34A). Blood glucose levels of Cadm1NesCreKO males were also 
significantly lower 15 min after intraperitoneal injections of insulin (Figure 34B). 
Furthermore, 30 min after intraperitoneal injections blood glucose levels showed a 
strong trend for being lower in Cadm1NesCreKO mice (p = 0.06) compared to control 
mice. 
Taken together, deletion of Cadm1 specifically in neuronal and glia cells decreases body 
weight, body length and fat mass, which is not caused by decreased food intake. 
Furthermore, sensitivity to glucose and insulin is improved by deletion of Cadm1 
specifically in neuronal and glia cells. These results are consistent with the phenotype 
observed in Cadm1KO mice with the exception that female but not male 
Cadm1NesCreKO mice showed changes in body composition. 
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Figure 34: Glucose and insulin sensitivity of Cadm1NesCreKO mice 
[A] Glucose tolerance test of male control (N = 6) and Cadm1NesCreKO (N = 5) mice 
between 12 and 16 weeks of age [B] Insulin tolerance test of male control (N = 3) and 
Cadm1NesCreKO (N = 3) mice between 12 and 16 weeks of age. Displayed values are 
means ± S.E.M.  p ≤ 0.05 
 Unaltered lean body mass and slightly increased insulin sensitivity in 3.3.2
mice with Cadm1 deletion in Lepr-expressing cells 
In order to address in which subpopulation of neuronal cells CADM1 might influence 
energy and glucose homeostasis, Cadm1 was deleted in specific cell types expressing 
Lepr. These cell types were chosen since leptin plays an essential role in regulating 
glucose and energy homeostasis in the brain (1.1.6). Therefore, mice carrying a floxed 
Cadm1 allele (Cadm1lox/lox) were crossed with mice carrying cre recombinase under the 
control of the promoter of the Lepr gene (LepRCre) (Balthasar, Coppari et al. 2004). 
Cadm1 deletion in the resulting Cadm1LepRCreKO mice was expected to be restricted to 
cells expressing Lepr, such as hypothalamic arcuate nucleus neurons. In order to 
visualize specific recombination in Lepr-expressing cells, reporter mice expressing 
LepRCre and yellow fluorescent protein (YFP) under the control of the ubiquitously 
expressed Rosa26 promoter were used (Rosa26-YFP). By using immunohistochemistry, 
YFP immunofluorescence could be detected in a subpopulation of neurons in the ARC 
and median eminence (Figure 35), confirming recombination in a subpopulation of cells 
as shown before (Louis, Leinninger et al. 2010). This suggests that recombination of 
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LepRCre and Cadm1lox/lox might yield a similar cell specific deletion of Cadm1 in the 
hypothalamus and in other Lepr-expressing cells.  
 
Figure 35: Recombination of LepRCre and Rosa26-YFP in the arcuate nucleus and 
median eminence 
Immunohistochemistry of the hypothalamic arcuate nucleus (ARC) and median 
eminence (ME) of mice expressing LepRCre and Rosa26-YFP (YFP: green) between 12 
and 16 weeks of age. Blue shows DAPI staining for nuclei. Immunohistochemistry and 
visualization was conducted by Kun Song, AG Siemens, MDC Berlin-Buch. 
To test whether CADM1 might affect energy and glucose homeostasis in Lepr-expressing 
cells, the phenotype of Cadm1LepRCreKO mice was analyzed in a similar manner as 
Cadm1KO mice. Cadm1LepRCreKO mice of both genders did not show significant 
differences in body weight at 13 weeks of age compared to control mice (Figure 36A). 
Since body weight was unchanged in Cadm1LepRCreKO mice, it was questioned whether 
body composition was also unchanged in these mice. Indeed, absolute body fat and lean 
body mass (Figure 36B,C) as well as body fat and lean body mass normalized to body 
weight (Figure 36D,E) did not show differences between the genotypes in both genders 
at 13 weeks of age.  
In addition, absolute food intake was not significantly different between female 
Cadm1LepRCreKO and control mice (Figure 37A). Similarly, food intake and body weight 
loss after 24 h food deprivation were unchanged in Cadm1LepRCreKO females (Figure 
37B,C).  
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Figure 36: Body weight and body composition of Cadm1LepRCreKO mice 
[A] Body weight and [B] Absolute body fat content and [C] Absolute lean body mass and 
[D] Relative body fat content normalized to body weight and [D] Relative lean body 
mass normalized to body weight of male control (N = 12) and Cadm1LepRCreKO (N = 7) 
mice and female control (N = 15) and Cadm1LepRCreKO (N = 8) mice between 13 - 16 
weeks of age. Displayed values are means ± S.E.M.  
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Figure 37: Food intake of Cadm1LepRCreKO mice 
[B] Absolute food intake of 5 consecutive days and [B] 3 h food intake after 24 h 
starvation and [D] Relative body weight change after 24 h starvation of female control 
(N = 7) and Cadm1LepRCreKO (N = 4) mice between 12 and 16 weeks of age after 24 h 
starvation. Displayed values are means ± S.E.M  
Furthermore, it was addressed whether glucose homeostasis is affected by deletion of 
Cadm1 in Lepr-expressing cells. Sensitivity tests for insulin and glucose did not show 
significant differences in female Cadm1LepRCreKO mice at 15, 30 or 60 min after 
intraperitoneal injections of either insulin or glucose compared to their littermate 
controls (Figure 38 A,B). Only 120 min after intraperitoneal insulin injections, female 
Cadm1LepRCreKO mice showed a slight but significant increase in insulin sensitivity 
(Figure 38 B). 
In summary, mice which presumably carry a Cadm1 deletion in cells expressing Lepr do 
not exhibit changes in body weight, body composition or glucose sensitivity as opposed 
to Cadm1KO mice, while insulin sensitivity is slightly improved by Cadm1 deletion in 
Lepr-expressing cells. 
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Figure 38: Glucose and insulin sensitivity of Cadm1LepRCreKO mice 
[A] Glucose tolerance test of female control (N = 6) and Cadm1LepRCreKO (N = 4) mice 
between 12 and 16 weeks of age [B] Insulin tolerance test of female control (N = 17) and 
Cadm1LepRCreKO (N = 9) mice between 12 and 16 weeks of age. Displayed values are 
means ± S.E.M.  p ≤ 0.05 
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4 Discussion 
CADM1 has been described as a mediator of synapse formation and functioning with 
implications in spatial memory and learning behavior (Robbins, Krupp et al. 2010; Stagi, 
Fogel et al. 2010). In the past, several studies provided basic descriptions of CADM1 in 
pancreatic islets (Koma, Furuno et al. 2008; Suckow, Comoletti et al. 2008; Poy, Hausser 
et al. 2009). However, a role of CADM1 in controlling energy and glucose homeostasis in 
pancreatic islets, the brain or other tissues has not been investigated yet. 
The aim of our work was to evaluate the influence of CADM1 in peripheral and central 
tissues on glucose and energy homeostasis of the body. Our data suggest that CADM1 
influences both energy and glucose homeostasis in mice. Analyses of energy 
homeostasis showed that male Cadm1KO mice have increased energy expenditure 
through enhanced locomotor activity. Furthermore, Cadm1KO males displayed 
decreased relative fat mass and increased relative lean body mass and thus showed 
changed body composition. Blood leptin levels were also decreased in Cadm1KO males. 
Glucose-stimulated insulin secretion was enhanced in male Cadm1KO animals. In 
addition, insulin sensitivity of Cadm1KO males was enhanced after HFD feeding. In 
Cadm1KO female mice, insulin sensitivity was increased and glucose-stimulated insulin 
secretion was strongly, but not significantly enhanced. Female Cadm1KO mice did not 
show changes in energy expenditure or body composition. Cadm1KO mice of both 
genders showed reduced postnatal growth and unchanged body weight gain after four 
weeks of age as well as reduced body length as adult mice. Food intake was unchanged 
in both genders of Cadm1KO mice compared to control mice.  
Cadm1 deletion in models of genetic and diet-induced obesity improved sensitivity to 
insulin but did not prevent weight gain, suggesting that CADM1 improves obesity-
induced insulin resistance but does not influence susceptibility to obesity. Mice with 
neuronal and glia cell specific Cadm1 deletion showed similar changes in body 
composition, body length, food intake and insulin sensitivity like Cadm1KO mice. As 
Cadm1 deletion in neuronal and glia cells results in a similar phenotype like Cadm1 
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deletion in the whole body, an important role of CADM1 in these tissues for energy and 
glucose homeostasis can be suggested. 
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4.1 Validation of Cadm1 deletion models 
While mouse models with Cadm1 deletion in different tissues are available and 
relatively easily to study, human patients with CADM1 missense mutations have not 
been investigated for their metabolic phenotype (Murakami 2005). However, CADM1 is 
highly conserved in vertebrates with highest homology between human and mouse 
reaching 98 % sequence homology (Biederer 2006). Mice are therefore a useful model 
organism for the prediction of CADM1 functions in other vertebrate species, including 
humans. 
 Mice completely deficient for Cadm1 and deficient for Cadm1 in 4.1.1
neuronal and glia cells 
In order to address whether CADM1 might play a role in energy and glucose 
homeostasis, we assessed mice with total Cadm1 deletion and tissue specific Cadm1 
deletion for changes in energy and glucose homeostasis. Deletion of Cadm1 in 
hypothalamus, lung and pituitary gland of total Cadm1KO mice was confirmed by 
Western blotting (Figure 31). Mice with a specific Cadm1 deletion in neuronal and glia 
cells (Cadm1NesCreKO) exhibited deletion in the hypothalamus but not in lung and 
pituitary gland (Figure 31). These data confirm the previously described expression 
pattern of NesCre in neuronal tissue (Tronche, Kellendonk et al. 1999). Cadm1KO and 
Cadm1NesCreKO mice are therefore expected to carry deletion in Cadm1 in the whole 
body or in neuronal and glia cells only, respectively. 
 Mice deficient for Cadm1 in Lepr-expressing cells 4.1.2
In addition, we used a previously described mouse model expressing cre recombinase 
under the control of the Lepr promoter (LepRCre) to generate Cadm1LepRCreKO mice 
(DeFalco, Tomishima et al. 2001) in order to study the contribution of CADM1 in leptin 
sensitive cell types. However, deletion of genes and their corresponding proteins in a 
defined subpopulation of cells in the hypothalamus is usually difficult to detect by gene 
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or protein expression analysis, since the cells affected by gene deletion reflect a very 
small portion in the whole hypothalamus (Konner, Janoschek et al. 2007). Using 
immunohistochemistry to visualize Cadm1 deletion in hypothalamic Lepr-expressing 
cells is also not possible, since available antibodies for immunohistochemistry also 
detect CADM2, CADM3 and CADM4 (Sandau, Mungenast et al. 2011) (Figure 13). 
Therefore, mice carrying LepRCre were crossed with reporter mice expressing YFP under 
the control of the Rosa26 promoter (Rosa26-YFP). Immunofluorescent detection of YFP 
could be detected in a subpopulation of cells in the ARC and ME (Figure 35), similar to 
what was shown before (Louis, Leinninger et al. 2010). It is therefore expected, that 
crossing mice carrying LepRCre with Cadm1lox/lox mice would yield animals with a similar 
deletion of Cadm1 specifically in cells expressing Lepr. However, a clear prove for correct 
recombination of the LepRCre and Cadm1lox/lox alleles is missing and results of the 
Cadm1LepRCreKO mice have to be interpreted with caution. Furthermore, Lepr 
expression was found in several peripheral tissues of the body (Fruhbeck 2001), 
including pancreas. Endocrine cells of the pancreas also express Cadm1 (1.3.2) and 
conditional deletion of Cadm1 in these cells might influence glucose homeostasis in 
Cadm1LepRCreKO mice. 
  
Discussion   107 
4.2 Role of CADM1 in energy homeostasis 
 CADM1 influences locomotor activity and body composition 4.2.1
Male Cadm1 deficient mice showed increased locomotor activity (Table 5, Figure 14). 
These findings could be confirmed in diet and genetic-induced obese Cadm1 deficient 
mice (Figure 24,  
Figure 29). Furthermore, relative and absolute body fat content was decreased in 
Cadm1KO males and in genetic-induced obese Cadm1 deficient mice (Figure 10, Figure 
22). Enhanced physical activity influences body composition in humans and rodents 
mainly by reducing body fat content (Yki-Jarvinen and Koivisto 1983; Davies, Gregory et 
al. 1995; Saltzman and Roberts 1995; Swallow, Koteja et al. 2001). These data suggest 
that increased locomotor activity caused by deletion of Cadm1 might lead to changes in 
body composition in Cadm1 deficient mice.  
The brain has a fundamental role in the control of locomotor activity and genetic 
variations which induce hyperactivity, e.g. through altering GABA signaling in the brain, 
have been described (Viggiano 2008; Mignogna and Viggiano 2010). CADM1 is also 
highly expressed in the brain and can influence GABA signaling there (1.3.1; 1.3.3). 
Direct measurements of locomotor activity in Cadm1NesCreKO mice have not been 
conducted in our studies for technical reasons. However, Cadm1NesCreKO males 
showed strongly reduced body fat content (Figure 32), suggesting that locomotor 
activity might be increased in these mice. We therefore postulate that CADM1 controls 
locomotor activity through its action in neuronal tissues.  
Unlike genetic-induced obese Cadm1KO males, diet-induced obese Cadm1KO mice lack 
significant changes in body fat content (Figure 22, Figure 28). This might be explained by 
the previously shown high variations in susceptibility to diet-induced obesity in the 
C57BL/6N strain that we used as background strain for our Cadm1KO mice (de Leeuw 
van Weenen, Parlevliet et al. 2011). These high variations in susceptibility to obesity 
could hide the differences between Cadm1KO and control mice. The reason why 
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genetic-induced obese Cadm1KO and Cadm1NesCreKO females showed significantly 
changed body composition but Cadm1KO females did not is currently not clear (Figure 
22, Figure 32, Figure 10).  
Taken together, we suggest that Cadm1 deletion increase locomotor activity through its 
action in the brain and subsequently changes body composition by reducing body fat 
content. 
 CADM1 effects on locomotor influence insulin sensitivity  4.2.2
Locomotor activity was increased in male Cadm1KO mice (Figure 14, Table 7), while 
body fat content of male Cadm1KO mice was reduced (Figure 10). Insulin sensitivity was 
increased in male Cadm1KO mice under HFD feeding (Figure 28). Similar, Cadm1/ob 
showed increased locomotor activity, reduced body fat content and increased insulin 
sensitivity (Figure 24, Figure 22, Figure 25). Also Cadm1NesCreKO mice showed 
increased insulin sensitivity and reduced body fat content (Figure 34, Figure 32). 
Enhancement of energy expenditure can increase insulin sensitivity in humans and mice 
(Hu, Sigal et al. 1999; Kriska, Saremi et al. 2003; Birkenfeld, Lee et al. 2011; Choi, 
Yablonka-Reuveni et al. 2011). The improving effect of physical activity on insulin 
sensitivity can be explained by two independent mechanisms. On one hand, physical 
activity can increase glucose uptake in skeletal muscle through mechanisms such as 
increased GLUT4 expression (Nesher, Karl et al. 1985; Wallberg-Henriksson and Holloszy 
1985; Kraniou, Cameron-Smith et al. 2006). On the other hand, physical activity reduces 
body fat content, which is associated with increased insulin sensitivity (Yki-Jarvinen and 
Koivisto 1983; Banerji, Faridi et al. 1999). These results implicate that increased 
locomotor activity might improve insulin sensitivity in Cadm1KO mice directly or through 
reducing body fat content.  
Cadm1KO male mice did not show significant changes in body fat content after HFD 
feeding (Figure 28). This might be caused by high variations in susceptibility to diet-
induced obesity as explained above (4.2.1). Alternatively, increased locomotor activity 
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might directly increase insulin sensitivity in these mice, through increasing glucose 
uptake as discussed above.  
In summary, we suggest that reduced body fat content or increased locomotor activity 
or both are at least partially responsible for improved insulin sensitivity in Cadm1 
deficient mice.  
 Influence of CADM1 on food intake and body weight 4.2.3
In our work, we demonstrated that male Cadm1KO mice showed increased locomotor 
activity compared to control mice (Figure 14). Furthermore, average body weight gain in 
Cadm1KO mice was not significantly different between 4 and 12 weeks of age (Figure 9). 
Decreased Pomc expression (Figure 12) and increased AMPK activity and expression 
(Figure 13) were measured in Cadm1KO mice. Both changes are expected to induce food 
intake in the brain (Minokoshi, Alquier et al. 2004) (1.1.4, 1.1.6). Starvation-induced 
food intake was enhanced in Cadm1KO mice (Figure 12). These results indicate that 
basal food intake in Cadm1KO mice is increased compared to control mice. We 
therefore suggest that enhanced locomotor activity in adult Cadm1KO mice together 
with enhanced food intake results in unchanged body weight gain for these animals.  
Due to technical limitations, energy expenditure and food intake have to be measured in 
single-housed animals, while body weight was measured in group-housed mice. In order 
to investigate energy expenditure and food intake in Cadm1 deficient mice, we allowed 
newly isolated mice to acclimatize for 24 hours in the measurement cages followed by 
three days of measurements. Acute isolation between one and 24 h induces anxiety-
related behavior in rats (Maisonnette, Morato et al. 1993). Cadm1 deficient mice were 
reported to display increased anxiety-related behavior, even under normal conditions 
(Takayanagi, Fujita et al. 2010). Therefore, Cadm1KO mice might be prone to anxiety-
related behavior under single housing conditions more than control mice, possibly 
influencing measurements of energy expenditure and food intake. Therefore data from 
single housing, such as the unchanged basal food intake from Cadm1KO mice (Figure 
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12), should be treated with caution. Nevertheless, the increased locomotor activity 
measured under single housing conditions is likely to occur also under group housing 
conditions, since changes in body composition, which were measured in group-housed 
animals, are thought to be caused by increased locomotor activity as discussed above 
(4.2.1). However, these results need further confirmation. Future studies should 
therefore include adaptation times to single housing of several weeks before measuring 
energy homeostasis in Cadm1 deficient mice. Alternatively, all animals used for 
experiments on energy and glucose homeostasis should be housed individually to avoid 
differences in behavior to influence experimental results.  
For young Cadm1KO mice between postnatal day 14 and 21, IPSC frequency onto 
hypothalamic Pomc-expressing neurons was decreased compared to control mice 
(Figure 19). A decreased IPSC frequency onto Pomc-expressing neurons is expected to 
enhance -MSH release, one anorexic product of the Pomc gene (Tung, Piper et al. 
2006). At this age, also body weight gain was impaired in Cadm1KO mice compared to 
control mice (Figure 9). It is therefore likely, that the decreased IPSC frequency onto 
Pomc-expressing neurons reflects reduced food intake in young Cadm1KO mice, which 
might explain the impaired body weight gain at that age. 
 CADM1 and its role in controlling leptin signaling  4.2.4
Cadm1/ob mice showed changes like Cadm1KO mice in locomotor activity, body weight, 
body weight gain and food intake (Figure 21, Figure 24). Since Cadm1/ob mice lack 
leptin signaling but show a similar phenotype like Cadm1KO mice, it is likely that leptin is 
dispensable for the effects of CADM1 on energy homeostasis signaling. 
Cadm1LepRCreKO mice showed no differences in body composition or body weight 
(Figure 36), indicating that deletion of CADM1 in leptin sensitive cells is unlikely to be 
responsible for the effects of CADM1 on energy homeostasis. Together, these data 
suggest that CADM1 does not mediate effects on energy homeostasis through 
regulating leptin signaling.  
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Leptin is an anabolic hormone enhancing energy expenditure and decreasing food intake 
(Balthasar, Dalgaard et al. 2005). Changes in leptin signaling should therefore lead to 
changes in body weight gain in adult mice (Satoh, Ogawa et al. 1997; Mori, Hanada et al. 
2004). However, body weight gain was not different in adult Cadm1KO mice and in diet 
and genetic-induced obese Cadm1 deficient mice (Figure 9, Figure 21, Figure 27). 
Instead, body weight differences in adult Cadm1KO animals were probably caused by 
differences in body weight gain during postnatal development (Figure 9). Recent 
literature suggests that leptin influences GABA signaling on postsynaptic Pomc-
expressing neurons (Cowley, Smart et al. 2001; Vong, Ye et al. 2011). Body weight gain is 
regulated by these leptin-mediated effects on postsynaptic Pomc-expressing neurons. 
Since body weight gain was not changed in Cadm1 deficient mice (Figure 9, Figure 21, 
Figure 27), also an effect of CADM1 on postsynaptic Pomc-expressing neurons through 
its influence on GABA signaling is unlikely to be the mechanism of CADM1-mediated 
changes on energy homeostasis. These data further implicate that CADM1 does not 
affect energy homeostasis through regulation of leptin signaling. 
Circulating leptin levels correlate with body fat content (1.1.6). Our results showed that 
male Cadm1KO mice have reduced leptin blood concentrations and reduced body fat 
content (Figure 11, Figure 10). Cadm1NesCreKO mice showed strongly reduced body fat 
content (Figure 32) and a similar phenotype in regards to body weight and food intake 
like Cadm1KO mice (Figure 32, Figure 33), suggesting that Cadm1NesCreKO might also 
show changes in leptin levels. Nestin expression is restricted to neuronal and glia cells 
(Tronche, Kellendonk et al. 1999) and Cadm1NesCreKO mice are expected to express 
Cadm1 in adipose tissue, the tissue responsible for leptin secretion (1.2.1). Therefore, it 
is unlikely that CADM1 regulates the release of leptin in adipose tissue. Instead, Cadm1 
deletion is likely to reduce body fat mass in Cadm1 deficient mice, which then causes 
secondary changes in leptin levels. It can therefore be suggested that CADM1-mediated 
effects on energy homeostasis are not caused by CADM1 acting on leptin signaling or 
leptin release. 
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In conclusion, we propose that Cadm1 deletion in male mice increases locomotor 
activity through its action in neuronal tissues, while food intake is compensatory 
increased or vice versa. Increased locomotor activity subsequently decreases body fat 
content. Reduced body fat content contributes to increased insulin sensitivity and 
causes decreased circulating leptin levels. 
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4.3 Role of CADM1 in neuronal insulin signaling 
We suggested that CADM1 influences insulin sensitivity by changing locomotor activity 
and subsequent body composition (4.2.2). In Cadm1KO females, insulin sensitivity was 
improved (Figure 16) but locomotor activity and body composition were unchanged 
(Figure 10, Figure 15). Therefore, insulin sensitivity seems to be improved in Cadm1 
deficient animals also by other mechanisms than body composition or locomotor 
activity alterations.  
 CADM1 might influence insulin sensitivity through regulating neuronal 4.3.1
insulin signaling 
As discussed above, CADM1 does not seem to exert its effects on energy homeostasis 
through influencing leptin signaling (4.2.4). Enhanced insulin sensitivity also occurred in 
leptin deficient Cadm1/ob mice (Figure 25), indicating that leptin signaling is dispensable 
for CADM1-mediated effects on insulin sensitivity. Another important regulator of 
insulin sensitivity in neuronal tissues is insulin itself (1.1.4). Könner et al. showed that 
neuronal insulin signaling enhances insulin sensitivity, the inulin-mediated decrease of 
blood glucose levels, through suppression of HGP (Konner, Janoschek et al. 2007). 
Insulin-mediated regulation of HGP involves reduced firing frequency of Agrp-expressing 
neurons and reduced release of AGRP and other neurotransmitters from these neurons. 
Due to technical limitations, insulin-stimulated firing frequency of Agrp-expressing 
neurons from Cadm1KO mice could not be measured. However, we showed that IPSC 
frequency onto Pomc-expressing neurons from Cadm1KO mice was reduced (Figure 19). 
It is known that Pomc-expressing neurons are inhibited by innervation from Agrp-
expressing neurons (Cowley, Smart et al. 2001; Tong, Ye et al. 2008) (1.1.4). It is 
therefore possible, that the reduced IPSC frequency onto Pomc-expressing neurons in 
Cadm1KO mice is caused by reduced firing frequency of Agrp-expressing neurons. 
Reduced firing frequency of Agrp-expressing neurons results in reduced HGP (Konner, 
Janoschek et al. 2007). Thus, reduced firing frequency of Agrp-expressing neurons and 
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subsequent reduced HGP might be the cause of the lower blood glucose levels after 
insulin injections in Cadm1KO mice (Figure 39). 
Basal and fasted blood glucose levels were unchanged in Cadm1KO mice compared to 
control mice (Figure 16). The study by Könner et al. also reported that basal and fasted 
blood glucose levels of mice with deficient insulin signaling in Agrp-expressing neurons 
were unchanged, suggesting that altered insulin signaling in Agrp-expressing neurons 
does not induce major disturbances in glucose homeostasis (Konner, Janoschek et al. 
2007). Our results confirm that CADM1 might influence HGP through neuronal insulin 
signaling without inducing major disturbance in glucose homeostasis. Furthermore, we 
measured enhanced glucose tolerance In Cadm1KO mice (Figure 16), which can partially 
be explained by increased glucose-stimulated insulin release (Figure 17). The study by 
Könner et al. showed that the decreased suppression of HGP in mice with deficient 
insulin signaling in Agrp-expressing neurons is balanced by increased glucose uptake in 
white adipose tissue (Konner, Janoschek et al. 2007), resulting in unchanged glucose 
tolerance. Other studies by Lin et al. showed that overexpression of insulin receptor in 
Agrp-expressing neurons does not lead to significant changes in peripheral glucose 
uptake, suggesting that a balancing glucose uptake in peripheral tissue does not exist in 
models with enhanced neuronal insulin sensitivity (Lin, Plum et al. 2010). We therefore 
suggest that Cadm1 deletion might increase neuronal insulin signaling through reducing 
firing frequency from Agrp-expressing neurons. Subsequent reduced HGP reduces blood 
glucose levels in Cadm1KO mice, which is not compensated by glucose uptake from 
peripheral tissues. This might contribute to enhanced glucose tolerance and results in 
increased insulin sensitivity. 
Our results showed that EPSC frequency was unchanged, while IPSC firing frequency was 
significantly reduced in the hypothalamus of Cadm1KO mice (Figure 19). Studies by 
Robbins et al. reported that EPSC frequency was significantly reduced in the 
hippocampus of Cadm1 deficient mice, while IPSC firing frequency was not affected in 
these mice (Robbins, Krupp et al. 2010). These differences can be explained by the 
predominant number of inhibitory GABAergic neurons in the ARC (Vong, Ye et al. 2011), 
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while excitatory glutamatergic neurons dominate in the hippocampus (Robbins, Krupp 
et al. 2010). While Cadm1 deletion reduces firing frequency in inhibitory and excitatory 
neurons, the neuron type affected by CADM1 seems to be dependent on the local 
abundance of each neuron type.  
 
Figure 39: Cadm1 deficiency might enhance neuronal insulin signaling 
Increased insulin levels in the blood enhance insulin signaling in Agrp-expressing 
neurons, which subsequently reduces firing frequency and AGRP release from these 
neurons. Reduced AGRP release reduces HGP and subsequent blood glucose levels. In 
addition, Agrp-expressing neurons innervate Pomc-expressing neurons. Reduced insulin-
mediated firing frequency from Agrp-expressing neurons increases -MSH release, the 
most important protein product of the Pomc gene, and subsequent locomotor activity. 
Cadm1 deficiency is postulated to further decrease insulin-mediated firing frequency 
from Agrp-expressing neurons or AGRP signaling or both, leading to decreased insulin-
mediated blood glucose levels and increased locomotor activity.  
Abbreviations: Agouti-related protein (AGRP); Hepatic glucose production (HGP); α-
Melanocyte-stimulating hormone (α-MSH) 
116  Discussion 
 CADM1 might influence locomotor activity through regulating neuronal 4.3.2
insulin signaling 
Our results showed that IPSC frequency onto Pomc-expressing neurons was reduced in 
Cadm1KO mice (Figure 19). Locomotor activity was increased in Cadm1KO male mice 
(Table 5, Figure 14). Strikingly, CADM1 effects on locomotor activity do not alter body 
weight gain (4.2.2). Recent literature reports that changes in neuronal insulin signaling 
can alter locomotor activity without changing body weight gain (Konner, Janoschek et al. 
2007; Lin, Plum et al. 2010). Insulin-mediated effects on locomotor activity involve 
increased insulin signaling in Pomc-expressing neurons and subsequent enhanced -
MSH release (Lin, Plum et al. 2010). Since we measured decreased IPSC frequency onto 
Pomc-expressing neurons in Cadm1KO mice, it can be assumed that these neurons also 
release increased -MSH amounts. This increased -MSH release might be responsible 
for increased locomotor activity in Cadm1KO mice. We therefore hypothesize that 
CADM1 regulates locomotor activity through regulation of excitation of Pomc-expressing 
neurons (Figure 39). This might involve regulation of AGRP release, as discussed above 
(4.3.1), or GABA signaling between Agrp-expressing neurons and Pomc-expressing 
neurons, since CADM1 was implicated to be involved in GABA-mediated inhibitory 
signaling (Fujita, Tanabe et al. 2012) (1.3.1) and GABA is coexpressed in Npy/Agrp-
expressing neurons (Cowley, Smart et al. 2001; Tong, Ye et al. 2008) (1.1.4).  
The study by Könner et al. showed that inhibition of insulin signaling in Agrp-expressing 
neurons or Pomc-expressing does not change circulating leptin levels. The data from 
Könner et al. further suggested that body composition and possibly locomotor activity is 
not changed in mice with deletion of insulin receptor in Agrp-expressing or Pomc-
expressing neurons (Konner, Janoschek et al. 2007), since leptin levels directly correlate 
with body fat content and body fat content is negatively regulated by physical activity 
(1.1.6, 4.2.1). In contrast, overexpression of insulin receptor in Pomc-expressing neurons 
reduces circulating leptin levels and increases locomotor activity (Lin, Plum et al. 2010). 
It can therefore be concluded that inhibition of neuronal insulin signaling does not 
change locomotor activity and leptin levels, whereas induction of neuronal insulin 
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signaling increases locomotor activity and reduces leptin levels. Our data showed that 
male Cadm1KO mice also exhibit reduced circulating leptin levels besides increased 
locomotor activity (Figure 11, Figure 14). These data further support our hypothesis that 
deletion of Cadm1 might increase locomotor activity through enhancing neuronal insulin 
signaling. Changes in locomotor activity likely decrease leptin levels as disused before 
(4.2.4).  
Male Cadm1KO mice exhibited increased locomotor activity (Figure 14). Hypothalamic 
Pomc expression was decreased in Cadm1KO mice (Figure 12). Recent literature 
suggests that increased locomotor activity can be induced by increased signaling from 
Pomc-expressing neurons (Lin, Plum et al. 2010). Increased signaling from Pomc-
expressing neurons correlates with increased Pomc expression (Birnberg, Lissitzky et al. 
1983; Loeffler, Demeneix et al. 1986). These findings seem to contradict our findings of 
increased locomotor activity besides decreased Pomc expression. It has been shown that 
different subpopulations of Pomc-expressing neurons exist in the hypothalamus with 
differing functions (Balthasar, Dalgaard et al. 2005; Williams, Margatho et al. 2010; 
Sohn, Xu et al. 2011). It is therefore possible that locomotor activity and food intake 
might be regulated by distinct Pomc-expressing neuron populations. The majority of 
Pomc-expressing neurons might regulate food intake and decrease overall Pomc 
expression in hypothalami of Cadm1KO mice in order to increase food intake (Figure 12) 
(4.2.3). A minority of Pomc-expressing neurons might regulate locomotor activity and lie 
in a distinct region compared to food intake regulating Pomc-expressing neurons. 
Enhanced -MSH release from these neurons might increase locomotor activity in 
Cadm1KO mice.  
In summary, we suggest that Cadm1 deletion might increase locomotor activity through 
decreasing insulin-mediated signaling between Agrp-expressing and Pomc-expressing 
neurons. Activity of Pomc-expressing neurons is subsequently increased, resulting in 
increased locomotor activity in Cadm1KO mice. Regulation of food intake and locomotor 
activity seems to be mediated through different subpopulations of Pomc-expressing 
neurons. 
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 CADM1 might influence signaling from insulin receptor-expressing 4.3.3
neurons but not from Lepr-expressing neurons 
Recent publications suggested that insulin receptor and Lepr might be expressed on 
different subpopulations of Pomc-expressing and Agrp-expressing neurons and cross-
talk between these different subpopulations connect both signaling cascades (Williams, 
Margatho et al. 2010). We hypothesized that CADM1 influences signaling from Agrp-
expressing neurons or between Pomc- and Agrp-expressing neurons (4.3.1, 4.3.2). Our 
experiments revealed that leptin signaling is dispensable for the effects of CADM1 on 
energy homeostasis (4.2.4). We therefore suggest that CADM1 might be expressed in 
Agrp-expressing neurons which express insulin receptor, but not in Agrp-expressing 
neurons expressing Lepr. This way, CADM1 would influence insulin signaling, but not 
leptin signaling from Agrp-expressing neurons. 
Our experiments showed that mice with specific Cadm1 deletion in neurons expressing 
Lepr (Cadm1LepRCreKO) displayed only slight improvements of insulin sensitivity (Figure 
38). These data indicate that CADM1 does not influence insulin sensitivity mainly 
through influencing leptin signaling in Lepr-expressing cells. Slight changes on insulin 
sensitivity in Cadm1LepRCreKO mice might be a result of deletion of Cadm1 in a few 
cells expressing insulin receptor and Lepr. However, we expect the majority of Cadm1-
deleted neurons to express only Lepr, which does not affect insulin signaling. 
Alternatively, slight changes on insulin sensitivity in Cadm1LepRCreKO mice might be a 
result of Cadm1 deletion in Lepr-expressing cells affecting neighboring cell types, such as 
insulin receptor-expressing cells, since cross-talk between Lepr- and insulin receptor-
expressing cells has been described (Williams, Margatho et al. 2010). 
 CADM1 influences neuronal insulin signaling in male mice differently 4.3.4
than in female mice 
Our experiments showed that male Cadm1KO mice have increased locomotor activity 
after CHOW and HFD feeding (Figure 14, Table 7) and improved insulin sensitivity after 
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HFD feeding (Figure 30). Female Cadm1KO mice exhibited improved insulin sensitivity 
but did not show changes in locomotor activity or energy expenditure (Figure 16, Figure 
15). These data point to a gender-specific effect of CADM1 on the regulation of energy 
and glucose homeostasis. Gender-specific effects have also been reported for NIRKO 
mice (Bruning, Gautam et al. 2000). Under CHOW diet, female NIKRO mice showed a 10 
to 15 % increase in body weight accompanied by an increase in food intake, fat mass, 
leptin levels and insulin resistance. Male NIRKO mice also showed increased fat mass 
and leptin levels but without effects on food intake and body weight. However, when 
NIRKO mice were fed a HFD, both genders developed DIO. In addition to these defects in 
energy and glucose homeostasis, NIRKO mice suffer from hypogonadism, with reduced 
luteinizing hormone (LH) concentrations in both genders. The reason for the gender-
specific effects in energy and glucose metabolism in NIRKO mice has not been identified 
but it was speculated that the hypogonadism might be associated with the observed 
differences (Konner, Janoschek et al. 2007). Gonadotropins, such as LH and follicle-
stimulating hormone (FSH), are produced in the anterior pituitary, also called 
adenohypophysis, and are responsible for reproduction in both genders (Schmidt, Thews 
et al. 2000; Löffler and Petrides 2003). In female humans and rodents, insulin resistance 
was shown to be associated with hypergonadism (Mauras, Welch et al. 1998; Niklasson, 
Daneryd et al. 2000). In male humans, obesity and type 2 diabetes is associated with 
hypogonadism (Dhindsa, Miller et al. 2010). From these results we conclude that 
disturbance of the hypothalamic-pituitary axis might affect glucose and energy 
homeostasis of females and males differently. CADM1 was shown to affect 
gonadotropin-releasing hormone (GnRH) release by controlling cell adhesion between 
hypothalamic astrocytes and GnRH neurons (Sandau, Mungenast et al. 2011; Sandau, 
Mungenast et al. 2011). GnRH is produced in the hypothalamus and responsible for the 
release of FSH and LH (Schmidt, Thews et al. 2000; Löffler and Petrides 2003). Therefore, 
Cadm1 deficiency might induce changes in the hypothalamic-pituitary axis, affecting 
insulin sensitivity and locomotor activity differently in each gender.  
Alternatively, deletion of the insulin receptor might affect different areas with different 
effects on energy and glucose homeostasis. Indeed, gender-specific differences in 
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regional expression of insulin receptors have been reported before (Xu, Huber et al. 
2007; Hami, Sadr-Nabavi et al. 2012). The gender-specific effects of Cadm1 deletion on 
energy and glucose homeostasis observed in our experiments might be caused by 
gender-specific expression of the insulin receptor or Cadm1. These differences might 
result in different regional interactions between CADM1 and insulin signaling in male 
and female mice and different effects on insulin sensitivity and locomotor activity in 
both genders. 
 Possible molecular mechanisms of CADM1 influencing neuronal insulin 4.3.5
signaling 
The recently identified function of CADM1 in localizing to postsynaptic receptor 
complexes might be a mechanism how CADM1 influences neuronal insulin signaling 
(Fujita, Tanabe et al. 2012). CADM1 might regulate neurotransmitter receptor signaling 
by stabilizing inhibitory GABA or AGRP receptor complexes at postsynaptic membranes. 
Binding to postsynaptic GABA and glutamate receptor complexes have been shown 
recently for CADM1 (1.3.1) (Fujita, Tanabe et al. 2012). Postsynaptic receptor complexes 
influenced by CADM1 might exist in Pomc-expressing neurons, which we measured in 
our studies (Figure 19), or other second-order (Figure 40 (1)). Cadm1 deletion might 
lead to destabilizing of these complexes and subsequent reduced AGRP signaling, 
decreasing HGP and enhancing locomotor activity, as discussed above (4.3.1, 4.3.2).  
Alternatively, CADM1 might influence presynaptic neurotransmitter release of Npy-
expressing neurons (Figure 40 (2)). Potential binding partners of CADM1 at the 
presynaptic membrane include N-type Ca2+ channels, which are known to bind to the 
VELI-CASK-MINT1 complex (Maximov, Sudhof et al. 1999) (1.3.1). Blockage of N-type 
Ca2+ channels inhibits potassium-stimulated NPY release (King, Widdowson et al. 1999). 
Cadm1 deficiency might destabilize and similarly block presynaptic N-type Ca2+ channels. 
This blockage would reduce AGRP release from Agrp-expressing neurons. Since GABA is 
co-expressed with NPY from Npy-expressing neurons (Cowley, Smart et al. 2001), GABA-
mediated IPSC frequency on Pomc-expressing neurons would be decreased in Cadm1KO 
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mice (Figure 19). In conclusion, CADM1 might stabilize presynaptic N-type Ca2+ channels 
in Npy-expressing neurons, which prevents insulin-mediated inhibition of NPY release.  
Last, CADM1 might influence glucose and energy homeostasis by regulating 
synaptogenesis between insulin sensitive neurons and other neurons during postnatal 
development. CADM1 is an important regulator of synaptogenesis (1.3.1). Alterations in 
neurotransmitter trafficking between insulin sensitive neurons and other neurons could 
be consequences of loss of CADM1. Since CADM1 is proposed to be necessary to 
maintain synaptic numbers (Robbins, Krupp et al. 2010), these alterations cannot be 
compensated in adult mice and might cause increased locomotor activity and insulin 
sensitivity in adult Cadm1KO mice. 
In summary, we hypothesize that Cadm1 deletion reduces insulin-mediated suppression 
of AGRP or GABA signaling between Agrp-expressing neurons and Pomc-expressing 
neurons and between Agrp-expressing neurons and second-order neurons. These 
effects are likely to include CADM1 action at the postsynaptic or presynaptic 
membranes or CADM1 regulating synaptogenesis. Decreased AGRP and GABA signaling 
increases -MSH release and subsequent locomotor activity and reduces HGP and blood 
glucose levels, increasing insulin sensitivity. Enhanced locomotor activity reduces body 
fat content and circulating leptin levels, which further increases insulin sensitivity. 
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Figure 40: Postulated mechanisms of CADM1 inhibiting insulin-mediated suppression 
of neurotransmitter release 
Insulin signaling in 1st order neurons expressing insulin receptor and Agrp (left) leads to 
opening of ATP-sensitive K+-channels and subsequent hyperpolarization. Insulin-
mediated hyperpolarization of Agrp-expressing neurons represses release of 
neurotransmitters, such as NPY, AGRP and GABA. Reduced neurotransmitter release 
signals through 2nd order neurons and hepatic innervation and results in decreased HGP. 
In Pomc-expressing neurons (right), insulin signaling causes release of -MSH, a 
transcribed protein of the Pomc gene, directly through inhibition of FOXO1 and 
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indirectly through inhibited release of NPY, AGRP and GABA. Insulin-mediated -MSH 
release promotes locomotor activity.  
CADM1 is postulated to be a positive regulator of postsynaptic NPY, AGRP and GABA 
signaling by stabilizing their neurotransmitter receptor complexes (1). Alternatively, 
CADM1 might be a suppressor of presynaptic insulin-mediated inhibition of NPY, AGRP 
and GABA release (2). Cadm1 deficiency therefore decreases insulin-mediated NPY, 
AGRP and GABA release and subsequently inhibits HGP and increases locomotor activity.  
Abbreviations: Agouti-related protein (AGRP); -aminobutyric acid (GABA); Hepatic 
glucose production (HGP); Insulin receptor (IR); α-Melanocyte-stimulating hormone (α-
MSH); Neuropeptide Y (NPY); Pro-opiomelanocortin (Pomc)  
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4.4 Role of CADM1 in insulin secretion 
Our data showed that glucose-stimulated insulin release was enhanced in Cadm1KO 
mice compared to control mice (Figure 17). We also observed increased glucose-
stimulated insulin secretion in Cadm1-depleted MIN6 cells (Figure 18). Basal glucose 
levels were unchanged in Cadm1KO mice (Figure 16). In addition, pancreatic insulin 
content was unchanged in Cadm1KO mice (Figure 17). Based on these data, we suggest 
that CADM1 negatively regulates glucose-stimulated insulin release in pancreatic -cells 
but does not affect basal insulin levels or pancreatic insulin content.  
CADM1 has been described as a target of miR-375 (Poy, Hausser et al. 2009) (1.2.3). 
MiR-375KO mice showed enhanced CADM1 expression as well increased glucose-
stimulated insulin secretion (Poy, Eliasson et al. 2004; Poy, Hausser et al. 2009). 
Overexpression of Cadm1 has not been conducted in our studies but we observed 
increased glucose-stimulated insulin secretion after reduced CADM1 expression. 
Enhanced CADM1 expression, like in miR-375KO mice, is therefore unlikely to also result 
in increased glucose-stimulated insulin secretion. MiR-375 seems to target other genes 
than CADM1 to effect insulin secretion. 
Our data showed that Cadm1-depleted MIN6 cells, a cell line derived from pancreatic -
cells, have increased insulin secretion in response to glucose compared to control MIN6 
cells (Figure 18). While indirect effects on in vivo insulin secretion, such as sympathic 
innervation, cannot be excluded in mice, cell culture in vitro experiments provide a 
model with only one cell type involved. Our data of Cadm1 depletion enhancing insulin 
secretion in MIN6 cells therefore emphasizes that CADM1 might regulate insulin 
secretion in an autocrine manner. Nevertheless, MIN6 cells have been reported to 
express genes which resemble a mixed pancreatic endocrine cell line rather than a pure 
insulin-secreting cell line (Nakashima, Kanda et al. 2009). These results might question 
the validity of MIN6 cells as model for pancreatic -cells. Therefore, results of a function 
of CADM1 in MIN6 cells should be confirmed by in vivo models. Currently, all available 
models to investigate genes in pancreatic -cells in vivo have severe limitations. The 
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mouse lines express cre recombinase driven by the rat insulin promoter (RIP) in -cells, 
but also show cre recombinase activity in the brain, e.g. in the hypothalamus 
(Wicksteed, Brissova et al. 2010). This region influences glucose homeostasis and might 
therefore confound -cell specific knock-down effects, as shown previously (Nguyen, 
Tajmir et al. 2006; Kong, Tong et al. 2012). However, the unpublished mouse line 
expressing cre recombinase under the control of the mouse insulin 1 promoter (MIP-
Cre) expresses cre activity only in -cells and might be useful in future studies to 
investigate the role of CADM1 in -cells only (Wicksteed, Brissova et al. 2010). 
Cadm1 deficient mice were shown to have enhanced glucagon release from pancreatic 
-cells (Ito, Ichiyanagi et al. 2012). These data are similar to our observations that 
Cadm1 deficient mice have enhanced insulin release from pancreatic -cells. It is 
therefore possible that CADM1 influences hormone release from - and -cells through 
similar mechanisms. Early studies suggested that CADM1 influences hormone release 
similarly in - and -cell (Koma, Furuno et al. 2008). Insulin-mediated GABA signaling 
inhibits insulin secretion in an autocrine manner (1.1.1) as well as glucagon release from 
-cells (Wendt, Birnir et al. 2004). In light of the function of CADM1 in binding to 
postsynaptic receptor signaling complexes (Hoy, Constable et al. 2009; Fujita, Tanabe et 
al. 2012) (1.3.1), CADM1 might stabilize GABAR complexes of pancreatic- and -cells 
(Figure 41 (1)). Cadm1 deficiency would therefore decrease glucose-induced GABA 
signaling and subsequently increase insulin release from pancreatic -cells and glucagon 
release from pancreatic -cells.   
Alternatively to a role of CADM1 in GABA signaling in -cells, CADM1 might influence 
communication between autonomic nerves and -cells in order to regulate insulin 
secretion. CADM1 is known to regulate neurotransmitter trafficking (1.3.1) and to be 
expressed in neuronal crest cells of pancreatic islets (Shimada, Tachibana et al. 2012) 
(1.3.2). Recent literature showed that neuronal crest cells differentiate into neuronal 
cells, such as autonomic nerves (Shimada, Tachibana et al. 2012). Therefore, CADM1 
might positively regulate sympathic innervation (Figure 41 (2)) or negatively regulate 
parasympathic innervation (Figure 41 (3)) of pancreatic -cells. In both cases, loss of 
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CADM1 would increase glucose-stimulated insulin secretion as observed in Cadm1KO 
mice. Likewise, a role of CADM1 in regulating autonomic innervation in the brain might 
be possible. Autonomic innervation of pancreatic -cells is regulated by neurons of the 
ventromedial hypothalamus (VMH) (Tokunaga, Fukushima et al. 1986; Evans, 
McCrimmon et al. 2004; Osundiji, Lam et al. 2012). These neurons are sensitive to 
glucose and downstream signaling cascades of these neurons are dependent on GABA 
receptor signaling (Jetton, Liang et al. 1994; Chan, Lawson et al. 2007; Zhu, Czyzyk et al. 
2010). In addition, reduced insulin signaling in the VMH impairs pancreatic insulin 
secretion (Paranjape, Chan et al. 2011). CADM1 is highly expressed in the brain 
(Biederer, Sara et al. 2002; Fujita, Urase et al. 2005) and influences GABA signaling 
(Fujita, Tanabe et al. 2012). Therefore, CADM1 might regulate GABA signaling from 
glucose sensitive neurons or neuronal insulin signaling in the VMH, as discussed above 
(4.3.1). Molecular mechanisms of CADM1 action in autonomic innervation or pancreatic 
islets might include presynaptic or postsynaptic mechanisms or regulation of 
synaptogenesis as explained above (4.3.5).  
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Figure 41: Postulated mechanisms of CADM1 inhibiting glucose-stimulated insulin 
secretion 
Glucose is taken up by insulin-independent GLUT2 and metabolized to NADH and 
pyruvate through glycolysis. Pyruvate is fueled into the TCA cycle, generating FADH2 and 
NADH. The electron transport chain in mitochondria converts NADH and FADH2 to ATP, 
increasing cytosolic ATP/ADP ratio. Enhanced ATP/ADP ratio closes ATP sensitive K+ 
channels, which depolarizes the membrane and opens voltage-gated Ca2+ channels. 
Increased cytosolic Ca2+ concentrations trigger docking of insulin-containing secretory 
vesicles and insulin release. Furthermore, GABA contained in secretory vesicles and 
synaptic like microvesicles is secreted similarly to insulin. Autocrine GABA signaling and 
sympathic innervation negatively regulate insulin secretion. Parasympathic innervation 
positively regulates insulin secretion. CADM1 might stabilize GABAR complexes (1). 
Alternatively, CADM1 might positively influence sympathic innervation (2) or negatively 
influence parasympathic innervation (3). In all cases, Cadm1 deficiency would increase 
glucose-stimulated insulin secretion.  
Abbreviations: Adenosine diphosphate (ADP); Adenosine-5'-triphosphate (ATP); -
aminobutyric acid (GABA); -aminobutyric acid receptor (GABAR); Glucose transporter 
(GLUT2); Muscarinic cholinergic receptor 3 (M3); Nicotinamide adenine dinucleotide 
(NADH); Sympathetic nervous system (SNS); Parasympathetic nervous system (PSNS); 
Tricarboxylic acid cycle (TCA)  
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4.5 Alternative models of CADM1 influencing insulin sensitivity 
and energy homeostasis 
 CADM1 might regulate postnatal growth, energy homeostasis and 4.5.1
insulin sensitivity by influencing autistic-like behavior 
Cadm1KO mice showed reduced postnatal growth (Figure 9). It has been shown that 
increased insulin levels in the body increase postnatal body weight (Catlin, Cha et al. 
1985), while lack of insulin signaling in the brain results in unchanged body weight of 
male mice (Bruning, Gautam et al. 2000). Increased neuronal insulin signaling, which 
likely contributes to increased locomotor activity and insulin sensitivity in Cadm1KO 
mice (4.3), is therefore most likely not responsible for postnatal growth deficiency. It can 
therefore be suggested that another mechanism causes postnatal growth deficiency in 
Cadm1KO mice. 
The basis of the hypothesized role of CADM1 in neuronal insulin signaling was built on 
our data showing that IPSC frequency onto hypothalamic Pomc-expressing neurons is 
decreased in Cadm1KO mice (Figure 19). However, alterations of postsynaptic potentials 
do not have to be caused by signaling from presynaptic neurons but might be caused by 
neurons in other areas of the brain. Recent studies showed that electrical stimulation of 
the hippocampus directly induces synaptic changes in the thalamus (Tsanov, Vann et al. 
2011). Other studies emphasized that changes in certain brain areas can induce synaptic 
alterations through alterations of the phenotype: Rodents that were sleep-deprived 
through lesions of the ventrolateral preoptic nucleus showed synaptic changes in the 
hippocampus (Arrigoni, Lu et al. 2009). Furthermore, rats, which were obesity-induced 
through insulin receptor reduction in the hypothalamus, developed synaptic alterations 
in the hippocampus (Grillo, Piroli et al. 2011). These studies indicate that synaptic 
changes in certain areas might be caused in other areas of the brain through direct 
neuronal connections or indirect phenotypical changes. It is therefore possible that 
alterations in IPSC frequency onto hypothalamic Pomc-expressing neurons in Cadm1KO 
mice are caused by CADM1 deficiency effects in other brain areas.  
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A function of CADM1 has been described in Purkinje cells of the cerebellum (Fujita, 
Tanabe et al. 2012; Fujita, Tanabe et al. 2012) (1.3.3). The loss of these cells is associated 
with ASD in humans (Ritvo, Freeman et al. 1986; Fatemi, Halt et al. 2002; Martin, 
Goldowitz et al. 2010; Tsai, Hull et al. 2012). The loss of Purkinje cells in ASD patients 
occurs during the final weeks of gestation in humans, a time corresponding to the 
second and third postnatal week in rodents (Whitney, Kemper et al. 2009). Therefore, 
Cadm1 deficiency might reduce postnatal growth through inducing autistic-like behavior 
in the cerebellum. These alterations might further affect other regions of the brain. 
In particular, loss of CADM1 in rodents or humans might destabilize postsynaptic 
GABBR2 complexes (Fujita, Tanabe et al. 2012) (Figure 42). The destabilization of the 
GABBR2 complex might lead to loss of cerebellar Purkinje cells. Alternatively, CADM1 
might attach cerebellar Purkinje cells to other surrounding cell types, such as astrocytes. 
CADM1 expression in astrocytes has been confirmed before (Sandau, Mungenast et al. 
2011; Sandau, Mungenast et al. 2011). Loss of CADM1 expression might destabilize 
Purkinje cells number and result in decreased cell number and alterations in GABA 
signaling. Lastly, loss of Purkinje cells and altered cerebellar GABA signaling might be 
independent consequences of loss of CADM1 expression and one or both events 
contribute to the occurrence of autism-like behavior.  
4.5.1.1 Role of repetitive behavior in insulin sensitivity of Cadm1 deficient 
mice  
Our experiments showed increased locomotor activity in male Cadm1KO mice (Figure 
14) and increased food-seeking behavior in female Cadm1KO mice (Figure 12). One 
clinical criterion for the diagnostic auf autism in humans is restricted, repetitive behavior 
(American Psychiatric Association 2011). Murine models of autism show increased 
repetitive behaviors, hyperactivity and increased food-seeking behavior (Martin, 
Goldowitz et al. 2010; Tsai, Hull et al. 2012). Increased locomotor activity is known to 
induce increased insulin sensitivity directly through induction of glucose uptake in  
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Figure 42: Postulated mechanism of loss of CADM1 expression influencing insulin 
sensitivity and postnatal growth through induction of autistic-like behavior 
Loss of CADM1 protein expression destabilizes Mupp1–GABBR2 complex and might lead 
to altered GABA signaling (left). Altered GABA signaling might decrease Purkinje cell 
number in the cerebellum, which is associated with autistic-like behavior. Alternatively, 
loss of CADM1 as cell adhesion molecule between Purkinje cells and other cell types 
might decrease Purkinje cell number and lead to alterations in GABA signaling and 
subsequent induction of autism-like behavior (right). Also loss of Purkinje cell number or 
alterations in GABA or both as consequence of loss of CADM1 might directly induce 
autistic-like behavior (middle). Autism-like behavior, such as decreased USVs, reduces 
caretaking behavior from the mother, leading to malnutrition and impaired postnatal 
growth in Cadm1KO pups (lower left). Autism-like behavior, such as repetitive behavior, 
increases locomotor activity and subsequent insulin sensitivity (lower right). Dashed 
lines show alternative mechanisms. 
Abbreviations: Ultrasonic vocalizations (USVs); -aminobutyric acid (GABA)  
Figure based on data from (Fujita, Tanabe et al. 2012; Fujita, Tanabe et al. 2012). 
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skeletal muscle and indirectly through reduction of body fat content (4.2.2). Loss of 
Cadm1 expression in Cadm1KO mice might therefore induce autistic-like behavior and 
subsequently increased locomotor activity (Figure 42). Increased locomotor activity 
might increase insulin sensitivity through enhanced glucose uptake or changes in body 
composition or both.  
Of note, female Cadm1KO mice did not show changes in locomotor activity despite 
increased insulin sensitivity (Figure 15, Figure 16). A higher prevalence for autistic-like 
behavior was reported in male humans and mice (Yeargin-Allsopp, Rice et al. 2003; 
Stack, Lim et al. 2008; Guariglia, Jenkins et al. 2011; 2012). In humans, a higher 
occurrence of repetitive behavior was reported in males compared to females with ASD 
(May, Cornish et al. 2012). It is therefore possible that female Cadm1KO mice show less 
autistic-like behavior, such as repetitive behavior, compared to male Cadm1KO mice. 
The increased insulin sensitivity of female Cadm1KO mice might be a consequence of 
the above discussed hypothesized mechanism of CADM1 influencing neuronal insulin 
signaling (4.3). 
4.5.1.2 Postnatal growth deficiency might be caused by reduced ultrasonic 
vocalizations in Cadm1 deficient mice  
Our data showed that Cadm1KO mice exhibit impairments of body weight gain during 
postnatal development (Figure 9). Adult Cadm1KO mice showed decreased body length 
(Figure 9). This was also observed in other Cadm1 deficient mice in recent studies 
(Fujita, Tanabe et al. 2012), confirming our findings. In these studies, Cadm1 deficient 
mice were identified to have severely decreased postnatal USVs, which was suggested 
to be similar to impairment of language in autistic human patients (Fujita, Tanabe et al. 
2012). USVs are important for the communication between pup and mother during the 
first two weeks of life and evokes caretaking behavior (Branchi, Santucci et al. 2001). An 
impairment of postnatal USVs might reduce caretaking behavior from the mother and 
lead to undernourishment and decreased growth of Cadm1KO pups. Reduced postnatal 
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growth due to reduced USVs might be the first manifesting phenotype of autistic-like 
behavior in Cadm1KO mice (Figure 42). Since USVs decrease naturally two weeks after 
birth in mice (Branchi, Santucci et al. 2001), the deficiency to produce USVs might not 
affect the feeding of Cadm1KO mice later on.  
 Effects of CADM1 on growth hormone signaling 4.5.2
The reduced postnatal growth and increased insulin sensitivity of Cadm1KO mice might 
imply that Cadm1 deletion impairs GH signaling. This is however unlikely as we discuss in 
the following. Growth retardation and altered glucose homeostasis can be found in 
mouse models with defective GH signaling due to mutations in Gh or growth hormone 
receptor (Ghr). Mice with defective GH signaling exhibit a smaller increase in body 
weight during their first four weeks of life and similar growth speed compared to control 
mice after 6 weeks of life (Meyer, Korthaus et al. 2004). Furthermore, increased insulin 
sensitivity (Liu, Coschigano et al. 2004), reduced IGF-1 levels (Donahue and Beamer 
1993; Meyer, Korthaus et al. 2004) and unchanged absolute food intake (Coschigano, 
Holland et al. 2003) are phenotypical characteristics of these mice. These data show 
similarities to our observations in Cadm1KO mice. However, mice and humans with 
dysfunctional GH signaling suffer from obesity (Donahue and Beamer 1993; Roemmich, 
Huerta et al. 2001; Li, Knapp et al. 2003; Meyer, Korthaus et al. 2004). Complete absence 
of GH signaling is likely to cause obesity, reflecting the lack of lipolytic effects of GH on 
adipocytes (LeRoith and Yakar 2007). However, in our studies male Cadm1KO mice 
showed decreased and female Cadm1KO mice showed unchanged relative body fat 
content (Figure 10). Thus, Cadm1KO mice do not suffer from obesity more than control 
mice, suggesting that GH signaling is not impaired in these animals. Furthermore, 
Cadm1KO mice display normal Ghrh, Gh and Ghr expression and respond normally to a 
GH release challenge (Figure 20), suggesting that synthesis and release of GH is not 
impaired in Cadm1KO mice. It can therefore be suggested that Cadm1 deficient mice are 
not deficient in GH or GH signaling and changes in insulin sensitivity and postnatal 
growth in these mice cannot be explained by changes in GH signaling. 
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4.6 Conclusions and perspectives 
Type 2 diabetes has become a world-wide pandemic disease. The disease is 
characterized by resistance to insulin, largely caused by overweight and obesity, and 
subsequent hyperglycemia. Failure of pancreatic -cells to meet increased insulin 
demands dramatically increases blood glucose levels and marks the onset of type 2 
diabetes. 
MiR-375 is the highest expressed miRNA of the pancreas. This miRNA regulates -cell 
growth and insulin secretion and was suggested to influence the development of type 2 
diabetes. Genes regulated by miR-375 had been identified but their role in the function 
of this miRNA in pancreatic islets had not been established. Therefore, we studied the 
role of the miR-375 target Cadm1 initially in pancreatic -cells in order to investigate a 
possible role of CADM1 in growth and function of-cells. These initial studies also 
showed increased insulin sensitivity and reduced body weight in Cadm1KO mice. Since 
body weight is a major determent for insulin sensitivity and therefore for the 
pathogenesis of type 2 diabetes, we also investigated the influence of CADM1 on energy 
homeostasis. 
The initial analyses of glucose homeostasis revealed an increased glucose-stimulated 
insulin secretion of Cadm1KO mice compared to control mice. In vitro cell culture data 
confirmed enhanced glucose-stimulated insulin secretion after Cadm1 depletion. 
Furthermore, male Cadm1KO mice exhibited increased locomotor activity, reduced body 
fat content and improved insulin sensitivity after diet and genetic-induced obesity. 
Cadm1KO females showed improved insulin sensitivity, unchanged locomotor activity 
and body fat content. Cadm1KO mice of both genders exhibited reduced postnatal 
growth and unchanged body weight gain after four weeks of age. Mice deficient for 
Cadm1 in neuronal and glia cells confirmed the phenotypical changes in insulin 
sensitivity, body fat content and body weight. 
Our data suggest that deletion of Cadm1 in mice increases locomotor activity, which 
reduces body fat content. Reduced body fat content improves insulin sensitivity and 
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decreases leptin levels in Cadm1KO mice. Body weight gain seems to be balanced by 
enhanced food intake in Cadm1 deficient mice. We further hypothesized that CADM1 
regulates neuronal insulin signaling, which influences insulin sensitivity and locomotor 
activity. The basis of this postulated mechanism was built on our data showing that IPSC 
frequency onto hypothalamic Pomc-expressing neurons is decreased in Cadm1KO mice. 
CADM1 is hypothesized to be a possible mediator of neurotransmitter signaling between 
hypothalamic Agrp-expressing neurons and second-order neurons and between Agrp-
expressing neurons and Pomc-expressing neurons. The result of this influence would be 
a decreased HGP, resulting in improved insulin sensitivity, and increased locomotor 
activity in Cadm1 deficient mice. An alternative postulated mechanism is based on the 
role of CADM1 in autism. CADM1 has been linked to the induction of autistic-like 
behavior before. We hypothesize that increased repetitive behavior, typical for autistic-
like behavior, increases locomotor activity and subsequently reduces body fat content 
and increases insulin sensitivity. Decreased postnatal USVs might lead to impaired 
caretaking behavior of the mother and cause impaired postnatal growth of Cadm1KO 
mice. However, changes in energy and glucose homeostasis and postnatal growth of 
Cadm1 deficient mice cannot be explained by only one of the two mechanisms. We 
therefore postulate that both mechanisms might be relevant in Cadm1 deficient mice.  
In future studies, the role of the two postulated mechanisms in energy and glucose 
homeostasis of Cadm1 deficient mice should be investigated. Euglycemic-
hyperinsulinemic clamp studies, as previously used (Konner, Janoschek et al. 2007), can 
uncover the contribution of each tissue in insulin-mediated glucose uptake. Increased 
insulin signaling in Agrp-expressing neurons results in increased HGP (Konner, Janoschek 
et al. 2007; Lin, Plum et al. 2010). Acute and chronic exercise is known to enhance 
insulin-mediated glucose uptake in skeletal muscle (Nuutila, Knuuti et al. 1994; Hardin, 
Azzarelli et al. 1995; Thorell, Hirshman et al. 1999; Frosig, Roepstorff et al. 2009). 
Therefore, euglycemic-hyperinsulinemic studies would help to elucidate whether 
increased insulin sensitivity in Cadm1KO mice is caused by enhanced locomotor activity 
or increased neuronal signaling or both.  
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In addition, investigations of mice with deletions of Cadm1 in restricted areas of the 
brain might help to identify mechanisms of the CADM1 actions. For this purpose, mice 
carrying a conditional Cadm1 allele could be crossed to mice carrying a cre-expressing 
gene under the control of promoters, such as the PCP-2 promoter. This promoter 
restricts cre expression to Purkinje cells in the cerebellum and bipolar neurons in the 
retina (Barski, Dethleffsen et al. 2000). This cre line was used before to identify Purkinje 
cells of the cerebellum as responsible region for autistic-like behavior caused by 
mutations in tuberous sclerosis complex (Weber, Egelhoff et al. 2000; Reith, McKenna et 
al. 2012). A mouse line with deletion of Cadm1 in cerebellar Purkinje cells might 
therefore help to elucidate whether the observed changes in glucose and energy 
homeostasis of Cadm1KO mice are caused by Cadm1 deletion in cerebellar Purkinje 
cells. Similarities in the phenotype of Cadm1KO mice and mice with Purkinje cells-
restricted Cadm1 deletion might suggest that mutation in Cadm1 cause autistic-like 
behavior and the observed changes in glucose and energy homeostasis. Similar, mice 
with Cadm1 deletions in Pomc- or Agrp/Npy-expressing or both might help to 
understand whether CADM1 has a functional role in these neurons. Initial studies with 
mice carrying a conditional Cadm1 allele and an allele with cre expression under the 
control of the Pomc promoter (Balthasar, Coppari et al. 2004) did not show changes in 
body weight, food intake, glucose or insulin sensitivity (own data, data not shown). 
However, mice with Cadm1 deletion in Agrp/Npy-expressing neurons (Tong, Ye et al. 
2008) have not been investigated in depth but might help to understand whether 
Cadm1 expression in these neurons plays a role in energy and glucose homeostasis. In 
addition, we hypothesized that CADM1 might facilitate neurotransmitter trafficking 
between Npy-expressing neurons and second-order neurons and Npy-expressing 
neurons and Pomc-expressing neurons (4.3). Since CADM1 also binds to CADM2 (Fogel, 
Akins et al. 2007), deletion of Cadm1 on pre- and postsynaptic membranes might be 
necessary to cause similar phenotypical changes like in Cadm1KO mice. Therefore, 
analyses of mice with Cadm1 deletions in Npy-expressing neurons and Pomc-expressing 
neurons should be included. Of note, CADM1 expression has also been confirmed in 
non-neuronal cells of the brains, such as glia and granule cells (Thomas, Akins et al. 
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2008). Since deletion of Cadm1 in these cell types might be necessary for the full 
induction of changes in glucose and energy homeostasis, region specific knock-down of 
Cadm1, such as virus-mediated knockdown (Garza, Kim et al. 2008), should be used. 
Specific knock-down of Cadm1 in the hypothalamus or cerebellum might help to decide 
on the contribution of the two postulated mechanisms.  
Besides the investigation whether CADM1 might regulate neuronal insulin signaling or 
influence autistic-like behavior or both, the function of CADM1 in pancreatic -cells 
should be investigated in future studies. These studies could include mouse models to 
elucidate whether CADM1 regulates glucose-mediated insulin secretion directly in -
cells or indirectly by influencing autonomic islet innervation or both as discussed before 
(4.4). Insulin secretion experiments in mice with Cadm1 deficiency in pancreatic -cells 
(Cadm1MIPCreKO) might help to investigate if CADM1 regulates insulin secretion 
directly in -cells. Insulin secretion studies in mice with Cadm1 deletion in neuronal and 
glia cells might identify an indirect regulation of insulin secretion by CADM1. The 
deletion of Cadm1 in neuronal and glia cells is driven by the promoter of the nestin 
gene. Expression of nestin was confirmed in early neural crest cells (Lothian and Lendahl 
1997), suggesting that neural crest cells of pancreatic islets express nestin during 
development. Pancreatic neural crest cells of Cadm1NesCreKO mice are therefore 
expected to be Cadm1 deficient. Insulin secretion experiments with these mice would 
help to understand whether neural crest cells or other nestin expressing cells in the CNS 
contribute to enhanced glucose-stimulated insulin secretion of Cadm1KO mice. 
Furthermore, pharmacologic manipulations of the autonomic system can further 
establish a possible role of CADM1 in influencing-cells through the autonomic nervous 
system and whether CADM1 influences the SNS or PSNS or both.  
In addition to the investigation of the putative role of CADM1 in the brain and 
pancreatic islets, future studies could elucidate the role of possible interaction partners 
of CADM1. These interaction partners might include MINT1, which was shown to bind to 
CADM1 (Biederer, Sara et al. 2002) (1.3.1). Mint1KO mice show, similar to Cadm1KO 
mice, decreased postnatal growth and alterations in behavior and synaptic GABA 
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trafficking (Mori, Okuyama et al. 2002; Ho, Morishita et al. 2003). Studies of the energy 
and glucose homeostasis of Mint1KO mice might help to understand whether the 
molecular mechanism of CADM1 action includes binding to the VELI-CASK-MINT1 
complex as discussed before (4.3.5). 
Finally, the role of CADM1 pancreatic insulin secretion and whole body insulin sensitivity 
in the pathogenesis of type 2 diabetes should be investigated. For this purpose, Cadm1 
deficient mice could be crossed to diabetic murine models, such ob/ob or db/db mice on 
the C57BL/KsJ-background (Coleman 1978). These data would help to understand 
whether CADM1 as a regulator of energy and glucose homeostasis contributes to the 
development of type 2 diabetes.  
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